Genetic Factors Associated with Anti-Factor H Autoantibodies in Atypical Hemolytic Uremic Syndrome (aHUS) by Valoti, Elisabetta
Open Research Online
The Open University’s repository of research publications
and other research outputs
Genetic Factors Associated with Anti-Factor H
Autoantibodies in Atypical Hemolytic Uremic
Syndrome (aHUS)
Thesis
How to cite:
Valoti, Elisabetta (2018). Genetic Factors Associated with Anti-Factor H Autoantibodies in Atypical Hemolytic
Uremic Syndrome (aHUS). PhD thesis The Open University.
For guidance on citations see FAQs.
c© 2018 The Author
Version: Submitted Version
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
 
 
GENETIC FACTORS ASSOCIATED WITH 
ANTI-FACTOR H AUTOANTIBODIES IN 
ATYPICAL HEMOLYTIC UREMIC 
SYNDROME 
 
 
Thesis submitted by 
Elisabetta Valoti, Biol. Sci. D 
 
for the degree of 
Doctor of Philosophy 
 
Discipline of Life and Biomolecular Sciences 
 
The Open University, United Kingdom 
IRCCS, Istituto di Ricerche Farmacologiche Mario Negri, Italy 
 
 
Director of Studies 
Dr. Marina Noris, PhD 
 
PhD Supervisor 
 Prof. Tim Goodship, MD 
 
 
April 2018
 II 
 
 
 III 
 
Abstract 
Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic 
microangiopathy characterized by renal failure and determined by genetic and 
acquired defects of alternative pathway (AP) of the complement system. 
Autoantibodies against factor H (anti-FHs), a regulator of the AP, were reported 
in 10% of patients, and are associated with the deficiency of factor H related 1 
(FHR1), a FH homologous protein. 
The aim of this thesis was to evaluate the contribution of genetics to the 
development of anti-FHs in aHUS. 
Thirty patients affected by aHUS resulted positive for anti-FHs (9.8%) and FHR1 
deficiency was present in 83.3% of them. A healthy control also showed anti-FHs 
in concomitance with FHR1 deficiency documenting that the lack of FHR1 
strongly predisposed to anti-FH development also in healthy subjects although 
this condition was not sufficient for the disease manifestation. 
The presence of infectious prodromal signs and an age at the disease onset around 
8 years indicated that common infections may trigger the development of 
autoantibodies in subjects with at risk genetic background. 
Likely pathogenetic variants in complement genes were observed in 37% of our 
patients with anti-FHs. At variance, common variants in complement genes did 
not seem to contribute to the disease, as documented by comparing patients with 
super controls, unaffected subjects carrying FHR1deficiency.  
 IV 
 
Finally, I report that the HLA-DRB1*11:04 allele could be a predisposing genetic 
variant for anti-FH associated aHUS. Further works will be necessary to confirm 
this finding and to explore the presence of other genetic susceptibility factors that, 
in combination with the HLA-DRB1*11:04 allele and the FHR1 deficiency, could 
increase the risk for anti-FHs. 
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1  Introduction 
1.1 Complement system 
The complement system represents a main part of the innate immune system and 
it plays an important role to defense the organism from pathogens and to maintain 
homeostasis. Upon infection complement is activated leading to inflammation, to 
recruitment of immune cells which are involved in the elimination of the 
pathogens and in the clearance of immune complexes and cell debris, and to the 
activation of adaptive immunity.1-4 
The complement system is composed by more than 30 proteins indicated by the 
letter C followed by a progressive number, which are either produced by the liver 
and secreted in the circulation or associated to cell membranes. Complement 
proteins are zymogens activated by proteolytic cleavages. There are three major 
pathways of complement activation: the alternative, the classical, and the lectin 
pathways (Figure 1-1). Each pathway leads to the cleavage of C3 resulting in the 
formation of activated products and the disruption of pathogens.1, 2 
Introduction 
2 
 
 
Figure 1-1. Graphical representation of the three pathways of activation of the complement 
system. 
Complement activators and regulators involved in the classical, the lectin, and the alternative 
pathways are shown (adapted from Ricklin et al. Molecular Immunology, 2017).5 
 
The alternative pathway (AP) represents the oldest component of the innate 
immune system and the first components have been identified in a coral 
suggesting their presence since cnidaria.6, 7 C3 is continuously hydrolyzed at low 
rate to generate C3(H2O) in a spontaneous process called “tick over”. C3(H2O) 
dramatically changes its conformation and C3 thioester domain flips out exposing 
the previously hidden thioster bond which recognizes the plasma protein factor B 
(FB). FB bound to hydrolyzed C3(H2O), is cleft by the plasma serine protease, 
factor D (FD) to generate Ba and Bb fragments. Bb remains bound to C3(H2O) 
and forms the fluid phase AP C3 convertase which cleaves C3 molecules to C3a 
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and C3b. Through the tick over process, C3b is constantly produced at low rate in 
physiological conditions and can bind –OH groups present on pathogens or on 
other “activating surfaces” which support complement deposition. FB is then 
recruited to the bound C3b and this association is promoted by factor P 
(properdin) which is released by activated neutrophils. FD cleaves FB and Bb 
remains bound to C3b forming the C3bBb AP C3 convertase. Then, C3bBb 
convertase cleaves other C3 molecules producing an amplification loop and other 
C3b molecules that remain attached to the cell surface. The other C3a fragment 
released by C3 convertase activity acts as anaphylatoxin.1, 2 
The classical pathway (CP) is initiated by binding of the complement protein C1 
to immunoglobulins (Igs) present on pathogens or other foreign antigens. C1 is a 
large multimeric protein complex composed of C1q, C1r, and C1s molecules that 
binds to the Fc portion of IgG or IgM. C1q subunit is constituted by 6 chains 
forming an umbrella-like structure with a globular head. C1r and C1s are serine 
proteases that form a tetramer containing two molecules of each protein. Binding 
of two or more C1q molecules to IgG or IgM lead to enzymatic activation of the 
associated C1r, which cleaves and activates C1s. Activated C1s cleaves C4 into 
C4a and C4b, and C2 into C2a and C2b. C4b contains a thioester bond that forms 
covalent linkages with Igs. C2b is soluble while C2a remains associated to C4b on 
the cell surface. The resulting C4bC2a complex is defined as the CP C3 
convertase and is able to bind and cleaves C3 molecules. Of note, pentraxin, 
which belongs to a class of pattern recognition receptors, can interact with 
pathogens, binds directly C1q, and activates the CP.1, 2 
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The lectin pathway (LP) is activated in the absence of antibodies when either 
mannose binding lectin (MBL) or ficolins, which are soluble plasma proteins 
structurally similar to C1q, bind to microbial polysaccharides. MBL is a member 
of collectin family with a hexameric structure and presents an N-terminal 
collagen-like domain important for oligomerization and a C-terminal lectin 
domain which binds the mannose residues on microbial glycoproteins and 
glycolipids. Ficolins are structurally similar to MBL and show a collagen-like 
domain and, instead of the lectin domain, present a C-terminal fibrinogen-like 
domain which binds N-acetylglucosamine and lipoteichoic acid present in the cell 
walls of Gram positive bacteria. MBL and ficolins circulate associated to MBL-
associated serine proteases (MASPs), which are structurally homologous to C1r 
and C1s proteases, called MASP1, MASP2, and MASP3. Binding to pathogens 
induces conformational changes leading to auto-activation of MASP2 which is the 
only MASP that can cleave C4 to form C4a and C4b. C4b recognizes microbial 
surfaces inducing the binding of C2, which is cleaved by MASP2 to form C2b and 
C2a. C4b together with the attached C2a forms the LP C3 convertase, C4bC2a, 
which is identical to the CP C3 convertase.1, 2 The function of MASP1 and 
MASP3 are more unclear than MASP2. Of note, MASP-1 seems able to cleave 
C4b-bound C2 and both MASP1 and MASP3 show the ability to convert the pro-
enzyme FD to its active form, suggesting their involvement in both the LP and AP 
of complement activation. 1, 2, 8, 9 
AP C3 convertases, C3bBb, and CP and LP C3 convertases, C4bC2a, cleave C3 
to form C3a and C3b. C3b can bind C3 convertases to form the C5 convertases of 
the AP, C3b2Bb and of the CP/LP, C4bC2aC3b. The C5 convertases cleave C5 
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into the C5a anaphylatoxin and C5b, which remains bound to the cell surface. C5b 
can bind the terminal complement components, C6 and C7. C7 is hydrophobic 
and C5b-7 complex is able to insert into the lipid bilayer of cell membranes where 
it can bind C8 molecules. The formation of terminal complement complex (TCC), 
C5b9, requires the presence of polymerized C9, the final component of 
complement cascade. The resulting membrane attack complex (MAC) is able to 
distort the lipid bilayer of cell membrane leading to the activation of signaling 
pathways which have an important role in the MAC derived cell lysis..1, 2, 10 
Interestingly, C5b-7 also has the ability to bind the terminal components C8 and 
C9 forming a soluble complex, called sC5b9, containing the S protein (a plasma 
glycoprotein produced by endothelial cells, also called vitronectin), and clusterin 
(also called SP-40). The sC5b9 does not determine the cell lysis but it can bind 
endothelial cells forming the membrane TCC (mTCC) which promotes the 
expression of adhesion molecules, inflammation, and increased vascular 
permeability.11 
Interestingly, other non-complement proteases are reported to be able to generate 
complement active products. Coagulation factor XIIa (FXIIa) is able to cleave C1r 
and thereby promotes the CP activation. Furthermore, thrombin (also called FIIa), 
FXa, FXIa, FIXa, and plasmin can activate both C5 and C3 and the derived 
products C3a and C5a are biologically active.12, 13 Of note, the concentrations of 
the coagulation factors required to cleave complement proteins in in vitro studies 
are higher than the concentrations present in physiological conditions suggesting 
that the coagulation components may have a minor effect on complement 
activation in in vivo situation.13 Indeed, discordant results have been recently 
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obtained in baboons infused with FXa and phospholipids which led to a strong 
thrombin and plasmin generation but did not produce measurable levels of 
complement activation fragments compared to results obtained with infusion with  
E. coli.14 Finally, FXIIa is able to cleave pre-kallikrein forming kallikrein, which 
is a serine protease involved in the kinin and plasmin activation, also able to 
cleave C3 and FB leading alone to the generation of active components of the C3 
convertase.15, 16  
The MAC is one of the main effector of complement activation. Nevertheless, 
some Gram positive bacteria are able to repair membrane lesions produced by 
MAC and are resistant to its mediated lysis due to the presence of a very thick cell 
wall. Another important effector function mediated by complement in the first line 
of defence against infections is the opsonization of pathogens mediated by C3b 
and its degradation products iC3b (inactive C3b) and C3d, called opsonins, which 
lead to their recognition, ingestion, and elimination by phagocytes. The pro-
inflammatory effect mediated by opsonins is determined by their interactions with 
the complement receptors expressed on phagocyte surface (CR1, CR2, CR3, CR4, 
and CRIg). CR1 is expressed on monocytes, macrophages, neutrophils, 
erythrocytes, and kidney glomerular podocytes and it binds C3b and C4b. The 
binding of C3b to CR1 is not sufficient to determine phagocytosis, but enhances 
IgG mediated phagocytosis of targets recognized by both IgG and C3b molecules. 
CR3 and CR4 are expressed on macrophages, monocytes, dendritic cells, 
neutrophils, natural killer (NK) cells, and endothelial cells and are specific 
receptors for iC3b. CR3 and CR4 belong to integrin family and CR3 presents a 
lectin site capable of recognizing pathogen carbohydrates. Some tissue resident 
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macrophages (such as Kupffer cells in liver) express CRIg, a receptor belonging 
to the Ig family which determines the phagocytosis mediated by iC3b-coated 
pathogens. Instead, CR2 is expressed on B cells and interacts with C3d and iC3b 
on surface antigens. The interaction between CR2 and C3d-opsonized antigen 
induces an increase of B cell receptor (BCR) signaling.17  
Also the anaphylotoxins C3a and C5a play an important role by enhancing 
inflammation and by activating immune cells that express anaphylatoxin receptors 
(C3aR and C5aRs) on their surface. Anaphylatoxins act as potent 
chemoattractants for neutrophils to sites of inflammation, promoting cell 
migration and adhesion to the endothelium, trigger oxidative bursts from 
neutrophils, macrophages, eosinophils, and bind mast cells and basophils inducing 
degranulation with release of vasoactive mediators such as histamine.17 
 C3aR and C5aRs are also expressed on endothelial cells and their stimulation can 
lead to a rapid mobilization of Weibel-palede bodies containing von-Willebrand 
factor, which mediates platelet adhesion, and P-selectin, which promotes the 
adhesion of leukocytes.17 
The complement system plays an important role not only in innate immunity, but 
also in adaptive immunity. 
Complement modulates T lymphocyte survival and immune responses acting 
directly on complement receptors C3aR and C5aR. C3a and C5a can enhance T 
cell proliferation and inhibit apoptosis, and can increase the strength of the 
immune response.17 On the other hand, complement can indirectly enhance 
cytokine production from antigen presenting cells (APCs) that lead to up-
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regulation of costimulatory molecules, amplification the immunological response 
and determination in which effector phenotype the T cell will differentiate.17, 18 
The complement regulator CD46 (also called membrane cofactor protein, MCP) 
acts as a costimulatory molecule in CD4+ T cells favoring their activation and 
proliferation. CD46 is involved in the regulation of T cells ability to respond to 
interleukin 2 (IL-2) because it is necessary for the normal expression of IL-2 
receptors. In addition, in in vitro and in vivo experiments, T cells isolated from 
rare CD46-deficient patients are unable to produce interferon and this can 
determine a susceptibility state for infection diseases.17, 19 
Complement also plays an important role in B lymphocyte immune responses. As 
described above, CR2 is expressed on B cell surface and interacts with C3d and 
iC3b opsonized antigens. The C3d-CR2 interaction leads to an increase of BCR 
signaling inducing selection and expansion processes of B cells that determine the 
correct antibody repertoire formation.  The C4 binding protein (C4BP) is another 
protein important in B cell activation because it can bind directly the CD40 
costimulatory protein on B cells determining their proliferation and differentiation 
20. Finally, C4 is essential to maintain peripheral B cell tolerance and its 
deficiency can promote the generation of self-reactive B cells in the germinal 
centers.17 
The role of the complement system is not limited to fighting pathogens and 
promoting inflammation, but it is crucial to promote the clearance of apoptotic 
cells and immune complexes maintaining homeostasis. During the removal of 
cellular debris the complement system limits the production of a strong 
inflammation and of a damage signal. Apoptotic cells express on their surface 
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signal molecules which allow the opsonization by C3b and C4b and subsequent 
recognition by phagocytes. However, a number of complement membrane bound 
or soluble regulators are able to modulate the complement amplification, limiting 
the complement activation and the inflammation. The CP plays a crucial role in 
the clearance of apoptotic cells. C1q can directly bind apoptotic cells inducing 
opsonization by C3b and C4b or indirectly interacting with several molecules 
present on cell surfaces (such as IgM, pentraxin, C reactive eprotein - CRP -, 
phosphatidylserine, glyceraldehydes 3-phosphate dehydrogenase – GAPDH -, 
double strand DNA, and calreticulin). C1q is able to increase the secretion of anti-
inflammatory ILs by macrophages, decreasing their expression of CD40, and 
increasing the expression of inhibitory PD-L1 and PD-L2 (programmed death-
ligands) molecules on dendritic cells and macrophages21. In general C1q is able to 
inhibit the inflammasome activity and facilitates the clearance of apoptotic cells 
avoiding the release of intracellular components which can determine the 
activation of an immunologic response and the risk to develop autoimmune 
diseases 21, 22. Inactive C3b (iC3b) also supports the tolerogenic clearance of 
apoptotic cells. The opsonization mediated by iC3b and the CR3-dependent 
phagocytosis determine a downregulation of IL-12, a reduction of oxidative burst 
in macrophages and of the costimulatory molecule expression and impaired 
maturation of dendritic cells.17, 22-24  
1.2 Regulation of complement activation 
The activation of the complement system is finely regulated so that it is restricted 
to microbial cells and foreign surfaces and spares host cells (Figure 1-1).25 
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Complement is also tightly controlled on microbial surfaces to ensure that its 
activation is limited to the pathogens and is not spread to adjacent normal cells 
which can be damaged.25 Regulation is mediated by several circulating and cell 
membrane proteins that appeared early during evolution.25 Indeed, regulators of 
the complement system have been first recognized in Agnatha.26 
The C3b and C4b deposited on host cell surfaces can be bound by several 
regulatory proteins, such as CD46, CR1, and factor H (FH), which are not 
produced by microbes and therefore inhibit the activation of the complement 
system selectively on host cell surfaces. CD46 is expressed on all nucleated cells, 
CR1 is expressed on leukocytes, erythrocytes, and glomerular podocytes, while 
FH is a plasma protein. The presence of high levels of sialic acid on host cells can 
favor the binding of FH on cell surfaces. By binding C3b and C4b, these 
regulators compete with the other components of the C3 convertase, such as Bb of 
AP and C2a of CP, preventing the assembly of the C3 convertases and blocking 
the progression of the complement activation. 
Complement activation is regulated not only by preventing the assembly of the C3 
convertase but also by promoting its dissociation. The decay of AP C3 convertase 
is mainly mediated by FH. CR1, and the decay acceleration factor (DAF/CD55) 
can mediated the decay of the C3 and C5 convertases of the AP and CP, while 
C4BP is the major regulator of the CP and the LP. 
C3b and C4b are also quickly inactivated by the plasma serine protease FI, which 
needs the presence of specific cofactors such as CD46, CR1, and FH. FI-mediated 
proteolytic cleavage generates fragments called iC3b, C3dg, C3c, C4d which are 
recognized by receptors on phagocytes and B lymphocytes. 
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The C1 inhibitor (C1 INH) can regulate the CP and the LP. It is a serine protease 
inhibitor that mimics the normal substrates of C1r and C1s and dissociates them 
from C1q. Moreover, it also inactivates MASP-1 and MASP-2 proteases 
in MBL complexes of the LP and inhibits plasma FXII, FXI, and kallikrein.27, 28 
The terminal complement pathway is also finely regulated. The MAC assembly 
on cell surfaces is inhibited by S protein, clusterin, lipoproteins, anti-thrombin III, 
proteoglycans, and protamine, which can bind to nascent C5b-7 complex and 
prevent its insertion into the cell membrane. Moreover, vitronectin and clusterin 
interact with the nascent lypophilic C5b-9 making it more soluble and lytically 
inactive. Protectin, also called CD59, is associated to host cell membrane via 
a glycophosphatidylinositol (GPI) anchor and by interacting with C9 molecules 
can impair its polymerization and MAC membrane insertion.29 
Instead, the inflammation generated by anaphylatoxins is quickly reduced by 
plasma carboxypeptidases that cleave the C-terminal Arginine, resulting in C3a 
des-Arg and C5a des-Arg, each of which has less than 10% of their original 
biological activity.2 Recent studies have reported that thrombin-activatable 
fibrinolysis inhibitor (TAFI) can also inactivate C3a and C5a anaphylatoxins.30 
Thrombomodulin (THBD), a transmembrane endothelium glycoprotein, by 
binding to thrombin enhances the specificity of the latter for TAFI increasing its 
proteolytoic activation. Moreover, THBD binds C3b accelerating its FI-mediated 
inactivation in the presence of FH.31  
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1.3 Factor H  
FH is the main regulator of the AP of complement system. It has old origin and a 
homologous FH protein called “sand bass cofactor protein 1 (SBP1) was first 
described in teleosts.32 
It is a plasma glycoprotein encoded by the CFH gene that is located on 
chromosome 1q32, in the Regulators of Complement Activation (RCA) gene 
cluster that includes genes with conserved structures and functions.33 It is 
produced mainly by the liver, but is also secreted by endothelial cells, monocytes, 
fibroblasts, keratinocytes, platelets, and retinal pigment epithelial cells. The 
plasma concentration of FH is approximately 1-2 μM (about 110 to 615 mg/L) 
and can reach higher concentrations when it is released locally in tissues.33, 34 
FH is composed by a single chain constituted by 1213 amino acids and it is 
formed by 20 short consensus repeats (SCRs) each composed by about 60 amino 
acids and stabilized by two internal disulfide bonds. Each SCR presents a beta-
strand rich domain and a globular conformation. FH has a bent back structure, 
with a hairpin like form, in which the C-terminus interacts with the N-terminal 
domains of the molecule.33  It has eight N-glycosylation sites on SCRs 9, 12-14, 
15 (two), 17, and 18, for a total mass of 155 kDa.33 
FH regulates AP competing with FB for the binding to C3b, inhibiting the 
assembly of the C3 and C5 convertases, and promoting convertase decay. It also 
acts as a cofactor for FI in the cleavage and inactivation of C3b.33, 35, 36 
These regulatory activities are mediated by the four N-terminal SCRs 1-4, which 
bind with high affinity the C3c part of C3b. SCRs 12-14 and SCRs 19-20 can also 
bind C3b while SCRs 19-20 are the main binding sites for polyanionic molecules 
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on cell surfaces (such as glycosaminoglycans and sialic acid). Other binding sites 
for polyanions have been found in FH SCRs 7-9. Of note, glycosaminoglycans 
and sialic acids are normally not present on microbial surfaces, so that FH cannot 
bind resulting in selective complement activation on pathogens.37 
In addition to C3b and polyanions molecules, FH can also bind CRP, pentraxin-3, 
fibromodulin, osteoadherin, chondroadherin, prion protein, adrenomedullin, DNA, 
annexin-II, and histones.38 The interactions with these molecules allow FH to 
regulate the complement activation on cell surfaces which are not protected by 
complement regulators (glomerular basement membrane, extracellular matrix, and 
apoptotic cells).38 
CFH encodes for another shorter isoform called factor-H like protein (FHL1) 
which results from an alternative splicing. It is a 43 kDa protein consisting of the 
first 7 FH SCRs and 4 additional amino acids (Ser-Phe-Leu-Thr) encoded by CFH 
exon 10. FHL1 has the same N terminal regulatory activities of FH and the SCR7 
binding site for polyanions.33 
The CFH promoter controls the expression of both FH and FHL1 which can be 
modulated by cytokines and inflammatory mediators, such as INF-γ, TNF-α, IL-1, 
IL-6, and by anti-inflammatory molecules (dexamethasone). Others molecules can 
influence FH expression such as LPS, retinoic acid and growth factors.39, 40 
1.4 Factor H related proteins 
FH belongs to a protein family that includes five factor H related proteins (FHRs): 
FHR1, FHR2, FHR3, FHR4, and FHR5. FHRs are produced from the liver and 
secreted into the circulation. All these proteins are composed by different numbers 
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of SCR units and show a high similarity suggesting conserved biological 
functions.41 
FHRs are encoded by CFHR1, CFHR2, CFHR3, CFHR4, and CFHR5 genes, 
which are located downstream from CFH on chromosome 1q32 within the RCA 
gene cluster (Figure 1-2). This cluster is characterized by large repeated genomic 
regions with high degree of sequence identity, which can increase the risk of non-
homologous recombination leading to duplication and deletion events. The most 
common rearrangement reported in CFHR genomic region is the polymorphic 
deletion of 84kb including CFHR3 and CFHR1. The allele frequency of such 
deletion has high variability across worldwide populations ranging from 0% in 
Asia to more than 50% in Africa.42  
 
 
Figure 1-2. Schematic representation of CFH and CFHR gene cluster on human chromosome 1. 
CFH, CFHR1, CFHR2, CFHR3, CFHR4, and CFHR5 genes are shown. The polymorphic deletion 
of 84kb including CFHR3 and CFHR1 is highlighted in the red box. 
 
FHR proteins are composed by different number of SCRs (Figure 1-3). The N-
terminal domains of FHRs are highly homologous to SCRs 6-9 of FH which bind 
polyanions present on cell surfaces. The amino terminal SCRs 1 and 2 of FHR1, 
FHR2, and FHR5 are highly conserved and mediate protein dimerization leading 
to FHR homodimers and heterodimers. On the contrary, FHR3 and FHR4 lack the 
N-terminal dimerization domain and circulate as monomers. The FHR C-terminal 
Introduction 
15 
 
domains show a very high homology with the FH C-terminus that includes the 
anchor site to cell surface and the C3b recognition site, suggesting the presence of 
conserved protein domains that can bind similar surface molecules.34, 41 
 
 
Figure 1-3. The FHR protein family. 
Each short consensus region (SCR) of FH and FHRs is indicated by a circle. N-terminal, central, 
and C-terminal domains of FH, FHR1, FHR2, FHR3, FHR4, and FHR5 are shown. Protein 
domains with conserved amino acid sequences and functions are shown with the same colors 
(adapted and modified from Skerka et al. Mol Immunol 2013).41 
For the purpose of this thesis, here I focus on FHR1. 
FHR1 has a plasma concentration about 70-100 ug/ml and given that FH has a 
higher mass than FHR1, the FHR1/FH molar ratio is estimated to be 0.3:1. FHR1 
circulates in two different glycosylated isoforms, alpha (37 kDa) and beta (42 
kDa). It presents a dimerization domain at N-terminus and can form homodimers 
and heterodimers with FHR2 and FHR5. It can also be present in the circulation 
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associated to high-density lipoprotein particles.34 FHR1 is composed by five 
SCRs. SCRs 1 and 2 have high degree of amino acid identity with SCRs 1-2 of 
FHR2 (97% and 100%) and with SCRs 1-2 of FHR5 (91% and 83%). The 
similarity at N-terminus SCRs 1-2 with the FH SCRs 6-7 is not very high (34% 
and 42%, respectively) while a high degree of sequence identity is present 
between C-terminal SCR3-5 of FHR1 and FH SCRs 18-20 (Figure 1-4). Of note, 
the FHR1 SCR4 and FH SCR19 are identical. There are two different FHR1 
isoforms: acidic FHR1 (called, FHR1A, pI = 7.1) characterized by SCR3 157His, 
159Leu and 175Glu and basic FHR1 (called FHR1B, pI = 7.53) with SCR3 
Tyr157, Val159 and Gln175 which corresponds to FH SCR18 (Tyr1058, Val1060 
and Gln1076) and makes SCR3 of FHR1 identical to FH SCR18. Instead, FHR1 
SCR5 differs from FH SCR20 for 2 amino acids: Leu290 (that corresponds to 
Ser1191) and Ala296 (corresponding to Val1197).34 
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Figure 1-4. Alignment of FHR1A SCRs 3-5, FHR1B SCRs 3-5 and FH SCRs 18-20. 
The SCR 3 of FHR1B is identical to the SCR18 of FH as FHR1 Tyr157, Val159, and Gln175 
correspond to FH Tyr1058, Val1060, and Gln1076. On the contrary, the SCR5 from both FHR1A 
and FHR1B is different from FH SCR20 for the presence of Leu290 and Ala296 (adapted and 
modified from Abarrategui-Garrido et al. Blood, 2009).43 
 
FHR1 has been reported to bind C3b in the C5 convertase preventing the 
progression of the complement activation mediated by C5.44 During the hemolytic 
assay performed on sheep erythrocytes, it can reduce the generation of C5a but 
not of C3a, suggesting its inhibitory activity is restricted to C5 convertase.44 
Indeed, the C5b deposition was absent on erythrocyte surfaces in presence of 
FHR1.44 Furthermore, it seems that FHR1 can inhibit the assembly of the TCC by 
binding C5 and C5b6 through its N-terminal domain, but this observation needs 
confirmation.44, 45 FHR1 does not show FI cofactor activity and C3 convertase 
decay activity.41 It is suggested that FHR1 may compete with FH for the C3b 
binding through its C-terminal domain promoting C3 convertase activity, although 
it has lower plasma concentration than FH. Furthermore, dimerization mediated 
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by N-terminal domain can increase the FHR1 ligand avidity causing an efficient 
competition with FH for the binding to the C3b. 34, 41, 45 
1.5 Mechanisms of complement evasion by pathogens 
The complement system plays a central role in defense against infections but 
across evolution some pathogens have developed several strategies to escape 
complement attack and these mechanisms are determinant for their virulence.46 
The recruitment of soluble complement regulators is a common strategy adopted 
by several bacteria, but it is also described in viruses, fungi, and parasites. In 
many microbes, C4BP, FH, and FH-like1 have been found associated to the 
pathogen cell surface proteins to give protection from complement activation (i.e. 
Escherichia coli, Borrelia spp, Neisseria spp, and Streptococcus spp). The FH 
amino acids localized at SCR20 (Arg1182, Arg1203, and Arg1206) are mainly 
involved in interaction with pathogens as described for OspE protein from B. 
burgdorferi which can bind FH SCRs 19-20.47 Other binding sites are also 
reported in FH SCR6-8. For example, Por1A protein from N. Gonorrhoaea can 
interact with both SCRs 19-20 and SCR6 of FH.47, 48 Membrane-bound regulators 
such as MCP, DAF, and CD59 are also suggested to mediate evasion mechanisms 
although the primary strategies to escape complement attack are represented by 
the soluble complement regulators.46 Another evasion mechanism consists in the 
expression of complement regulations-like proteins. Viruses like orthopoxvirus 
variola, monkeypox, and cowpox produce RCA-like proteins with typical SCR 
domain structure which show complement inhibitor activities, like cofactor 
activity and decay acceleration activity. The degradation of complement 
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components into non-functional fragments is another evasion strategy. The 
degradation of C1q is described in Pseudomonas spp and it prevents the activation 
of CP. Furthermore, properdin is degraded by Streptococcus spp and inactivation 
of C3 is reported in Pseudomanas spp and Porphyromonas spp. Other pathogens 
directly bind complement proteins leading to inhibition of their activity. 
Staphylococcus aureus through SpA protein recognizes Fc domain of IgG 
blocking the C1q binding sites. The CD59-like protein from Borrrelia burgdorferi 
and SIC protein from Streptococcus aureus inhibit MAC formation by binding its 
components. In Herpes viruses, gC1 and gC2 glycoproteins bind C3b and 
accelerate the decay of the AP C3 convertase. Other proteins which directly 
interact with the complement system have been found in parasites, such as 
Schistosoma and Trypanosoma. 17, 46 
1.6 Complement mediated diseases 
Since the complement system represents one of the most important lines of 
defence of innate immunity against pathogens, defects in its activation can 
predispose to infections. Indeed, complement deficiencies have been associated 
with several infectious diseases. The loss of the opsonization mediated by 
complement receptors CR3 and CR4 is reported to predispose to pyogenic 
infections. C2, C3, and C4 deficiency can also predispose to susceptibility for 
Neisseria, Haemophilius influenzae and other respiratory tract infections. Defects 
in terminal complement pathway that impair the complement lytic activity 
mediated by complement components from C5 to C9 can also increase the 
probability of Neisserial infections and the same applies to deficiencies in FB and 
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FD. Properdin deficiency is also reported to predispose to mortality associated to 
Neisseria meningitides infections. Interestingly, low levels of MBL in young 
children are associated with recurrent pyogenic infections and failure to thrive. 
Deficiency of complement receptors is also implicated in human infections. For 
example, CR1 expressed on erythrocytes acts as a receptor for Plasmodium 
falciparum and a low expression is reported to protect against malaria. 2, 49 
As, the role of the complement system is not limited to promote inflammation to 
fight infections, but it is also important in the clearance of apoptotic cells and 
immune complexes, some complement deficiencies predispose to the 
development of inflammation and autoimmunity. Homozygous deficiency of the 
first components of the CP (C1q, C1r, and C1s, and more rarely C4, and C2), is 
associated with an increased susceptibility to systemic lupus erythematosus 
(SLE). SLE is a systemic autoimmune disease characterized by specific clinical 
features, such as joint pain, fever, malar rash, fatigue, glomerulonephritis, and 
hemolytic anemia. The disease is associated with the presence of autoantibodies 
which appear as the consequence of the immune response induced by an 
inefficient clearance of apoptotic cells. It was observed that, on specific genetic 
backgrounds, C1q-deficient mice develop antinuclear antibodies and 
glomerulonephritis characterized by uncleared apoptotic bodies, suggesting that 
C1q is crucial to promote the clearance of apoptotic cells preventing the exposure 
of self-antigens and reducing the risk of autoimmunity.23, 50 
The complement system is finely regulated to maintain a homeostatic balance. 
When this equilibrium is perturbed by regulation defects, complement is 
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continuously activated leading to acute or chronic inflammatory diseases and also 
autoimmunity.17 
The deficiency of C1-INH leads to the uncontrolled and spontaneous activation of 
C1 with the consumption of C4 and C2. Since C1-INH is the most important 
inhibitor of plasma FXII, FXI, and kallikrein, its deficiency can predispose to 
hereditary angioedema, a rare disorder characterized by an increased vascular 
permeability and swelling caused by leakage of fluid from blood vessels into 
connective tissues.51  
CD59 and DAF are both GPI-linked molecules. In paroxysmal nocturnal 
hemoglobinuria (PNH), hematopoietic cell clones in PIGA (phosphatidylinositol 
N-acetylglucosaminyltransferase subunit A), a protein involved in the synthesis of 
GPI anchors, have been found. The result is a decreased expression of GPI-linked 
proteins, mainly CD59, which results in hemolytic anemia caused by 
complement-mediated lysis of PIGA-deficient red blood cells.52 
AP dysregulation is well documented in membranoproliferative 
glomerulonephritis (MPGN), a kidney disorder characterized by proteinuria in 
nephritic or nephrotic ranges, hematuria, hypertension, and glomerulonephritis. 
By immunofluorescence microscopy, MPGN has been reclassified in immune 
complexes mediated MPGN (IC-MPGN) and C3 glomerulopathy (C3G). IC-
MPGN is characterized by glomerular C3 staining and significant Ig and C1q 
deposition. On the contrary, C3G is characterized by dominant C3 deposition with 
no or scanty Ig and C1q. On the basis of electron microscopy C3G is subdivided 
into dense deposits disease (DDD) with osmiophilic mesangial and 
intramembranous dense deposits, and C3 glomerulonephritis (C3GN) with 
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amorphous mesangial, subendothelial, and subepithelial deposits.53 Low serum C3 
levels associated with auto-antibodies that stabilize the AP C3 convertase 
(C3NeFs, which means “C3 nephritic factors”) are observed in most C3G 
patients, especially in DDD patients.54 In rare C3G patients, autoantibodies to 
factor H, factor B or C3b have been also identified. Interestingly, genetic defects 
in genes encoding C3, FB, FH, FI and CD46 have been described in both C3G 
and IC-MPGN patients suggesting that genetic abnormalities in the AP are 
implicated in the pathogenesis of both diseases.52, 54, 55 
Genetic and acquired defects of the AP are strongly associated to atypical 
hemolytic uremic syndrome (aHUS), a rare thrombotic microangiopathy 
characterized by renal involvement.52 The details of genetic and acquired drivers 
in aHUS will be described in the next sections. 
Age-related macular degeneration (AMD) is the leading cause of visual disability 
in individuals over 60 years and is characterized by progressive dysfunction of the 
retinal pigment epithelium and visual loss.  The FH common variant 402 Hys has 
a great impact on the AMD progression because it affects the FH binding to 
glycosamminoglycans leading to accelerated protein deposition in Brunch’s 
membrane known as “drusen” which determines the progressive loss of retinal 
cells. 52, 56 
Involvement of complement are described in other inflammatory and autoimmune 
diseases, such as multiple sclerosis (MS), rheumatoid arthritis (RA), Alzheimer’s 
disease, autoimmune myocarditis, and asthma. Animal models, in which 
complement proteins are specifically manipulated, have provided strong evidence 
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of the involvement of the complement system in the pathogenesis of these 
diseases.52 
1.7 Hemolytic Uremic Syndrome  
The hemolytic uremic syndrome (HUS, also defined as typical HUS) is a rare 
disease belonging to the group of the thrombotic microangiopathies (TMAs). It is 
characterized by non-immune microangiopathic hemolytic anemia (Coombs 
negative), thrombocytopenia, and acute kidney injury. It has an annual incidence 
of 1-2 cases per 100,000 people and a worldwide prevalence around 1:10,000 
(http://www.orphanet-italia.it).57 HUS occurs mainly in children and has a good 
prognosis despite in the last outbreak in Germany (2011) many affected adults 
(88%) had severe manifestations. The typical HUS in children is also called 
STEC-HUS because it is mostly triggered by strains of Shiga-like toxin (Stx)-
producing Escherichia coli, such as O157:H7, O111:H8, O104:H4, O103:H2, 
O145, O123, O121, and O26 serotypes and other Stx-producing bacteria, such as 
Shigella disenteriae serotype 1. 
STEC infection can be acquired by humans consuming contaminated food or 
water and from contact with infected animals or humans (or their excreta). 
Diagnosis is based on detection of Stx-E. coli in stool cultures, anti-Stx or anti-E. 
coli LPS serological tests and molecular tests. After the exposure to the 
pathogens, about half of cases show hemorrhagic colitis and 3-20% of cases 
develop HUS. Seventy-percent of patients who progress to HUS need blood 
transfusions, 50% dialysis, and 25% present neurologic signs. In the developed 
countries about 5% of patients die during the acute phase of the disease.58 
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There are two Stxs, Stx-1 and Stx-2, which are characterized by different degrees 
and types of tissue damage. Both Stx-1 and Stx-2 are about 70 kDa proteins and 
are composed of a single A subunit and five B subunits. After oral ingestion, E. 
coli reaches the gut and adheres to epithelial cells. Stxs are picked up by 
gastrointestinal epithelium via transcellular pathway and translocate into the 
circulation, probably bound to circulating polymorphonuclear leukocytes. 
Through the B subunit, Stx binds the globotriaosylceramide Gb3 receptor which is 
highly expressed on glomerular endothelial cell surface. Stx-2 is 1000-fold more 
toxic than Stx-1 on human endothelial cells in vitro and this can be explained by 
its very slowly dissociation rate from Gb3. After internalization by receptor-
mediated endocytosis, Stxs are transported through the Golgi apparatus to the 
endoplasmic reticulum, where the A and B subunits dissociate. The A subunit is 
translocated to the cytosol where it blocks the protein synthesis, and to the nucleus 
where it leads to the upregulation of several genes encoding chemokines (IL-8, 
MCP-1, and SDF-1), chemokine receptors (CXCR4 and CXCR7), cell adhesion 
molecules (P-selectin, I-CAM, PECAM-1, and VCAM) and transcription factors 
(EGR-1 and NF-KB), favoring leukocyte recruitment. Stx also induces endothelial 
apoptosis by the inhibition of the expression of anti-apoptotic MCL-1 gene. 
Finally, Stxs can also directly activate platelets and inflammatory cells causing 
inflammation and microvascular thrombosis.58, 59 
The histological lesions in patients with STEC-HUS are characterized by 
thickening of arterioles and capillaries, swelling and detachment of endothelium, 
accumulation of subendothelial proteins and cellular debris, and presence of 
thrombi which obstruct endothelial vessels. TMA lesions are typically detected in 
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glomeruli but also in many other organs, such as the brain, heart, lungs, 
gastrointestinal tract, and pancreas. Abnormal or fragmented erythrocytes are also 
a clear evidence of hemolysis in blood smears.57  
The therapy for STEC-HUS is based on supportive treatments. Early antibiotic 
therapy rapidly can resolve hematologic and renal abnormalities with the 
exception of Stx-HUS by S. dysenteriae serotype 1 which can lead to death unless 
antibiotics are started early. In general, the late antibiotic treatments can increase 
the risk of complications because it might favor the acute release of large amounts 
of toxins. The anti-C5 humanized monoclonal antibody, Eculizumab, which 
blocks the terminal pathway of the complement system, was used during the last 
German STEC-HUS outbreak, alone or in combination with plasma exchange. No 
significant difference in treatment efficacy has been reported in patients who 
received the combined therapies compared with patients who received the plasma 
exchange alone.58 
Neuroamminidase producing pathogens, such as Streptococcus pneumonia have 
been also reported to be an uncommon cause of HUS. Neuroamminidase also 
called sialidases, catalyze the hydrolysis of terminal sialic acid residues from cell 
surfaces determining the exposition of the Thomsen-Friedenreich (T) antigen, 
which is recognized by IgM leading to erythrocyte agglutination, hemolysis, 
microvascular thrombosis, thrombocytopenia and the clinical picture of HUS. 
Early recognition of this form of HUS is critical to avoid therapy based on plasma 
or blood products because a lot of healthy donors contain anti-T IgM in their 
serum. The use of washed blood products has been shown to improve the 
outcome.60, 61 
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1.8 Atypical Hemolytic Uremic Syndrome 
Ten percent of HUS cases are not caused by Stx-E. coli or S. pneumonia 
infections. These patients are characterized by an uncontrolled activation of the 
AP of the complement system caused by genetic or acquire defects in AP 
complement components and regulators and the disease is defined as atypical 
HUS (aHUS). Atypical HUS is more severe than STEC-HUS, and before the 
introduction of anti-complement therapy, the clinical outcome was unfavorable: 
up to 50% of cases progressed to end-stage renal disease (ESRD) and 10-15% 
died during the acute phase of the disease.57  
Familial forms are described in less than 20% of cases of aHUS and had a poor 
prognosis: 50-80% of patients developed end-stage renal disease or died. Both 
autosomal dominant and recessive inheritance have been reported. Atypical HUS 
that develops in patients who do not have affected family members is defined as 
sporadic. 57 
The disease can be preceded by proteinuria in nephrotic range, diarrhea may 
occurs but it is not a common feature. Different triggers can be associated to the 
disease manifestation, as bacteria, virus and parasite infections (often upper 
respiratory tract and non-Stx gastrointestinal infections), cancer, organ 
transplantation, pregnancy, and anticancer therapies (mitomycin, cisplatin, 
bleomycin, and gemcitabine), immunotherapeutic agents (cyclosporine, 
tacrolimus, OKT3, and IFN), and contraceptive drugs. In about 10% of female 
patients with aHUS, the disorder develops during pregnancy or post-partum.57 
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The presence of inherited defects that determine uncontrolled activation of 
complement system on host cell surfaces has been documented in familial cases 
and also in sporadic patients with aHUS. Of note, in about 40% of sporadic cases 
no genetic defects have been found.62 
Clinical and histological features 
The diagnosis of aHUS is based on the presence of specific clinical features. The 
most important is the presence of microangiopathic hemolytic anemia which is 
defined by hematocrit less than 30%, hemoglobin less than 100 g/L, serum lactate 
dehydrogenase greater than 460 U/L, undetectable haptoglobin, fragmented 
erythrocytes in the peripheral blood smear, platelets less than 150 × 109/L and 
negative Coombs test to exclude autoimmune hemolytic anemia. Other important 
inclusion criteria for the aHUS diagnosis are the presence of acute kidney injury 
with hematuria, proteinuria and/or reduced renal function, the absence of STEC 
infections to exclude typical HUS, and ADAMTS13 activity >10% to exclude 
thrombotic thrombocytopenic purpura (TTP). Extra-renal manifestations are 
described in about 20% of aHUS patients including seizures, coma, cardiac 
ischemic events, pulmonary hemorrhage, pancreatitis, hepatic cytolysis, and 
intestinal bleeding.57 Patients with aHUS may have reduced serum levels of 
complement C3 with normal levels of C4, as a consequence of C3 activation and 
consumption through the AP. High levels of activated complement components, 
such as C3b, C3c, and C3d are also present. 
The kidney histology shows the typical TMA lesions with intima proliferation and 
thrombosis signs, which are indistinguishable from those of STEC-HUS. Patients 
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with aHUS and low serum C3 levels show high levels of C3 and C9 deposits in 
glomeruli and small arterioles during the acute phase of the disease indicating the 
presence of uncontrolled complement activation in the kidney and a local C3 
consumption. The hyperactivation of complement leads to glomerular endothelial 
cell damage and to the formation of thrombi, which consume platelets and 
obstruct blood vessels. Erythrocytes are deformed and lysed by passage through 
microvessels obstructed due to the presence of thrombi, causing hemolytic 
anemia.57 
Therapy 
Eculizumab (Soliris, Alexion Pharmaceuticals) is a high-affinity humanized anti-
C5 monoclonal antibody which binds specifically to C5 preventing its cleavage 
into C5a and C5b and blocking the generation of MAC. It is administered to 
patients with paroxysmal nocturnal hemoglobinuria (PNH) because it reduces 
intravascular hemolysis, hemoglobinuria, and the need of transfusions.63 
Successful therapy with Eculizumab has been reported in literature and clinical 
trials in more than 80% of aHUS cases.64-66 The drug is highly effective to treat 
aHUS on native kidneys and also to prevent post-transplant aHUS recurrences.67 
Eculizumab efficacy has been demonstrated both in patients with or without 
genetic defects.65 Of note, Eculizumab increases the risk of meningococcal 
infections, and vaccination in combination with antibiotic prophylaxis is 
recommended.68 Before the introduction of Eculizumab for the therapy of aHUS, 
plasma exchange was used as the gold standard in management of aHUS patients 
and it is still used if Eculizumab is not available or in the emergency treatment of 
critical patients with severe TMA.68 Plasma treatments reduced the mortality rate 
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in aHUS patients from 50% to 25%. Plasma exchange appears more effective than 
plasma infusion because it eliminates toxic molecules and mutant proteins from 
the circulation.57 Plasma therapy induced remission also in patients with genetic 
mutations in complement system. In some patients with severe hypertension and 
extensive microvascular thrombosis, bilater nephrectomy has been performed to 
achieve blood pressure control.57  
Genetics  
Dysregulation or hyperactivation of the AP of complement system are the main 
causes of aHUS. In about 40% of familial cases the complement activation is 
related to the presence of loss-of-function mutations in the CFH but also 10-20% 
of sporadic cases show CFH genetic abnormalities.62 The large majority of CFH 
mutations are heterozygous point mutations which lead to amino acid changes or 
to truncated proteins and cluster mainly in the C-terminal part of FH which is a 
crucial domain for the FH binding to the endothelial cells and to ensure FH 
mediated surface protection from the complement activation.69 Since FH can form 
oligomers through its C-terminus, the presence of heterozygous defects in this 
domain can lead to a dominant negative effect, caused by the functional blocking 
of the wild type FH.70 Anyway, in most cases, the haploinsufficiency is the 
mechanism that determines the aHUS phenotype, as documented by hemolytic 
assay in which the lysis of sheep erythrocytes occurs in presence of serum from 
aHUS patients carrying heterozygous mutations in CFH and is stopped addition of 
normal serum.71 Homozygous mutations have been found in about 15% of 
patients and lead to complete FH deficiency and very low C3 levels. 
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Genomic rearrangements in CFH-CFHR cluster have been also described in a few 
aHUS cases and are favored by the presence of repeated regions with a high 
degree of sequence identity. CFH/CFHR1 and CFH/CFHR3 hybrid gene and 
CFHR1/CFH reverse hybrid genes which encode FH/FHR1, FH/FHR3, and 
FHR1/FH fusion proteins have been reported in both familial and sporadic cases. 
Functional studies have demonstrated that CFH/CFHR1 and CFH/CFHR3 hybrid 
genes can determine a complement dysregulation at cell surface since the C-
terminal domain of FH is substituted by the C-terminal domain of FHR1 leading 
to the formation of an abnormal regulator which is less efficient to protect 
endothelium than FH. Instead, CFHR1/CFH reverse hybrid gene was described to 
be a strong competitor of FH for the binding to the cell surface since during the 
hemolytic assay addition of purified FHR1 from heterozygous CFHR1/CFH 
hybrid gene carriers determined a dose-dependent sheep erythrocyte hemolysis 
compared to the addition of equal amounts of purified FHR1 from normal serum 
which had no effect.72-76 
Genetic abnormalities have been also found in other regulatory proteins of the AP, 
such as CD46 and CFI.62, 77-79 Mutations in CD46 are present in about 10-15% of 
aHUS cases and are usually heterozygous mutations, although also homozygous 
or compound heterozygous mutations have been found. CD46 mutations usually 
affect the extracellular domains of the protein which are implicated in the C3b 
binding and in the cofactor activity for factor I.80, 81 Mutation in CFI are described 
in 5-10% of patients with aHUS. Only heterozygous mutations in CFI are 
reported in literature and the most of them cluster in the serine protease domain. 
Half of patients with defects in CFI shows low FI plasma levels.80, 82 
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Heterozygous mutations in CFB and C3 are reported in about 2% and 4-10% of 
aHUS cases, respectively. Some defects in C3 gene can lead to impaired binding 
of C3b to the regulator MCP and thus resistance to cleavage by FI.83 Instead, other 
C3 abnormalities can increase the binding affinity of C3 to FB causing a more 
stable C3 convertase.84 Mutants of FB are gain-of-function mutations which lead 
to an enhanced formation of the C3 convertase that is resistant to the inactivation 
mediated by complement regulators.85 
Incomplete penetrance of the disease suggests that additional genetic factor and/or 
environmental hits are necessary for aHUS manifestation. In about 3% of aHUS 
patients combined mutations are reported: 25% of patients with mutations in 
CD46 and CFI also carried defects in other genes while only 8-10% of patients 
with CFH, C3, and CFB defects also carry other mutations suggesting that these 
mutations are sufficient alone to predispose to aHUS.86 Moreover, about half of 
the individuals carrying CFH or CD46 mutations are healthy subjects suggesting 
that these mutations could be predisposing for the disease development but need 
other risk factors for the disease to manifest.80 
Also common variants in CFH (single nucleotide polymorphisms, SNPs) have 
been described to increase the risk to development of aHUS in subjects carrying 
mutations in complement genes. CFH c.1-332 C>T (rs3753394), c.2016 A>G 
p.Gln672Gln (rs3753396), and c.2808 G>T p.Glu936Asp (rs1065489) are found 
to be predisposing factors in aHUS patients.87 No evidences of functional effects 
have been reported for these CFH variants, but all of them belong to the H3 CFH 
haplotype (CFHTGTGGT), which is defined by c.1-332T (rs3753394), c. 184G 
p.Val62 (rs800292), c.1204T p.Tyr402 (rs1061170), c.2016G p.672Gln 
Introduction 
32 
 
(rs3753396), IVS15 −543G intron 15 (rs1410996) and c.2808T p.936Asp 
(rs1065489), and it is strongly associated with aHUS risk.88 Furthermore, 
Bernabeu et al. observed the presence of an extended CFH-CFHR3-CFHR1 
haplotypes defined by the CFHR3 SNPs rs446868, rs138675433, and 
rs138675433 and the CFHR1 SNPs rs4230, and rs414628 in addition to the CFH 
SNPs above described. The extended CFH(H3)-CFHR3*B-CFHR1*B haplotype 
was found  to be strongly associated with aHUS and with lower FH levels.89 The 
FH 402Hys variant which has no direct effect on complement activation but can 
influence the binding of FH to cell surface, has not been found in association with 
aHUS but it can increase the risk for AMD and DDD, despite conflicting results 
have been reported in a recent study on DDD in which no significant association 
between FH 402Hys and the disease was present55, 90, 91. Functional studies on FH 
62Ile variant have demonstrated that is able to increase the FH ability to bind to 
C3b which leads to an enhanced cofactor activity and iC3b formation. This 
variant is associated with a lower risk to develop aHUS, AMD, and DDD.92, 93 
Esparza-Gordillo et al. described a MCP haplotype (MCPGGAAC), which is defined 
by c.1-652G (rs2796267), c.1-366G (rs2796268), c.1-78A (rs1962149), 
c.1+638A (rs859705) and c.1+4070C (rs7144), as predisposing to an increased 
risk of aHUS.94  
Other common polymorphisms in FB and C3 were reported to influence the risk 
to develop human immune-mediated diseases despite they have never been 
described in association with aHUS. The FB 32Gln variant shows a lower affinity 
for C3b compared to the Arg variant and forms the AP convertase less efficiently. 
The FB 32Gln is a protective variant for AMD but it is a predisposing genetic 
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factor in infections and is overrepresented in autoimmunity.92 The C3 102Gly and 
314Leu variants also increase the risk of DDD and are also associated with IgA 
nephropathy, systemic vasculitis, and kidney allograft dysfunction.92, 95 Harris et 
al. showed that although each polymorphism can determine only a small change 
in complement activity, the presence of an inherited set of the more active 
common variants (defined as “complotype”) can contribute to the inflammatory 
disease phenotype.96   
Of note, abnormalities in complement genes were reported in about 60% of aHUS 
cases and also acquired defects, such as antibodies against FH and FI have been 
described.97, 98 Others aHUS cases can be determined by genetic drivers not 
belonging to the complement system. Important pathways that are linked to the 
complement system are the coagulation and the fibrinolysis. Indeed, 
coagulation/fibrinolytic proteins such as Thrombin, FXIa, FXa, FIXa, and plasmin 
can directly cleave C5 and C3 determining the activation of complement 
independently from other complement components.13  Alterations in proteins of 
the coagulation/fibrinolytic pathway, like thrombomodulin (THBD) and 
plasminogen (PLG) have been reported in aHUS cases.31, 99 Heterozygous 
missense mutations in THBD are reported in about 5% of aHUS cases and in vitro 
studies have demonstrated that they can determine a moderate reduction of THBD 
expression on cell surface and an inefficient regulation of the complement AP 
activation caused by a defect of FI-mediated C3b inactivation.31 Moreover THBD 
abnormalities cause impairment in thrombin activatable fibrinolysis inhibitor 
(TAFI) activation impairing the degradation of C3a and C5a. The THBD common 
variant Ala473 has been also reported to be associated to an increased risk to 
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develop C3G.55 PLG mutations are reported to affect about 5% of aHUS patients. 
Three PLG variants which cause plasminogen deficiency have been found in 
aHUS patients suggesting that a decreased activity of plasminogen/plasmin can 
predispose to aHUS caused by inefficient thrombi degradation.99 
A rare recessive form of aHUS is associated with mutation in DGKE which 
encodes the diacylglycerol kinase-epsilon kinase. Arachidonic acid-containing 
diacylglycerols (DAG) activate protein kinase C, promoting thrombosis and 
DGKE can inactivate DAG, producing phosphatidic acid which confers protection 
from thrombi formation. Loss of function mutations in DGKE have been found in 
aHUS patients with a disease onset before 1 year of age. These mutations lead to 
the activation of endothelium, complement activation and prothrombotic 
phenotype.100, 101 
Cobalamin C deficiency is also another non-complement form of HUS. It is rarer 
than complement mediated aHUS and it is determined by a recessive disorder of 
vitamin B12 metabolism. It is caused by mutations in MMACHC gene which are 
associated to methylmalonic aciduria and homocysteinuria, conditions 
characterized by elevated levels of methylmalonic acid and homocysteine and 
decreased methionine.102 
1.9 Anti-FH antibody mediated aHUS 
In 2005 Dragon-Durey et al. described the presence of auto-antibodies against FH 
(anti-FHs) in three children affected by aHUS who presented recurrent disease, 
identifying for the first time an autoimmune form of aHUS.98  
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Detection of anti­FH antibodies in aHUS patients and in healthy controls 
The presence of anti-FH antibodies (anti-FHs) was evaluated by Dragon-Durey et 
al. using an ELISA assay in which 5 μg/mL of purified FH were coated on a plate 
(Nunc MaxiSorp, Roskilde). After washing and blocking with PBS with 1% BSA, 
1:50 diluted patient plasma was incubated for an hour at room temperature. After 
washing, goat anti-human IgG antibody specific for γ chain and conjugated with 
horse radish peroxidase (Sigma Aldrich, Steinheim), was incubated for an hour at 
room temperature. After the last washing, peroxidase activity was revealed with 
orthophenyldiamine substrate. The reference sample used for titration curve was 
collected from one patient at month 6 of follow up, used at 1:200 dilution and 
arbitrary considered to have 1000 AU/ml (Arbitrary Units). Optical density higher 
than the mean +2SD of those obtained in 50 healthy controls was considered 
positive. Antibody titer was calculated as: (sample absorbance – blank 
absorbance) x 1000 / (absorbance of reference positive sample at 1/200 dilution – 
blank absorbance). These 3 patients showed 2323, 317, and 1830 arbitrary 
units/ml (AU/mL), respectively at the beginning of the follow up (FU start: day 0, 
2 months, and 3 months after onset, respectively) and 955, 1162, and 2160 
AU/mL respectively at the end of the follow up (FU end: 18 months, 27 months, 
and 29 months after disease onset, respectively).98 
Another assay to detect anti-FHs in plasma samples was described by Goodship et 
al.103 According to the Goodship’s method (Newcastle), the blocking was 
performed with 200 ul of AbDserotec, and a duplicate plate was set up in absence 
of FH coating in which only blocking solution was added to evaluate the presence 
of non-FH specific readings caused by high background. Goat anti-human IgG 
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antibody conjugated with horse radish peroxidase (Stratech Scientific) was 
incubated. After washing, tetramethyl benzidine (TMB) was used as peroxidase 
substrate and the absorbance was detected at 450 nm. The absorbance derived 
from the well background in which the coating was performed with blocking 
solution only in the absence of FH, was subtracted from the sample absorbance 
obtained in presence of FH coating. The reference sample was a known positive 
sample provided by Dr. Dragon Durey and it was arbitrary established to have 
100,000 relative units at 1/25 dilution. The antibody positivity threshold was 
considered to be the 97.5 percentile obtained studying 100 healthy controls and it 
was 350 relative units.103  
Late, research groups of The European Working Party on Complement Genetics 
in Renal Disease have worked together to set up a standard procedure to evaluate 
anti-FHs.104  First of all, Paris and Newcastle methods were used to study 36 
plasma samples which were positive (n=12), negative (n=12), and with high 
background (n=12). In a second step the Jena research group repeated the assay in 
their laboratories using the Newcastle and Paris methods. Then all the methods of 
all the participants (London, Madrid, Helsinki, and Lund research groups) were 
tested. The last step was to evaluate the commercial assay which was performed 
according to the manufacturer’s instructions (Abnova, Taiwan).104 
This integrated study showed that the Paris method is highly reproducible, robust, 
cost effective, and easy to set up. All the methods tested gave consistent results 
with some exceptions caused by high background samples or when the antibody 
titer was very low and likely irrelevant for the disease. It was recommended to use 
a common positive sample for the titration curve and a common negative sample 
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to ensure sufficient range is present in absorbance readings. It is also important to 
use a sample specific subtraction to exclude the presence of false positive samples 
caused by hemolysed, lipidemic, or rheumatoid factors. The presence of no-serum 
control is also recommended to ensure the absence of contaminants. The 
commercial assay seems to underestimate the levels of anti-FHs and the lack of 
background subtraction can increase the risk of false positive samples.104 
The consensus protocol based on the Paris method was the following:  
ELISA plate (NUNC) coated with 50 ul/well of purified FH (Calbiochem) at 5 
μg/mL in PBS (137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.76 mM 
KH2PO4, pH 7.4) and incubated overnight at 4°C. Plate washed with PBS and 
then blocked with PBS/0.1% Tween/well (200 ul PBS-T) for 1 hour at room 
temperature. A second replicate plate should be incubated with blocking solution 
only. Plasma/serum samples diluted 1/50 and analyzed in triplicate. For standard 
curve a known positive sample diluted from 1/25 to 1/3200. Plate washed 3 times 
with PBS-T. Sample, negative control, positive control, and no-serum control 
incubated for 1 hour. Three washes with PBS-T. Incubation of 1/500 conjugated 
horseradish peroxidase (HRP) goat anti-human IgG for 1 hour. Three washes with 
PBS-T. TMB added for 5-10 min, the reaction stopped with 10% H2SO4 and 
OD450 nm readings obtained. The readings from plate incubated with only 
blocking solution subtracted from readings derived from the factor H coated 
plate.104 
Introduction 
38 
 
Prevalence and pathogenicity of anti­FHs 
Following studies in other aHUS cohorts confirmed the presence of anti-FHs in 5-
11% of aHUS cases in European cohorts, with a very high proportion of pediatric 
cases (prevalence in children is 13-30%).43, 105-109 Interestingly, the prevalence of 
anti-FHs dramatically increased to 56.1% in aHUS cases in India.110 Of note, anti-
FHs have been described also in 1-4% of healthy subjects.103, 111-113 Also 4 out of 
21 healthy siblings reported in the Indian cohort by Sinha et al. showed high 
antibody titers ranging from 497.9 to 1356.6 AU/mL.110 
The anti-FHs were detectable in plasma/serum samples collected in both acute or 
remission phases of the disease. Especially during the acute phase anti-FHs can 
circulate with FH as immune complexes which can also be detected by ELISA 
assay.114  
Plasma samples from patients with anti-FHs were able to induce the lysis of sheep 
erythrocytes which was proportional to the antibody titer. The hemolysis was 
reduced with the addition of FH or using IgG depleted serum. In vitro studies 
demonstrated that the purified anti-FH IgGs can lead to a reduced FH binding to 
C3(H2O), C3c, and C3d and can also decrease the ability of FH to promote the C3 
convertase decay. The Fab’2 fractions also inhibited the FH activity. Anti-FHs 
can modify the FH cofactor activity for the cleavage of C3b by FI.109, 114, 115  
Clinical features and complement profile of patients with anti­FHs 
Anti-FHs affected mainly children and the age at the disease onset was reported to 
be between 5 and 15 years.109 It is different from the disease onset described in 
aHUS patients carrying mutations in CFH or DGKE mutations that occurs mainly 
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in the first years of life.62, 100 On the contrary, it is more similar to the disease 
onset described in patients with CD46 mutations.62, 109 Only few adult cases with 
anti-FHs were reported in literature.62, 106 No gender difference was described.106 
Most aHUS cases with anti-FHs presented prodromal signs. The large majority 
showed fever, upper respiratory tract infections or gastrointestinal signs (such as 
vomiting, diarrhea, and abdominal pain). Prodromal varicella, norovirus, STEC 
and Plasmodium vivax infections have been also reported.106, 110 Other patients 
showed urticaria, transient face edema, and seizures at the disease onset.106At the 
time of hospitalization, most patients presented thrombocytopenic anemia, 
oligoanuria, hematuria, and severe hypertension. As reported by Dragon-Durey et 
al., hepatitis and pancreatitis were observed in many patients and anti-nuclear 
antibodies were found in 24% of tested patients, but this association was not 
confirmed in other studies.106 
Low C3 levels were reported in about half of patients with anti-FHs indicating the 
AP of complement was activated. C4 was normal in the large majority of them. 
The FH antigen levels were not reported to be correlated with the anti-FH titer 
despite in the acute phase of the disease decreased in few patients.109 
Outcome, therapy and transplant 
Atypical HUS relapses have been reported in a variable number of patients with 
anti-FHs in different studies (ranging from 13% to about 50%) and in the large 
majority of cases occurred within one year from disease onset.109 Dragon-Durey et 
al. reported that 27% of patients developed ESRD during a follow up of 39 
months.106 Sinha et al. also observed a high prevalence of renal failure in 33.6% 
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of patients at the last follow up.110 Plasma infusion was adopted in some patients 
but plasma exchange was more effective to induce hematological remission 
because it can remove autoantibodies from the circulation and provide free FH 
(but also FHR1) that can compete with FH for the antibody binding.116 Despite 
plasma exchange treatment, about 35% of aHUS patients with anti-FHs developed 
ESRD or died.109 Moreover, after plasma exchange, the antibody titer can increase 
with a high risk of relapses. For this reason prolonged immunosuppression is 
often used (prednisone, cyclophosphamide, rituximab, and mycophenolate 
mofetil, with different protocols) to prevent or control the new formation of anti-
FHs. The combined plasma exchange and immunosuppression treatment has been 
reported to be more effective therapy to protect renal function and to prevent 
aHUS relapses than plasma therapy alone (only 14.3% of patients with combined 
therapy developed ESRD or died).109, 110, 117 
A few aHUS cases with anti-FHs, in which Eculizumab therapy was adopted,  
resulted in the remission of the disease, discontinuation of plasma exchange, and 
renal recovery in the majority of patients.118-120 However, Eculizumab cannot 
prevent the generation of anti-FHs and thus combined immunosuppressive 
treatments are needed.109 
TMA recurrence after kidney transplantation was described in about 20% of 
aHUS cases with anti-FHs (total transplanted patients, n=21).109 In the group of 
aHUS patients with anti-FHs who received a preventive therapy based on plasma 
exchange and immunosuppression before the transplantation (n=9), only one 
patient developed TMA recurrence on the graft and two patients lost the graft for 
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acute rejection.109 Eculizumab was used as successful approach to prevent the 
disease recurrence on the graft in two cases.109  
Antibody isotypes and FH epitopes recognized by anti­FHs  
Antibody isotypes in patients with aHUS included mainly IgG and less frequently 
IgA. The identified IgG subtypes were IgG3 (present in 60-100% of tested 
samples) and IgG1 (rarely alone but present in 30% of tested samples in 
combination with IgG3).109 
Anti-FHs bind multiple FH epitopes mainly located at the FH C-terminal domain 
which is a mutation hotspot in aHUS, indicating that both anti-FHs and CFH 
genetic abnormalities have similar functional consequences on FH regulatory 
activity on cell surfaces.115 Anti-FHs recognized FH SCRs 15-20 in 97% of tested 
samples (63/65) and FH SCRs 19-20 in 77% of tested samples (48/62), as 
reported in literature.109 On the contrary, among 21 tested samples, none showed a 
binding activity to FH SCRs 15-19, indicating that the main target domain of anti-
FHs is the FH SCR20.109 Bhattacharjee et al. identified the autoantibody epitopes 
on FH SCR20 using FH mutants at the residues Thr1184, Lys1186, Lys1188, 
Leu1189, and Glu1198 which overlap with the heparin and glycosaminoglycans 
cell binding sites and also the amino acids used by microbes to bind FH and evade 
the immune system.121 Trojnar et al. performed a linear epitope mapping using 
synthetic FH peptides and validating the results with recombinant FH carrying 
point mutations. The results showed the anti-FHs specifically recognized FH 
epitopes at 1157-1171 (SCR 19), 1177-1191 and 1207-1226 (both in SCR 20) 
residues. The linear FH binding sites are located close to each other in the protein 
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tertiary structure, suggesting that the antibody binding site can be the result of 
specific FH conformation during the protein folding.122 
Although FH C-terminus is the main domain recognized by autoantibodies, others 
FH domains can be recognized. FH N-terminal SCRs 1-4 have been found to bind 
antibodies in 36% of tested aHUS samples (15/42) while SCRs 1-7 and SCRs 8-
14 are recognized in 36% (23/63) and 21% (12/56) of samples.109  
Genetics of anti­FH mediated aHUS 
The most important genetic finding in the study of the anti-FH mediated aHUS is 
the association with the FHR1 deficiency that is present in about 80-90% of aHUS 
patients with anti FHs.43, 105, 107, 108, 110, 123 For this reason the autoimmune form of 
aHUS was also defined as DEAP-aHUS, which means Deficiency of FHR plasma 
proteins and Autoantibody Positive form of Hemolytic Uremic Syndrome.124 
The large majority of aHUS patients with FHR1 deficiency was found to carry the 
homozygous CFHR3-CFHR1 deletion, which is a common polymorphism that 
has variable frequencies among human populations.42 A high frequency of the 
deleted allele is observed in DNA samples of healthy controls from South-
Saharan Africa and Nigeria (33.7% and 54.7%, respectively), it is around 15-25% 
in European Caucasoid populations and very low in East Asia and South 
America.42 This means that about 30% of Nigerian, 3-10% of the European, and 
about 0% in East Asia and South America are homozygotes for the deleted allele. 
About 15% of aHUS patients with anti-FHs were compound heterozygous for the 
CFHR3-CFHR1 and CFHR1-CFHR4 deletion.43, 107 The CFHR1-CFHR4 deletion 
was detected in about 0.9% of healthy subjects and it was not reported to be 
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abundant in aHUS patients with anti-FHs, but the concomitant presence of 
CFHR3-CFHR1 and CFHR1-CFHR4 deletions is significantly more frequent in 
aHUS patients with anti-FHs compared to healthy individuals. This observation 
suggests that the complete CFHR1 lack is the crucial genetic factor associated 
with the production of factor H autoantibodies in aHUS. Further confirmation is 
given by the fact that other very rare patients have shown the CFHR3-CFHR1 
deletion combined with nonsense CFHR1 mutation, which leads to FHR1 
truncated protein, or the homozygous CFHR1-CFHR4 deletion.43  
Whether the few healthy controls with anti-FHs reported in literature carry the 
homozygous CFHR1 deletion is not known, but all the four healthy siblings with 
high anti-FH titers described in Sinha et al. presented the homozygous CFHR1 
deletion.110 This finding could indicate that the CFHR1 deletion could have a 
main role in the predisposition to anti-FHs, although the presence of anti-FHs in 
healthy subjects could suggest that additional factors are required for the disease 
to manifest. 
The deleted CFHR3-CFHR1 allele was also reported to be a risk factor for SLE 
and hematopoietic stem cell transplantation-related thrombotic 
microangiopathy.112, 125 On the contrary it was a protective allele for AMD and 
IgA nephropathy.126, 127 Interestingly, anti-FHs mediated aHUS was more 
abundant in India than in Europe but this regional difference did not reflect the 
CFHR1 deletion frequency, which was rarer in India than in Europe. Furthermore, 
in Nigeria where the homozygous CFHR3-CFHR1 deletion is present in 30% of 
the population an increased risk of aHUS has been not been described. At 
variance, in IgA nephropathy, a direct correlation between the prevalence of the 
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disease and the frequency of the CFHR3-CFHR1 deletion was observed. Indeed, 
IgA nephropathy was more common in East Asia where the protective allele is 
very rare and less common in Africans in whom the protective allele is 
abundant.34 
The pathogenic mechanism that links the FHR1 deficiency with the risk of anti-
FH development is still under investigation. Atypical HUS associated anti-FHs 
cross-reacted with FHR1 SCRs 4-5 which show a very high amino acid sequence 
identity with SCRs 19-20 of FH.116 In this region indeed the only two amino acid 
differences are Leu290 (that corresponds to FH Ser1191) and Ala296 (that 
corresponds to FH Val1197). The addition of FHR1 reduced the sheep erythrocyte 
hemolysis in a dose-dependent manner during the hemolytic assay in presence of 
purified anti-FHs from aHUS plasma, an effect similar to that of the addition of 
FH.116 FH and FHR1 were both recognized by autoantibodies but the backbone 
and the loops of the auto-antigenic epitopes localized in FH SCRs 19-20 
(Arg1182-Leu1189) and FHR1 SCRs 4-5 (Arg281-Leu288) showed a different 
orientation at X-ray. The main difference is the formation of a prominent alpha 
helix in the loop Arg281 through Leu288 of FHR1 SCR5 while in the 
corresponding FH SCR20 region it was not observed. Interestingly, an altered 
conformation of the loop Arg1182 through Leu1189 of FH SCR20 is observed 
when FH was bound to its natural ligands (such as Borrelia OspE protein, sialic 
acid glycan, and C3b). This finding has suggested a model to explain the origin of 
the autoantibodies toward FH. It is possible that some of the microbial proteins, 
that bind FH SCRs 19-20, can induce a conformational modification of FH 
molecule which is similar to that spontaneously reached by FHR1. Whether the 
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FH epitope bound by the microbial protein is not masked during this binding it 
can generate the formation of an autoantigenic neoepitope which can lead to the 
risk of autoimmunity in the absence of FHR1. Indeed, in individuals with FHR1, 
an FHR1 epitope similar to the hypothetical FH autoantigenic epitope is present 
and it can guarantee the tolerance to FH.121  
In addition to FHR1 deficiency, other defects in genes encoding complement 
proteins have been reported in about 15% of aHUS patients with anti-FHs43, 105, 
107, 109, 128, 129. 
Heterozygous mutations in CFH were found in 5 patients (5% among 95 tested 
patients). The CFH c.2850G>T, p.Gln950His was reported in 2 of these patients 
(other genetic variants were not specified). Heterozygous CD46 mutations have 
been described in 2 patients with anti-FHs (2%, among 95 tested patients) and one 
of them did not show the FHR1 deficiency (carrying the CD46 c.718T>C, 
p.Ser240Pro). Heterozygous CFI mutations were described in 3 patients (3%, 
among 95 tested patients) and 2 of them showed the absence of FHR1 (in these 
last 2 patients the CFI mutations were c.1071T>G, p.Ile357Met and p.1216C>T, 
p.Arg406Cys). Three patients were carriers of C3 heterozygous mutations namely 
c.-3_-2dup and c.1898A>G, p.Lys633Arg in combination with the homozygous 
CFHR1 deletion in two patients, and c.481C>T, p.Arg161Trp alone in the third 
patient. Heterozygous CFB mutations were not reported in literature in 
combination with anti-FHs. Of note, a patient with anti-FHs showed a 
heterozygous mutation in THBD and another one was a compound heterozygotes 
for FXII gene mutations c.9277T>G, p.Trp222Gly and c.10468C>A, p.Arg447Ser 
which lead to a complete FXII deficiency. Most of the above mutations have 
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functional effects by in vitro assays or are predicted as damaging by in silico 
analyses. 109 
Not enough studies have been done to clarify the role of common variants in 
complement genes in the predisposition to anti-FHs mediated aHUS. Moore et al. 
reported the presence of CD46GGAAC haplotype in 10 out of 13 patients with anti-
FHs while only one presents the CFH H3 haplotype.107 Interestingly, the authors 
also reported that 12 out of 13 aHUS patients with anti-FHs carried the CFH “A” 
variant at the rs3753396 and “G” variant at rs1065489 suggesting a possible role 
of particular CFH haplotypes in predisposing to development of anti-FHs.107 
1.10 Anti-FHs in other diseases 
Anti-FHs antibodies have been reported in 23 patients affected by C3G or 
MPGN.103, 109, 130 Most C3G/MPGN patients were adults and showed low C3 
levels. In 30% of them anti-FHs were present in combination with C3NeF, which 
are auto-antibodies directed against AP C3 convertase C3bBb, preventing the Bb 
dissociation and leading to a more stable C3 convertase.109 Anti-FHs in 
C3G/MPGN patients recognized the FH N-terminal domains (SCRs 1-5) although 
additional binding sites have been found in the central and C-terminal domains. 
These findings are at variance with anti-FHs associated with aHUS which mainly 
target the C-terminus surface recognition domain of FH. Anti-FHs purified from 
C3G/MPGN patient samples were not able to decrease the binding of FH to C3, 
C3c, and C3d as occurred with anti-FHs derived from aHUS patients. Blanc et al. 
detected very low levels of FH-anti-FH immune complexes in C3G/MPGN 
patients.130 Taken together these data suggested that anti-FHs from C3G/MPGN 
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patients present a weaker avidity for FH compared to anti-FHs from aHUS 
patients. Interestingly, the homozygous CFHR1 deletion, which is found strongly 
associated with anti-FHs in aHUS, was not reported to predispose to anti-FH 
development in C3G/MPGN.103, 130 
Anti-FHs were also reported in a 17 year-old Caucasian woman with very low 
levels of ADAMTS13 and FH caused by anti-ADAMTS13 and anti-FH 
antibodies, in whom a combined diagnosis of thrombotic thrombocytopenic 
purpura (TTP) and HUS was done.131 Anti-FHs were also found in a consistent 
percentage of patients with rheumatic diseases, such as RA and SLE, in few 
patients with non-small-cell lung cancer, and in individuals who have developed 
TMA post hematopoietic stem cell transplantation.111, 112, 132 Recently, Senant et 
al. have shown anti-FHs in inflammatory myopathies (50% of patients with 
pediatric myositis and 43% of adults with myositis).133 Of note, the homozygous 
CFHR1 deletion was not reported in association with anti-FH formation in all 
above diseases with the only exception of aHUS. 
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1.11 Immunologic tolerance 
Lymphocytes are the principal components of the adaptive immunity. They are 
specialized for the recognition and the response to foreign antigens. Specifically, 
B lymphocytes are the only cells able to produce antibodies which recognize 
soluble antigens while T lymphocytes have membrane receptors (TCRs) which 
can interact with peptides derived from intracellular microbes displayed on host 
MHC (Major Histocompatibility Complex) molecules present on APCs. T 
lymphocytes are classified by different cell populations: 1) CD4+ Helper T cells 
which are specialized in secreting cytokines that stimulate the proliferation and 
differentiation of T cells themselves, B cells, and macrophages; 2) CD8+ 
cytotoxic T lymphocytes which kill cells infected by viruses; 3) regulatory T 
lymphocytes (Tregs), which can inhibit the immune response.  
In the thymus and bone marrow, the DNA encoding TCR and B cell receptor 
(BCR) of the immature T and B lymphocytes, respectively, randomly recombine 
and some rearrangements can obviously generate receptors able to recognise self-
antigens determining a potential risk for autoimmunity. To avoid this problem, 
immunologic tolerance has evolved in the adaptive immune system. Immunologic 
tolerance is defined as the unresponsiveness of B and T lymphocytes to an antigen 
induced by its previous exposure and is mediated by central and peripheral control 
mechanisms. Central tolerance leads to the maturation of lymphocytes which do 
not respond to self-antigens and eliminates immature lymphocytes which react 
against self-antigens. Since some self-reactive cells can escape the central 
tolerance control, a peripheral tolerance is needed to induce the apoptosis of 
escaped self-reactive lymphocytes, to prevent the activation of these potentially 
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reactive lymphocytes, and also to induce the tolerance to self-antigens that are 
expressed only in adults. Tregs cells are also important suppressors of auto-
reactive T cells contributing to the peripheral tolerance.134 
T lymphocyte central tolerance 
During the maturation in thymus, T lymphocytes with TCRs recognizing with 
high avidity self-antigens, which are presented on class I or II MHC molecules 
expressed on dendritic or epithelial cells in thymus, are induced to apoptosis and 
deleted (negative selection). Moreover, some of the T lymphocytes that recognize 
self-antigens are committed to the CD4+ lineage developing into Treg cells.  
In the thymus all the self-antigens of our organisms are represented: some of them 
are ubiquitously expressed, others are taken in from the blood circulation and 
others, which are tissue specific antigens (TSAs), such as insulin, are expressed in 
thymus by specialized medullary thymic epithelial cells (mTECs) through an 
elegant mechanism mediated by the AutoImmune REgulator (AIRE).134  
The human AIRE is a transcriptional factor which acts as a coactivator in a large 
transcriptional complex promoting the expression of more than 3000 different 
proteins, especially TSAs in thymus mTCEs.135 AIRE is a protein of about 56 kDa 
characterized by five domains: an oligomerization domain called CARD, the 
Nuclear Location Signal crucial for the migration of the protein to the nucleus; the 
SAND domain involved in the protein-protein interaction and two PHD domains, 
which are important in the interaction with chromatin and in its decondensation.136 
Mutations in AIRE have been found in patients affected by “Autoimmune 
polyendocrinopathy candidiasis ectodermal dystrophy”, APECED, also called 
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“Autoimmune Polyendromic Syndrome type 1” (APS1). The disease is 
characterized by development of auto-antibodies against multiple targets and 
lymphocyte mediated infiltration in several endocrine organs.136 In Aire-/- mouse 
model, the TSAs expression in thymus decreased, auto-antibodies against self-
antigens were detected, Treg population decreased, and activated self-reactive T 
cells were present in periphery leading to a general autoimmune reaction similar 
to that found in APS1 patients.136 The expression of AIRE is finely regulated by 
both negative and positive mechanisms and this leads to its expression in only a 
small percentage of mTECs (1–3%).135 Through its PHD domain, AIRE seems to 
recognize epigenetic marks at the promoter of TSAs, such as H3K4me and 
H3K27me3, and acts forming a complex with other transcriptional activators 
(such as pTEFb complex, CBP, DNA-PK, TOP2A, and SIRT1) which leads to 
chromatin modifications, to the recruitment of RNA polymerase II, and to the 
beginning of the transcription. Kumar et al. described that AIRE dimers and 
tetramers can recognize DNA sequence containing G-doublets with the 
ATTGGTTA motif and the TTATTA box. Through competition assays the 
authors demonstrated that sequence with one TTATTA motif and two tandem 
repeats of ATTGGTTA had the highest binding affinity for AIRE.137  
The expression of TSAs in the thymus and its relevance in autoimmune diseases 
have been demonstrated in genetic studies in which gene variants that affected 
thymus expression of human insulin and acetylcholine receptor determined 
susceptibility T1D and myasthemia gravis, respectively.138, 139 
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T lymphocyte peripheral tolerance 
In addition to the central tolerance, mechanisms such as anergy, suppression 
mediated by Treg cells, and apoptosis can maintain the immunologic tolerance 
also in periphery.134 
 Self-reactive T cells become anergic 
The full activation of peripheral T cells requires the recognition of self-antigens 
by TCR and also the production of costimulatory signals by APCs (such as B7-
1/CD80 and B7-2/CD86) which bind CD28 receptor on T cells. If the TCR binds 
self-antigen-MHC complex for prolonged time in the absence of CD28 activation, 
T cells become unresponsive to that antigen leading to anergy.134 
The anergy can be obtained not only with the absence of the costimulatory 
molecules but also with the engagement of inhibitory receptors on T cells, which 
also have an important role in self-tolerance. CTLA-4 is an inhibitory receptor 
which belongs to the CD28 receptor family and binds B7 molecules with higher 
affinity compared to CD28. It is expressed on CD4+ T cells and it is important to 
control the initial activation mediated by antigen-MHC-TCR interaction in 
lymphoid organs. It is also expressed on Treg cells and mediates their suppressive 
activity.140 Knockout mice for CTLA-4 develop uncontrolled T cells activation 
and an autoimmune phenotype.141 Complete loss of CTLA-4 leads to fatal 
autoimmune disease in mouse models and mutations in CTLA-4 are associated in 
humans with several autoimmune diseases, such as T1D, and Grave’s disease.142, 
143 PD-1 is another inhibitory receptor of CD28 family encoded by PDCD1 gene 
and expressed on T cells and on B cell progenitors, which recognizes two 
different ligands (PD-L1 and PD-L2) present on APCs. PD-1 interaction with PD-
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L1 or PD-L2 determines the inactivation of T cell responses to antigen stimulation 
through the inhibition of T cell proliferation and cytokine production. PD-1 is 
crucial to inactivate the peripheral immune responses of effector T cells. PD-1 
deficient mice developed autoimmune diseases, such as SLE and arthritis. In 
humans, polymorphisms in PDCD1 are associated to several autoimmune 
diseases, including SLE, T1D, MS, RA, Grave’s disease and ankylosing 
spondylitis (AS).134, 143-146 
 Self-reactive T cells are suppressed by Treg cells 
Treg cells are CD4+, Foxp3+, CD25high (interleukin-2 receptor α chain, IL-2R) T 
cells and their main role is to maintain the self-tolerance suppressing the 
proliferation of naive T cells and their differentiation to effector T cells. They can 
also suppress effector activities of differentiated CD4+, CD8+ T cells and natural 
killer cells.147 
Foxp3 is a transcription factor that is crucial for Treg cell development and 
functions, and a murine model with mutations in Foxp3 showed multisystemic 
autoimmune disease associated with the absence of Treg cells.147 In humans 
Foxp3 mutations are associated with a rare autoimmune disorder, called IPEX 
syndrome, that means “Immune dysregulation, polyendocrinopathy, enteropathy, 
X linked” and with a deficiency of Treg cells.148 
Knockout mice lacking IL-2 or IL-2R chains developed autoimmune hemolytic 
anemia, multiple autoantibodies, and inflammatory bowel disease.147 Moreover, in 
these animals the Treg population is not present and the disease phenotype can be 
corrected restoring Treg cells.147 These data indicated that IL-2 is essential for the 
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Tregs differentiation and maintenance. Treg cells express high levels of CTLA-4 
that is crucial for their suppressive function which are mediated by the production 
of immunosuppressive cytokines, such as IL-10 (that inhibits the expression of 
costimulatory molecule, class II MHC, and the production of IL-2 by APCs), and 
TGF-β (that inhibits the proliferation and effector functions of T cells, regulates 
the differentiation of CD4+ toward inflammatory TH17 cells, and also guarantees 
the Treg cell maintenance). Elimination of TGF-β signals determines a systemic 
inflammatory response because of uncontrolled T cell activation and lack of Treg 
cells.147 A mouse model where IL-10 was knocked out developed inflammatory 
bowel disease (IBD), which includes Crohn's disease and ulcerative colitis.149 
Moreover, Tregs can directly inhibit the activation of CD8+ T cells or suppress 
CD4+ helpers that are required for the full activation of CD8+ T cells.134  
 Self-reactive T cells die by apoptosis 
 
 
When TCR recognize self-antigens with high avidity in the absence of 
costimulatory molecules, T cells can activate a specific sensor protein called Bim 
which interacts with pro-apoptotic proteins belonging to the Bcl-2 family (Bax 
and Bak) and promotes the activation of cell apoptosis by the mitochondrial 
pathway. In the same way, when T cells are repeatedly stimulated, FasL is 
secreted and interacts with its receptor Fas (CD95) which activates the caspase 
cascade leading to apoptotic cell death. Murine models carrying mutations in Fas 
or FasL developed systemic autoimmune disease similar to SLE. In humans, 
defects in Fas-FasL pathway cause the autoimmune lymphoproliferative 
syndrome (ALPS), which is characterized by lymphoproliferation, and secondary 
cancers.134, 150  
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B lymphocyte tolerance 
B cell tolerance is important to prevent immunologic response against self-
antigens, also including self-polysaccharides and lipids, for which the tolerance is 
not mediated by thymus. An important mechanism to maintain the central B cell 
tolerance is the receptor editing. When BCRs recognize with high avidity self-
antigens present in bone marrow, immature B cells can upregulate RAG1 and 
RAG2 genes which are devoted to the VJ sequence recombination in Ig k light 
chain genes leading to the expression of a new BCR on cell surface which does 
not recognize the self-antigen. If the new rearranged VJ sequences are not 
productive, the immature B cells activate the apoptotic pathway. On the contrary, 
when BCRs recognize with weak avidity the self-antigens, B cells become 
anergic. In periphery, B cells, which bind self-antigens with high avidity and are 
repeatedly stimulated in absence of specific T helper activation, become anergic 
or die by apoptosis. If a peripheral B cell recognize a self-antigen with low 
avidity, inhibitory receptors, such as CD22 are engaged to attenuate BCR 
signaling, preventing B cell activation.134  
1.12 Autoimmunity 
Loss of tolerance to self-antigens causes autoimmune diseases. Autoimmune 
diseases affect many young individuals and represent a significant clinical 
problem because of their chronic and progressive nature and associated healthcare 
costs.151 Most of the current therapies can resolve the concomitant inflammation 
and can block the activation of self-reactive immune cells, but they cannot correct 
or prevent the loss of tolerance.151 
Introduction 
55 
 
In autoimmune diseases, hyper reactive T and B lymphocytes are often observed 
in combination with autoantibodies. In monozygotic twins the chances to develop 
an autoimmune disease is higher than in dizygotic twins suggesting that genetic 
factors are involved in predispose to the autoimmunity. Moreover, in the families 
with multiple affected subjects, the probability for the healthy family members to 
develop different autoimmune diseases is increased, suggesting the presence of 
genetic defects in general mechanisms of immunological tolerance which can 
predispose to several kind of autoimmune diseases. Rare autoimmune diseases are 
usually monogenic and are caused by mutations with a strong effect which impair 
tolerance pathways. IPEX and APECED are two of such examples determined by 
mutations in FOXP3 and AIRE genes, as described in the previous section of this 
introduction. Instead, common autoimmune diseases are complex disorders in 
which multiple genetic and environmental susceptibility variants are involved.152, 
153 
Genome wide association studies (GWAS) have identified hundreds of loci 
involved in common autoimmune diseases.151 The contribution of each variant is 
usually small and it is likely that the presence of multiple variants can favor the 
development of the disease.151 The single risk variant can be often found also in 
healthy subjects although at lower frequency than in patients and without the 
combination with other predisposing variants. Furthermore, some of these genetic 
variants are associated with different autoimmune diseases, suggesting that 
alteration of common pathways may play a role.151 Risk variants for autoimmune 
diseases are often located in non-coding regions suggesting their involvement in 
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the regulation of gene transcription, protein expression, or epigenetic 
modifications.153  
Genetic mutations or polymorphisms can lead to defects during the negative 
selection in T and B cells, during the BCR editing, in Treg cell functions, in 
apoptotic pathway of self-reactive lymphocytes, and in inhibitory receptors. These 
defects can determine a reduction of the lymphocyte activation threshold leading 
to a susceptibility state for the loss of self-tolerance.152 
The strongest association with autoimmunity has been found with human 
leukocyte antigen (HLA) loci which contribute to half or more of the genetic 
susceptibility in most autoimmune disorders.154  
Besides HLA, one of the most common genetic associations to autoimmune 
diseases is the rs2476601 (c.1858C>T, p.Arg620Trp), a non-synonymous SNP in 
PTPN22 which encodes a tyrosine phosphatase expressed in lymphocytes. The 
620Trp variant determines a significant alteration in TCR and BCR signaling and 
is reported to be strongly associated with T1D, autoimmune thyroiditis, SLE, 
Grave’s disease, vitiligo, and RA.153, 155 
Other loci associated with autoimmunity include genes encoding molecules 
expressed by lymphocytes and involved in costimulatory functions. For example, 
CD6 is a transmembrane glycoprotein of T and B lymphocytes. It binds the 
activated leukocyte cell adhesion molecule (ALCAM) expressed by APCs, 
leading to activation of the costimulatory cellular pathway. De Jager et al. have 
described an increased risk to develop MS in individuals carrying the CD6 
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rs17824933 G variant which determines the production of a shorter CD6 isoform 
that cannot bind ALCAM. 153, 155, 156 
Others susceptibility variants have been found in cytokines and cytokine receptor 
genes. Polymorphisms in IL-23R represent susceptibility factors for inflammatory 
bowel diseases and psoriasis. Indeed, IL-23 is an important cytokine that induces 
TH17 cell differentiation toward a pro-inflammatory phenotype.134 Tumor necrosis 
factor receptor superfamily member 1A, TNFRSF1A, can activate 
the transcription of pro-inflammatory factor NF-kB and the cellular apoptotic 
pathway. A polymorphism in the splicing acceptor site in exon 6 of TNFRSF1A 
has been reported in strong association with MS because it determines the 
formation of a shorter protein that enhances NF-kB activation and higher response 
to inflammatory stimuli.155, 156 Nucleotide-binding oligomerization domain-
containing protein 2 (NOD2) is a protein expressed in the peripheral 
blood leukocytes but also in intestinal epithelial cells able to recognize bacterial 
molecules and to activate NF-kB pro-inflammatory pathway. Defects in NOD2 
can leads to an inefficient immune response against intestinal microbes causing 
inflammatory bowel diseases, such as Crohn’s disease.134 
Infections can trigger autoimmune diseases activating the innate immune system 
which is per se a strong stimulus for adaptive immunity. Moreover, infections and 
tissue damages can promote the recruitment of self-reactive lymphocytes to the 
site of inflammation increasing the risk of their activation. After an infection, 
some self-antigens can be displayed to immune cells in a different fashion 
showing neo epitopes which can be recognized as non-self- antigens. Enzymatic 
modifications, increased expression and failure of clearance can render the self-
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antigens more immunogenic and can also protract the duration of the activating 
stimulus causing an increased risk of autoimmunity.134 Of note, infections can 
also induce autoimmunity via molecular mimicry of microbial proteins with self-
antigens.157 Interestingly, some infections paradoxically can protect from 
autoimmunity, as demonstrated in T1D and MS.134 Finally, the intestinal and 
cutaneous microbioma may also influence the development of autoimmune 
diseases.134  
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1.13 The HLA system 
The major histocompatibility complex (MHC) locus, also known as the leukocyte 
antigen (HLA) locus, spans around 4 Mbp on the short arm of chromosome 6 and  
contains both class I and class II MHC genes and also other genes involved in 
antigen presentation (Figure 1-5).154  
 
 
Figure 1-5. Schematic map of MHC loci on human chromosome 6. 
MHC class I genes (A, B, and C) and MHC class II genes (DP, DQ, and DR) are shown. The A1 
genes, encoding the alpha chains of class II MHC molecules, are represented in red and the B1 
genes, encoding the beta chains of class II MHC molecules, are represented in yellow. Here, a 
specific DR haplotype is represented with the HLA-DRA1, the HLA-DRB1, and the HLA-DRB5 
genes. 
 
Class I MHC genes include HLA-A, HLA-B, and HLA-C (Figure 1-5), each 
encoding an α chain which is non-covalently linked to a non-MHC subunit, called 
β2‐microglobulin, forming the class I MHC molecule (Figure 1-6). 
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Figure 1-6. Schematic structures of class I and class II MHC molecules. 
Class I MHC molecule is constituted by α chain and β2-microglobulin. Class II MHC molecule is 
formed by the α and the β chains. 
 
Class II MHC genes include HLA-DR, HLA-DQ, and HLA-DP (Figure 1-5). 
Each class II MHC molecule forms a heterodimer composed by an α chain and a 
β chain derived from A1 and B1 genes, respectively (for example an α chain from 
HLA-DQA1 and a β chain derived from HLA-DQB1, Figure 1-6). The β chain of 
a HLA-DR molecules is encoded by the gene product of HLA-DRB1 or the 
paralogue (DRB3, DRB4, or DRB5). Each individual presents two haplotypes and 
each haplotype generally contains one HLA-DRA1, one HLA-DRB1 plus one 
additional HLA-DRB(3-5) paralogue (Figure 1-5). 
The MHC genes are the most polymorphic genes in the whole human genome 
caused by the presence of several alleles (more than 5,000 different alleles 
described) and not caused by gene recombination (such as in T or B cell 
receptors). MHC molecules are also codominantly expressed in each individual. 
The polygenic structure, the polymorphisms, and the codominance determine the 
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presence of a high number of different MHC molecules on APC cell surfaces and 
this represents a sophisticated approach to bind several different antigens and 
display them to CD8+ or CD4+ T cells. The complex and refined MHC system 
structure allows, first of all, to educate the immune system to tolerate all the self-
antigens present in the organism, and also to guarantee the immune defense 
against the greatest number of pathogens.134  
Each MHC molecule is a transmembrane protein formed by an extracellular 
peptide cleft, an immunoglobulin (Ig)-like domain, a transmembrane domain, and 
a cytoplasmic domain. The cleft is composed by the N terminal amino acids of 
MHC chains which are located in 2 α helices forming the two walls and an 8 
stranded β-pleated sheet that form the floor of the groove. The polymorphic 
variants are located both in the walls and in the floor of the cleft.134  
Class I MHC 
Class I molecules are formed by two non-covalently associated polypeptide 
chains, the α chain (about 44-47 kDa) and β2 microglobulin (12 kDa). The α 
chain N-terminus is constituted by the extracellular domain while its C terminus is 
cytoplasmic. At N-terminal domain, two segments called α1 and α2, form the 
peptide binding cleft which carries the polymorphic variants. Another 
extracellular segment, called α3, contains the Ig domain which is conserved 
between all the class I MHC molecules and together with β2 microglobulin, is 
important for the interaction with the CD8 co-receptor on T cells. The MHC class 
I groove can bind only small peptides between 8 and 11 amino acid long in a 
flexible extended conformation because of its closed ends at the peptide binding 
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cleft. The assembled class I molecule is a trimer formed by α chain, β2 
microglobulin, and the bound peptide. The stable expression of this complex 
requires the presence of all these three components. Class I molecules are 
expressed on all nucleated cells which can be potentially infected by viruses or 
become tumors. CD8+ cytotoxic lymphocytes can recognize class I MHC 
expressing cells and kill them when are infected by intracellular microbes, like 
viruses, or when they are transforming themselves in tumors. Most individuals are 
heterozygous and express both alleles for each class I MHC gene. For this reason 
six different class I MHC molecules are present on cell surfaces of each 
individual.134  
Class II MHC  
Class II molecules are formed by two non-covalently linked polypeptide chains, α 
chain (32-34 kDa) and β chain (29-32 kDa). The N-terminal domains of both 
chains (called α1 and β1 segments) form the peptide binding cleft that is 
structurally identical to the class I MHC groove and contains the polymorphic 
variants, mostly in the β chain. The molecular structure of the class II MHC 
groove allows the accommodation of larger peptides than class I MHC with a 
weight around 30 amino acids or more. The α2 and β2 segments of class II 
molecules are folded into Ig domains and are non-polymorphic. Class II MHC 
molecules are expressed on APCs, such as dendritic cells, B lymphocytes, and 
macrophages. Extracellular antigens are endocytosed into vesicles in APCs, 
processed and displayed by class II MHC molecules which are recognized by 
CD4+ T cells.134 
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Genetics of HLA in autoimmune diseases 
Using SSP (Sequencing-Based Typing), SSO (Sequence Specific Oligonucleotide 
probes) and NGS (Next Generation Sequencing) technologies, in which 
locus/exon specific primer mixes are used, the accuracy of the MHC molecular 
typing has been improved compared to serologic tests or molecular typing based 
on the amplification of specific allele or allele families (SSP, Sequence Specific 
Primer method), leading to improved definition of which HLA alleles are 
associated with several autoimmune diseases. Several studies have demonstrated 
that some HLA alleles are present with a higher frequency in patients affected by 
autoimmune diseases than in the healthy individuals, increasing the odds ratio 
(OR) to develop the diseases in subjects who are carriers of these risk alleles. 
Some examples are HLA-B*27:02 and B*27:05 in AS, HLA-DRB1*01:03 in 
celiac disease, and HLA-DRB1*15:01 in MS and SLE indicating that both class I 
and II MHC alleles are implicated in autoimmune predisposition. In addition, 
some autoimmune diseases shared the same HLA risk allele suggesting the 
presence of common altered pathways. In some diseases, such as T1D, both class 
I and class II risk alleles have been associated, indicating that both CD8+ 
cytotoxic and CD4+ helper T-cells are involved in the pathogenesis. 
Several alleles in MHC locus are inherited together because of the presence of a 
strong linkage disequilibrium (LD) existing in this genomic region and this can 
lead to a more difficult interpretation of the results.158 Sometimes a disease can be 
found in association with a specific HLA allele, but the causative allele could be 
another one that is co-inherited in the same HLA haplotype.154 Furthermore, 
epistasis has been reported in many autoimmune diseases, such as SLE, MS, and 
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AS in which HLA and non-HLA genetic defects were observed, suggesting that 
more defects in the same pathway have to be present for the disease to manifest as 
it has been commonly described in complex diseases.154 Interestingly, others HLA 
alleles have been associated with protection from autoimmune disease also in the 
presence of predisposing alleles.154 
GWAS has allowed identification of the key amino acids that are shared by 
different MHC molecules associated with a higher risk of developing autoimmune 
diseases.154 A good example is RA in which three amino acids found in several 
HLA-DRβ1 molecules in combination to two amino acids, one in HLA-B and one 
in HLA-DP, conferred an increased risk for the disease. The amino acids are 
located within the peptide-binding cleft indicating their crucial involvement in 
antigen recognition during T cell maturation in the thymus or peripheral 
activation.159  
The mechanisms underlying MHC involvement in the autoimmunity remain 
poorly understood. MHC class II alleles have been found to be most strongly 
associated with autoimmune diseases compared to class I MHC alleles suggesting 
that the loss of self-tolerance may be caused by defective antigen presentation by 
class II MHC molecules on epithelial or dendritic cells to self-reactive T cells.154 
The peptide binding proprieties depend from the peptide size and the non-covalent 
interactions with polymorphic amino acids present in the binding cleft of MHC 
molecules which are determined by the presence of specific HLA alleles.134 
During the negative selection in thymus, T cells whose TCRs strongly recognize 
self-peptide-MHC complex are deleted. A weak affinity between self-peptides and 
MHC molecules can determine structural alterations in TCR-peptide-MHC 
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complex that compromise its overall stability leading to the loss of immunological 
tolerance of self-antigens.160, 161  
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2  Aims  
The global aim of the present thesis was to evaluate the contribution of genetics to 
the development of anti-FH antibodies in patients affected by aHUS. 
The first part of this thesis was focused on the development of an accurate ELISA 
assay to detect anti-FHs in patient samples and to evaluate the prevalence of anti-
FHs in our aHUS cohort. Another aim was to investigate the prevalence of the 
FHR1 deficiency in a large group of aHUS patients and controls and to evaluate 
the association between the presence of the FHR1 deficiency and the risk to 
develop anti-FH associated aHUS. Moreover, the evaluation whether additional 
genetic factors (mutations or polymorphisms) in complement genes can increase 
the risk to develop anti-FH associated aHUS was another important objective. Of 
note, the association with common variants was investigated using as reference 
group “super controls”, i.e. healthy subjects with the homozygous deletion of 
CFHR1. 
In a second part of the thesis the aim was to describe the clinical and biological 
features of aHUS patients with anti-FHs present in our cohort. 
In the last part, the presence of HLA-A, B, C, DRB1, DRB3, DRB4, DRB5, DQA1, 
DQB1, DPA1, and DPB1 risk alleles in aHUS patients with anti-FH antibodies 
compared to healthy controls both carrying the homozygous CFHR1 deletion was 
evaluated with the aim to estimate the OR for each risk allele. The final aim was 
to investigate the affinity of FHR1/FH peptides with the newly identified 
predisposing MHC molecules using in silico assay. 
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3  Materials and methods 
3.1 Patients 
Atypical HUS was diagnosed in all cases reported to have one or more episodes of 
microangiopathic hemolytic anemia and thrombocytopenia defined on the basis of 
hematocrit less than 30%, hemoglobin less than 100 g/L, serum lactate 
dehydrogenase greater than 460 U/L, undetectable haptoglobin, fragmented 
erythrocytes in the peripheral blood smear, platelets less than 150 × 109/L, 
negative Coombs test to exclude autoimmune hemolytic anemia, associated with 
acute renal failure. 
Three hundred and five (305) unrelated patients affected by aHUS were recruited 
through the International Registry of HUS/TTP (Ranica, BG, Italy). Patient data 
were handled in respect of confidentiality and anonymity. All patients provided 
informed written consent in accordance with the Declaration of Helsinki. The 
study was approved by the Ethics Committee of Azienda Sanitaria Locale, 
Bergamo, Italy. 
Twenty-seven aHUS patients and one patient affected by Dense Deposit Disease 
have been included in the HLA study. 
3.2 Healthy subjects 
One thousand three hundred and ninety-nine (1399) Caucasian healthy subjects 
(1358 were Italians) were used as controls. Samples of healthy subjects were 
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kindly provided by “Associazione Volontari Italiani Sangue” (AVIS, Milano, 
Italy) or by Italian Bone Marrow Donors Registry in collaboration with Prof. 
Amoroso (Azienda Ospedaliera – Universitaria, Città della Salute e della Scienza, 
Torino, Italy). Healthy subject data were handled in respect of confidentiality and 
anonymity. All controls provided informed written consent in accordance with the 
Declaration of Helsinki. The study was approved by the Ethics Committee of 
Azienda Sanitaria Locale, Bergamo, Italy. 
Sixty-four healthy subjects with the homozygous CFHR1 deletion were used as 
“super controls” in HLA study. 
3.3 Blood, serum/plasma and DNA samples 
Blood samples of patients and healthy subjects were collected on EDTA tubes and 
stored at –20°C. Patient blood samples were collected during the acute phase or, 
in most cases, during convalescence. Genomic DNA was isolated from blood 
using Nucleon BACC2 Genomic DNA Extraction Kit (Illustra), and stored at -
20°C.  
Nucleon BACC2 Genomic DNA Extraction protocol: 
o 4 volumes of Cell Lysis Buffer  was added to 6 ml of whole blood; 
o After 4 min mix incubation at room temperature (RT), centrifugation at 
1300g for 5 min; 
o Cell pellet was resuspended in 2 mL of Reagent B; 
o Solution was transferred to polypropylene tube and 0.75 μg of RNAse were 
added; incubation for 30 min at 37°C; 
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o 500 μL of NaClO4 solution was added to deproteinize the samples; 
o After mixing, 2 mL of pre-cooled chloroform was added; 
o 300 μL of Nucleon Resin was added followed by a centrifugation at 1300g 
for 3 min; 
o The top phase containing the non-precipitated DNA was moved into a 
polypropylene tube containing 3 volumes of cold absolute ethanol to 
precipitate the DNA; 
o DNA was then removed, air dried and resuspended in 1X TE (100 mM 
Tris-HCl, 10 mM EDTA, pH 7.5. 
 
DNA samples from Italian bone marrow donors of Turin were sent already 
available for genetic analyses. 
DNA concentration and quality were determined measuring the absorbance at 260 
nm using a UV microvolume spectrophotometer and taken as reference 1X TE 
Buffer without DNA. The ratios A260/A280 and A260/A230 were also evaluated to 
exclude the presence of protein and ethanol/phenol contaminations in the sample.  
Serum or plasma EDTA samples were obtained after centrifugation and stored at 
–80°C. For samples not collect in our clinical centre, sera and/or plasma were sent 
with dry ice. Serum or plasma EDTA aliquots were available for 305 patients and 
111 healthy controls. 
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3.4 Mutations screening and genotyping 
In all aHUS patients with anti-FHs, screening of CFH, CD46, CFI, CFB, C3, and 
THBD was performed by direct sequencing (Sanger method). The sequencing also 
included the CFH basal and proximal promoter and CD46 3’ UTR region. 
All primers used in PCR and sequencing reactions were designed using Primer 3 
online software 0.4 (http://frodo.wi.mit.edu/primer3/input.htm) to cover all exons 
and flanking intronic regions and to obtain amplicons ranging from about 300 bp 
to about 800bp sizes suitable for the direct sequencing performed on 3730 
Sequence Analyzer (Life Technologies). In addition, all primer sequences were 
imputed by looking for similar known sequences using the Blast program 
available from NCBI (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to avoid non-
specific amplifications. 
Ninety-five separate PCR protocols have been optimized in order to avoid non-
specific PCR products. Annealing temperatures were established for each 
amplicon based on the primers melting temperatures. Times for denaturation, 
annealing and extension steps were established accordingly to amplicon size and 
GC amplicon composition. Generally, a PCR mix contained: PCR Buffer (10X), 
dNTPs mix (200 μM), MgCl2 (1.25-2.25 mM), primers (5 μM), Ampli TaqGold 
DNA Polymerase (0.5 U, Thermo Fisher Scientific), patient/healthy control DNA 
(30-50 ng), and double-distilled H2O (ddH2O) to a final volume of 10 μL. In each 
PCR a blank sample was included which contained all the reagents with the 
exception of DNA. PCRs were performed in a thermocycler (2700 or 9700, 
Applied Biosystem) following specific protocols for each amplicon. A standard 
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amplification protocol was: initialization at 94C for 10 min; 35 cycles of 
denaturation at 94C for 45 sec, annealing at varying temperature for 30-35 sec, 
extension at 72°C for 45 sec; final extension at 72° C for 10 min. 
Genotyping of the CFH SNPs c.1-332C>T (rs3753394), c.184G>A Val62Ile 
(rs800292), c.1204T>C Tyr402His (rs1061170), c.2016A>G Gln572Gln 
(rs3753396), c.2808G>T Glu936Asp (rs1065489), CD46 SNP c.*783T>C 
(rs7144), C3 SNPs c.941C>T Arg102Gly (rs1047286), c.304C>G Pro3174Leu 
(rs2230199), CFB SNPs c.94C>T Arg32Trp (rs12614), c.95G>A Arg32Gln 
(rs641153), and THBD SNP c.1418C>T Ala473Val (rs1042579) was performed 
during the sequencing. The genotyping of CFH c.2237-543G>A (rs1410996) was 
additionally performed by direct sequencing (forward primer, 5’-
AATGTGCTGCAGGGTTGGTG-3’; reverse primer, 5’-
AGTCACACTGTAAGTGAATCAC-3’). A region starting from c.1-1070 
nucleotide including CFH distal promoter have been also sequenced (forward 
primer, 5’-TGCTCACTAACAGGCACA-3’, reverse primer, 5’ 
CATTGTCTGGGTGCTGATTG-3’). 
CFHR1 exons and flanking intronic regions were sequenced in all patients with 
anti-FHs that did not carry the homozygous deletion of CFHR1, as described in 
Abarrategui-Garrido et al.43  
 
The PCR success was evaluated by the agarose gel. To this purpose, 3 μL of PCR 
product were mixed with 1 μL Fermentas 6x Loading Dye (Thermo Fisher 
Scientific) and 2 μL ddH2O. The amplified product was electrophoresed at 120 
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volts for 20-30 min in 1% agarose gel prepared by melting agarose in 1X TBE 
buffer (Qiagen) in presence of fluorescent nucleic acid dye Gel Red (10,000X, 
Biotium). After electrophoresis, agarose gel was exposed to UV light and a digital 
photo was obtained. Finally, the band of the amplified product was compared to 
the band profile of GeneRuler 100 bp DNA ladder (Thermo Fisher Scientific) 
which contained control PCR products ranging from 100 bp to 1,000 bp. The PCR 
product was considered specific if the expected molecular weight of the band 
corresponded to the observed molecular weight and no other bands were present. 
Moreover, no amplification bands had to be present in the blank sample. 
 
In order to remove unused primers and deoxynucleotides from amplified PCR 
products before sequencing reaction, ExoSAP-IT product (USB Corporation, 
USA) was used. 
ExoSAP-IT purification protocol: 
o 2 μL of ExoSAP-IT mix was added to 5 μL of PCR product 
o Incubation at 37°C for 15 min and enzyme inactivation at 80°C for 15 min 
 
The purified PCR products were sequenced using the BigDye terminator v.3.1 
cycle sequencing kit (Life Technologies, USA) and appropriate primers. 
BigDye terminator v.3.1 cycle sequencing protocol: 
o BigDye v3.1 Sequencing Buffer (5X) 
o BigDye Terminator (0.5 μL) 
o primer (4 μM) 
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o purified PCR product (2 μL) 
o ddH2O to a final volume of 10 μL. 
 
The sequencing reactions were performed in a thermocycler (2700 or 9700, 
Applied Biosystem) following the subsequent steps: initialization at 96C for 1 
min; 25 cycles of denaturation at 96C for 10 sec, annealing at 50C for 5 sec; 
final extension at 60C for 4 min. 
Before loading the sequencing products into the 48-capillary 3730 DNA Analyzer 
(Life Technologies), the BigDye XTerminator Purification kit was used to 
sequester salt ions, unincorporated dye terminators and dNTPs to prevent their co-
injection with dye-labeled products. To perform the XTerminator purification, 55 
μL of BigDye Solution (10 μL of XTerminator Solution and 45 μL of SAM 
Solution) were added to 10 μL of sequencing product. After vortexing for 30 min 
and centrifugation at 1500g for 2 min, the purified dye-labeled products were 
present in the supernatant and were analyzed by the DNA Sequencer using 
specific BigDye XTerminator run module.  
The sequencing results were analyzed with Sequencher Analyzer 5.0 software 
(Gene Codes Corporation, USA) and comparing each electropherogram to the 
reference sequences of CFH, CD46, CFI, CFB, C3, THBD, and CFHR1 reported 
on the Ensembl database (www.ensembl.org). 
Genetic variants were defined according to Human Genome Variation Society 
(HGVS) guidelines. Likely pathogenic variants have been defined as genetic 
variants with a Minor Allelic Frequency (MAF) reported on ExAc database 
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≤0.001 or predicted as “probably damaging” by Polyphen 2 software available 
online (http://genetics.bwh.harvard.edu/pph2). The HumVar was the PolyPhen 2 
parameter used to evaluate the effect of rare variations as suggested by the 
Polyphen 2 software guidelines. I have also considered as pathogenic the variants 
with a functional effect proved by in vitro studies available in literature despite 
their frequencies could be higher than 0.001. 
The expectation maximization algorithm by Haploview software (Broad Institute 
of MIT and Harvard) was used to estimate CFH haplotype frequencies using as 
minimal informative CFH SNPs the rs3753394, rs800292, rs1061170, rs3753396, 
rs1410996, and rs1065489, as described by Rodriguez-De Cordoba et al.43, 162 
3.5 Measurement of CFH, CFHR1, and CFHR3 copy 
number 
Multiplex-ligation dependent probe amplification (SALSA MLPA P236-A3 
ARMD, MCR-Holland, Netherlands) was used to evaluate the presence of copy 
number variations (CNVs) in CFH, CFHR3, CFHR1, CFHR2, CFHR5 genes in 
aHUS patients with anti-FHs. In P236-A3 kit there were 9 probes for CFH, 4 
probes for intergenic region between CFH and CFHR3, 5 probes for CFHR3, 4 
probes for CFHR1, 4 probes for CFHR2, and 3 probes for CFHR5 (Table 2.1). In 
MLPA P236-A3 kit, probe mix also included 8 reference probes which recognized 
genomic regions for which CNV are absent. For each MLPA experiment, at least 
3 DNA from healthy controls with no CN abnormalities and a blank sample with 
all the reagents without DNA, have been included. 
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Table 3-1. MLPA probes used to determine CFH and CFHR copy number. 
Probes included in SALSA MLPA P236-A3 ARMD in black, probes designed in our laboratory in 
red. 
 
 
 
 
 
 
 
 
Probe number Probe Name Hybridisation Sequence (20 nt adjacent to ligation site) 
1 CFH exon 1 TGCTACACAA-ATAGCCCATA 
2 CFH exon 2 GGTCTGACCA-AACATATCCA 
3 CFH exon 3 TCCTTTTGGT-ACTTTTACCC 
4 CFH exon 4 ATTACCGTGA-ATGTGACACA 
5 CFH exon 6 AAAGAGGAGA-TGCTGTATGC 
6 CFH intron 10 TAGGTAGTCA-TATTTGGAAC 
7 CFH intron 12 TGGACACATT-ATGATTGAGT 
8 CFH exon 13 AGTTGGACCT-AATTCCGTTC 
9 CFH exon 18 GGAACCATTA-ATTCATCCAG 
10 CFH exon 19 AGGATGTGTA-TAAGGCGGGG 
11 CFH intron 20 GAATTCTATT-TACACTTCCG 
12 CFH intron 21 TAATAGGGTA-TATTATTTTC 
13 CFH intron 22 GAAAAATCTC-TGTGATGAGT 
14 CFH exon 23 AGCTTTATTC-GAGAACAGGT 
15 CFH intron 23 TCAATACATA-AATGCACCAA 
16 CFH intron 23 CACTTATACA-TGCAATCCGT 
17 CFH intron 23 AGTCCGAGGT-AGAAAGGGAC 
18 CFH intron 23 GTGGTAATCT-TGGCTCTCAG 
19 CFHR3 intron 1 AGGTAAGTTA-AAAGAGATCT 
20 CFHR3 intron 1 CATTTTCTTG-TGGAATTACAGC 
21 CFHR3 intron 3 CGGACGACAG-TCTCAGACTT 
22 CFHR3 intron 4 GGGTTATATG-AATTCCTACA 
23 CFHR3 exon 6 TCCCTTCCCG-ACACACTGCTTG 
24 CFHR1 intron 3 AGAGTTTCAG-GTCCATGTGT 
25 CFHR1 intron 5 AATCTGTGAT-TATTTTGTTA 
26 CFHR1 exon 6 CCTGTTCTCA-AATAAAGCTTCT 
27 CFHR1 exon 6 TTTTCCAAGT-TTTAATATGG 
28 CFHR2 intron 1 TGTCTGTACT-TGGAGTTTCG 
29 CFHR2 intron 2 AGATCATAAA-CACTTGATAA 
30 CFHR2 intron 3 AATACCTGTG-TGTGGTTTATAG 
31 CFHR2 exon 4 ATATGCTCCAGG-TTCATCAGTT 
32 CFHR5 exon 1 TGGGTATCCA-CTGTTGGGGG 
33 CFHR5 exon 2 TGAAGAAGAT-TATAACCCTT 
34 CFHR5 exon 3 CTTCAGGACT-AATACATCTG 
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MLPA protocol: 
 
 
DNA denaturation 
o 5 μL of DNA at 20 ng/μL (100 ng) were denatured at 98°C for 5 min and 
then cooled at 25°C; 
 
Hybridization of probes to DNA 
o 3 μL of hybridization mix (1.5 μL MLPA buffer and 1.5 μL probe mix) was 
added; 
o After mixing, incubation at 95°C for 1 min and at 60°C for 17 hours; 
 
Ligation of hybridised probes 
o After setting the thermocycler temperature at 54°C, 32 μL of ligase master 
mix was added (25 μL ddH2O, 3 μL Ligase Buffer A, 3 μL Ligase Buffer B, 
and 1uL Ligase-G5 enzyme); 
o After mixing, incubation at 54°C for 15 min (for ligation) and at 98°C 
hours for 5 min to inactivate the enzyme;  
 
PCR amplification of ligated probes 
All ligated probes were amplified simultaneously using the same PCR 
FAM labeled primer pair: 
o 10 μL of PCR master mix was added to each tube (7.5 μL ddH2O, 2 μL 
SALSA PCR primer mix, and 0.5 μL SALSA polymerase); 
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o After mixing, the tubes were placed in the thermocycler for the PCR 
amplification. PCR program: 35 cycles at 95°C for 30 sec, 60°C for 30 
sec, 72°C for 60 sec; final extension at 72°C for 20 min; 
All this steps was performed in 2700 thermocycler (Applied Biosystem). 
 
Capillary electrophoresis of PCR products 
o Fragment separation was done on the 48-capillary 3730 DNA Analyzer 
(Life Technologies) using as size marker LIZ GS500 and electrophoresis 
specifications reported on “MLPA General Protocol” available on 
www.mlpa.com. 
o GeneMapper Software (Life Technologies) provided the DNA sizing and 
quality for each amplified fragment and it was possible to extrapolate the 
raw data of the peak heights relative to each amplified fragment. 
 
Result analysis 
o MLPA data analysis was performed with Microsoft Excel. Geometric 
mean of the peak heights relative to the reference fragments has been used 
for the intrasample normalization. The ratio between the normalized peak 
heights of CFH-CFHR fragments of the patient and the normalized peak 
heights of CFH-CFHR fragments of the healthy control was used for the 
intersample normalization. Ratios between 0.7 and 1.3 were considered as 
correspond to 2 copies, ratios between 0.4 and 0.7 meant the presence of 1 
copy (heterozygous deletion) and absence of probe signals as correspond 
to 0 copies (homozygous deletion).  
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3.6 Measurement of terminal region of CFH copy number 
In addition to probes included into P236-A3 kit, 5 home designed probes covering 
the terminal region of CFH are used (showed in red in Table 2.1). For this 
analysis the SALSA MLPA P300-B1 probemix was used, which contained 14 
reference probes for the intrasample normalization. The MLPA protocol adopted 
was the same used with P236 kit, with the only exception for the hybridization 
step in which 3 μL of hybridization mix including 1.5 μL of MLPA buffer, 0.5 μL 
of home designed probe mix, and 1 μL of P300 reference probe mix was added. 
The home designed probe mix was obtained by combining 0.8 μL of each probe 
solution (1 μM) in a final volume of 200 μL in 1X TE. 
3.7 Measurement of CFHR4 copy number 
The CFHR4 CN was evaluated by a multiplex PCR (mPCR) as reported by Moore 
et al.107 The primers were specific for CFHR4 intron 1, CFHR4 exon 2, and 
CFHR1 intron 3. In addition as suggested in Moore et al. specific primers for 
KCNT2 exon 9, and KCNT2 exon 17 were added for the intrasample 
normalization step. All primers used were labeled with fluorescent 5’FAM. 
 
CFHR4 mPCR protocol 
o 150 μg of DNA 
o  Buffer 10X  
o 200 μM dNTPs mix  
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o 6.7 mM MgCl2 
o 12.5 pM of each primer  
o 0.5 U Ampli TaqGold DNA Polymerase  
o ddH2O to a final volume of 25 μL. 
 
The PCR was performed in a thermocycler (2700 or 9700, Applied Biosystem) 
and the PCR program was the following conditions: denaturation at 95°C for 10 
min; 20 cycles at 95°C for 30 sec, 60°C for 30 sec, 72°C for 60 sec; final 
extension at 72°C for 20 min. After PCR, the fragment separation was done by 
capillary electrophoresis on the 48-capillary 3730 DNA Analyzer (Life 
Technologies) using as size marker LIZ GS500  (Life Technologies) and the same 
electrophoresis specifications adopted for MLPA analysis. The mean of peak 
heights relative to KCNT2 amplified products were used for the intrasample 
normalization. The ratio between the normalized peak heights of CFHR4 
amplified products relative to the patient and the normalized peak heights of 
CFHR4 amplified products relative to the healthy control was used for the 
intersample normalization. Ratios between 0.7 and 1.3 were considered as 
correspond to 2 copies, and ratios between 0.4 and 0.7 meant the presence of 1 
copy (heterozygous deletion). The analysis of CFHR1 intron 3 CN by mPCR was 
used to validate the result making a comparison with the MLPA results.   
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3.8 Homozygous CFHR1 deletion evaluation in a large 
cohort of patients and controls 
Multiplex PCR to evaluate homozygous CFHR1 deletion in a large cohort of 
aHUS patients and controls was done co-amplifying a 133 bp fragment in intron 3 
of CFHR1 and a 83 bp control fragment in the promoter of RNAse P. The primers 
used were: 
CFHR1-For 5'-ATCACTACACATGGACCTGAAA-3', 
CFHR1-Rev 5'-GATGTGGAAAAATAAAAGAAAATAAGTC-3', 
RNAseP-For 5'-TAGATACCGTGTGCGTGCAT-3', 
RNaseP-Rev 5'-GGGGTTCCAATTCCCAACTA-3'. 
 
CFHR1 mPCR protocol 
o 70 ng of DNA 
o  Buffer 10X  
o 200 μM dNTPs mix  
o 3 mM MgCl2 
o 0.8 µM of each CFHR1 primer  
o 0.23 µM of each CFHR1 primer 
o 0.5 U Ampli TaqGold DNA Polymerase  
o ddH2O to a final volume of 15 μL. 
The PCR was performed in a thermocycler (2700 or 9700, Applied Biosystem) 
and the PCR program was the following conditions: denaturation at 95°C 10 min; 
38 cycles at 95°C 30 sec, 57°C 45 sec, 72°C 30 sec; final extension at 72°C 10 
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min. PCR products were run on 2.5% agarose gel. Concurrent absence of the 
CFHR1 amplicon band and presence of the RNAseP band in the agarose gel 
indicated homozygous CFHR1 deletion. 
3.9 SDS-PAGE and Western blotting 
The presence and band profile of FHR1 was studied by Western Blotting in all 
patients with anti-FHs and with at least one copy of CFHR1. Serum samples were 
diluted 1:40 in loading buffer (4X Laemmil Sample Buffer, Bio-Rad) in absence 
of reducing conditions and analyzed using sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE, Mini-Protean TGX Precast Gels, BioRad). 
Proteins were transferred to polyvinylidene difluoride membrane (PVDF, Trans-
Blot Turb Midi PVDF Transfer; Bio-Rad) and blocked with 4% skim milk and 
1% bovine serum albumin (BSA). Mouse anti-human FHR1 IgG (kindly given by 
Prof. Zipfel) at 1:1,000 dilution in blocking solution, which recognized the N-
terminal domains of FHR1, has been incubated for 1 hour. The antibody detection 
was performed after 1 hour incubation with horseradish peroxidase (HRP) goat 
anti-mouse IgG at 1:5,000 dilution in blocking solution followed by enhanced 
chemiluminescence (ECL) substrate (Amersham) addition. 
3.10 Anti-FH ELISA assay 
The presence of anti-FHs was evaluated by a home-made Enzyme-Linked 
ImmunoSorbent Assay (ELISA) as previously described in Dragon-Durey et al. 
with the addition of some modifications.98 Microtiter plates (Nunc MaxiSorp, 
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Denmark) were coated with 0.1 μg (100 μL at 1 μg/mL) of purified human FH 
(Calbiochem). After overnight incubation at 4°C, the plate was washed 3 times 
with 200 μL of PBS, 0.1% Tween20, 0.2M NaCl, and blocked with 200 μL of 
PBS, 0.1% Tween20 and 0.3% milk for 1h at room temperature (RT). After 3 
washes with PBS, 0.1% Tween20, 0.2M NaCl, 50 μL of plasma EDTA/serum 
samples at 1:100 dilution in blocking solution were added in duplicated wells, and 
incubated for 40 minutes at RT. A parallel plate was set up in absence of FH 
coating in which only blocking solution was added to evaluate the presence of 
non-FH specific background. After 4 washes with PBS, 0.1% Tween20, 0.2M 
NaCl, goat anti-human IgG antibody conjugated with HRP (Sigma-Aldrich) was 
added and incubated for 1 hour at RT. After 6 washes, 100 μl of 
tetramethylbenzidine substrate (TMB) were added, and incubated for 2-5 minutes. 
The reaction was stopped with 100 μL of 10% H2SO4, and the optical absorbance 
was read at 450 nm. For standard curve a positive control kindly gifted by Dr. 
Dragon-Durey with 2,000 AU/mL titer at 1:100 dilution was used. A positive 
control and a negative control were present in each experiment. The sample 
concentrations expressed in arbitrary units/ml (AU/mL) were determined by 
extrapolation from a sigmoidal curve obtained by Microplate Manager 6 Software 
(Bio-Rad) and the background derived from wells without FH coating was 
subtracted. To confirm the antibody positivity, the ELISA was repeated adding 15 
μL of FH into each serum/plasma sample to verify whether this excessive amount 
of FH was able to inhibit the autoantibody binding to FH coated on the plate 
wells. If the optical absorbance decreased about 50% with the addition of the 
exogenous FH compared to the optical absorbance obtained with the standard 
protocol (the diluted sample without the addition of FH), it indicated the presence 
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of specific autoantibodies against FH antigen. More details about the accuracy of 
the anti-FH ELISA assay are reported in the third chapter and are an integral part 
of thesis results. 
3.11 Epitope mapping of anti-FHs  
Molar equivalent concentrations of amino terminal FH (SCRs 1-5) and C terminal 
FH (SCRs 15-20) fragments (kindly given by Prof. Peter Zipfel) were 
immobilized on microtiter plates (Nunc MaxiSorp, Denmark). ELISA assay was 
performed following the standard protocol used to assess the presence anti-FHs. 
The results were expressed as absorbance at 450 nm and were obtained from 
replicated assays.   
3.12 FH ELISA assay 
FH levels were evaluated by a home-made ELISA method. Microtiter plates 
(Nunc MaxiSorp, Denmark) were coated with 0.15 μg (100 μL at 1.5 μg /mL) of 
purified sheep polyclonal anti-human factor H antibody (Abcam). After overnight 
incubation at 4°C, the plate was washed 3 times with 200 μL of PBS, 0.05% 
Tween20, and blocked with 200 μL of PBS, 1% BSA for 1h at RT. After 4 washes 
with PBS, 0.05% Tween20, 100 μL of plasma EDTA/serum samples at 1:10,000 
dilution in blocking solution were added in duplicated wells, and incubated for 2 
hours at RT. After 4 washes with PBS, 0.05% Tween20, 100 μL of mouse 
monoclonal anti-human factor H (LifeSpan BioSciences), which recognized the 
N-terminal domain of FH, were added at 1:10,000 dilution in blocking solution. 
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The plate was washed 4 times with PBS, 0.05% Tween20 and 100 μL of goat anti-
mouse antibody conjugated with HRP (Thermo Fisher) at 2,000 dilution were 
added and incubated for 1 hour at RT. The plate was washed 4 times with PBS, 
0.05% Tween20, and 100 μL of TMB were added. The peroxidase reaction was 
stopped after 8 minutes with 100 μL of 10% H2SO4. The optical absorbance was 
read at 450 nm. For the first point of the standard curve purified human FH 
(Calbiochem) at 1:4,000 dilution was used. Healthy control samples were added 
in each experiment. The sample concentration expressed in mg/mL was 
determined by extrapolation from a sigmoidal curve obtained by Microplate 
Manager 6 Software (Bio-Rad). The normal control range was 172-507 mg/L.  
3.13 HLA typing 
An high resolution sequencing using exon specific primers (SBT, Sequencing-
Based Typing) to include all variations coding for the antigen recognition site has 
been performed in exons 2 and 3 of MHC class I genes (HLA-A, HLA-B, and 
HLA-C) and in exon 2 of MHC class II genes (HLA-DRB1, HLA-DRB3, HLA-
DRB4, HLA-DRB5, HLA-DQA1, HLA-DQB1, HLA-DPA1, and HLA-DPB1) in 27 
aHUS patients with anti-FH autoantibodies (of whom 24 showing the FHR1 
deficiency), in 31 Italians healthy controls all carrying the homozygous CFHR1 
deletion, and in 1 patient affected by Dense Deposit Disease carrying anti-FHs 
and the homozygous CFHR1 deletion by Histogenetics (Ossining, New York, 
USA). 
Luminex technology for HLA typing by PCR-Sequence Specific Oligonucleotides 
Probes (SSO) was performed in 33 healthy controls by the Unit of 
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Immunogenetics and Transplant Biology directed by Prof. Amoroso (Azienda 
Ospedaliera – Universitaria, Città della Salute e della Scienza, Torino, Italy) 
For all patients and the large majority of controls the typing resolution was high 
enough to allow a four digit HLA nomenclature, according to the indications of 
World Health Organization Nomenclature Committee for Factors of the HLA 
system (www.ebi.ac.uk/imgt/hla/stats.html). 
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3.14 Statistical analyses 
All the statistical tests have been done with “MedCalc” software (Version 12.2.1.0 
Copyright © 1993-2012). Chi-square test or Fisher’s exact test were used to 
compare the frequency of genotypes and alleles between patients and healthy 
controls, as appropriate. Findings were considered statistically significant at p-
values < 0.05 after Bonferroni correction. Odds ratio (OR) was reported with the 
95% confidence interval. ANOVA and Mann-Whitney tests were used to compare 
the mean and the median of parametric and non-parametric variables, 
respectively.  
Power analysis for the HLA study has been performed with “PS Power and 
Sample Size Calculations” software (Version 3.0, January 2009, Copyright © 
1997-2009 by William D. Dupont and Walton D. Plummer). HLA allele and 
carrier frequencies were compared by Chi-square test or by Fisher’s exact test 
when the number of subjects in the 2 X 2 contingent tables was five or less. 
Bonferroni correction was applied to p-values considering the number of tested 
alleles at each HLA gene. Findings were considered statistically significant at p-
values < 0.05 after correction. OR was calculated only for risk alleles and given 
with the 95% confidence interval. 
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4  Variants in complement genes associated with 
anti-factor H autoantibodies in atypical Hemolytic 
Uremic Syndrome (aHUS) 
4.1 Introduction 
Atypical hemolytic uremic syndrome (aHUS) is a rare kidney disease with a 
prevalence of 1:100,000 and characterized by thrombotic microangiopathy and 
acute renal failure.57 It is mainly caused by dysregulation or hyperactivation of the 
alternative pathway (AP) of complement system and more rarely by defects in 
diacylglycerol kinase ε.57, 62, 100 About half of patients are carriers of mutations in 
genes encoding AP regulatory proteins (such as factor H, factor I, membrane 
cofactor protein CD46, and thrombomodulin) or in genes enconding C3 and factor 
B that form the AP C3 and C5 convertases, C3bBb and (C3b)2Bb.62 
Autoantibodies against factor H (anti-FHs) have been also reported in 5-14% of 
patients in European cohorts and up to 50% of aHUS cases in South Asia.98, 105-107, 
110 Anti-FHs bind multiple FH epitopes mainly located at the C-terminal domain 
which is often the hot spot of genetic alterations in aHUS.115, 121 The presence of 
anti-FHs determines the impairment of factor H functions compromising the self-
surface protection from complement activation and the development of aHUS.115 
Anti-FHs are strongly associated with the deficiency of factor H Related 1 
(FHR1).107, 123 FHR1 is encoded by the CFHR1 gene that is located in the 
regulator of complement activation (RCA) gene cluster on chromosome 1q32 
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together with CFH and other 4 factor H related genes (CFHR2-3-4-5). The high 
level of sequence identity among CFH and CFHR genes can favor genomic 
rearrangements through non allelic homologous recombination (NAHR). FHR1 
deficiency is most often caused by a polymorphic homozygous deletion of 
CFHR3 and CFHR1. The frequency of the homozygous deletion of CFHR3 and 
CFHR1 is 5% in European, 9% in Asian, and about 20% in sub-Saharian African 
populations.42, 110, 163 It appears clear that a common factor such as FHR1 
deficiency is not sufficient to cause the development of a rare disease like aHUS. 
In literature other defects in genes encoding complement proteins have been 
reported in about 15% of aHUS patients with anti-FHs but a correlation with the 
generation of FH autoantibodies has not been reported.43, 107, 128 Common variants 
in CFH and MCP (SNPs and haplotypes) have been reported to increase the risk 
of developing aHUS in subjects also carrying mutations in complement genes.86, 87 
Interestingly, in Moore et al. report of all 13 aHUS patients who were positive for 
anti-FHs carried the CFH “A” variant at the rs3753396 and “G” variant at 
rs1065489 suggesting a possible role of particular CFH haplotypes in 
predisposing to development of anti-FHs.107 Of note, the common variants in FH 
and in the AP C3 convertase proteins, FB and C3, have been also reported to be 
associated with other complement mediated diseases, such as age-related macular 
degeneration (AMD) and Dense Deposit Disease (DDD).164-167 Also THBD 
c.1418C (Ala473) common variant is described to increase the risk to develop C3 
glomerulopathy.55 
In this chapter of the thesis: 1) I report the results of the screening of 305 
unrelated patients affected by aHUS; 2) I identify a group of 30 patients with anti-
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FHs; 3) I document the association between the FHR1 deficiency and anti-FHs in 
our cohort of aHUS patients; 4) I focus on rare and common genetic variants in 
complement genes that can predispose to the development of aHUS in patients 
with anti-FHs. In these analyses “super controls”, i.e. healthy subjects carrying the 
homozygous deletion of CFHR1, were used as reference group.  
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4.2 Specific aims 
To set up an ELISA to specifically detect anti-FHs in plasma/serum samples 
To identify true and false positive samples for anti-FHs. 
To determine the prevalence of anti-FHs in our cohort of patients with aHUS. 
To study which FH epitopes are recognized by anti-FHs in our patients and to 
evaluate whether a correlation exists between the FHR1 deficiency and the anti-
FH recognition site. 
To statistically evaluate the association between homozygous deletion of CFHR1 
and the development of anti-FH-mediated aHUS. 
To evaluate whether genetic mutations in complement genes were associated with 
anti-FH - mediated aHUS. 
To evaluate whether common variants in complement genes were associated with 
anti-FH - mediated aHUS using as reference group “super controls”, i.e. healthy 
subjects with the homozygous deletion of CFHR1. 
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4.3 Results 
4.3.1 Assessment of anti-factor H antibodies by ELISA. 
An enzyme-linked immunosorbent assay (ELISA) was firstly performed in sera 
(or plasma EDTA) of healthy controls to set up the assay positivity threshold. 
Since anti-FH-mediated aHUS has been previously associated to the homozygous 
deletion of CFHR1, 98 Italian blood healthy donors over 40 years of age with 1 or 
2 copies of CFHR1 by MLPA were selected as reference negative control group 
to define the lower limit of the auto-antibody positivity (Figure 4-1). The mean 
antibody titer (± standard deviation, SD) assessed by ELISA in the control group 
was 8.0 AU/mL (±23.8). The threshold positivity has been set at the mean +5SD 
of individual values recorded in the negative control group (127 AU/mL, Figure 
4-1). A less stringent threshold at the mean+2SD (56 AU/mL) of the negative 
control group was also adopted (Figure 4-1). Samples with anti-FH titer <56 
AU/ml were considered as true negative, samples with antibody titer in the range 
56-127 AU/mL as possibly positive, and samples with antibody titer >127 as 
positive. 
The presence of anti-FHs was assessed by ELISA in 305 consecutive aHUS 
patients of the International Registry for whom serum or plasma was available. 
Forty-one patients showed an antibody titer higher than 56 AU/mL. Twenty-six 
patients had an anti-FH titer higher than 127 AU/mL and fifteen patients between 
56-127 AU/mL. 
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4.3.2 Assessment of the accuracy of the anti-FH antibody assay 
To exclude false positive results, all the samples were also analyzed using wells in 
which FH was not coated. Since anti-FHs should bind to FH-coated wells but not 
to those not coated with FH, in true positive samples a significant reduction of the 
absorbance in the non-FH-coated compared to the FH-coated wells was expected. 
On the contrary, absence of absorbance reduction in non-FH-coated wells 
suggested an aspecific signal. A reduction of at least 50% was observed in 30 out 
of 41 patients with anti-FH titer ≥ 56 AU/mL. To confirm these data the ELISA 
was repeated in all 41 patients with a titer ≥56 AU/mL adding 15 μg of FH into 
each serum/plasma sample which is 150-fold the amount of FH used to coat each 
well. The excessive amount of FH is expected to compete with the FH 
immobilized on the plate for the binding to the autoantibodies. An absorbance 
decrease of about 50% in samples added with exogenous FH, indicated that the 
antibodies were FH specific. Thirty out of 41 patients with a ≥56 AU/mL titer 
showed a significant reduction of the absorbance in the presence of an excess of 
FH and this confirmed the data obtained with non-FH-coated wells. This control 
step had highlighted that the percentage of false positive (11/41) was higher in the 
possibly positive group (8/15, 53.3%) compared to the likely positive group (3/26, 
11.5%). 
Overall, 30 out of 305 aHUS patients were found true positive for anti-FHs by 
ELISA suggesting a prevalence of 9.8% in our aHUS cohort (Figure 4-1). 
Noteworthy all 11 false positive samples did not show homozygous deletion of 
CFHR1 gene that is usually associated with anti-FH development further 
confirming the specificity of the results. 
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Figure 4-1. Anti-FHs in healthy controls and aHUS patients. 
111 healthy controls have been analyzed for anti-FHs through ELISA: 98 were carriers of 1 or 2 
copies of CFHR1 and 13 had 0 copies of CFHR1 (HomCFHR1Δ). 305 aHUS patients have been 
also analyzed for anti-FHs: 254 were carriers of 1 or 2 copies of CFHR1, and 51 had 0 copies of 
CFHR1 (HomCFHR1Δ). An aHUS patient with FHR1 deficiency (number 23, see Table 3) has 
been also included in the group of patients defined in this figure as “aHUS with HomCFHR1Δ”). 
For subjects with an anti-FH antibody titer ≥56 AU/mL, it was reported the anti-FH antibody titer 
obtained from wells coated with FH after the background subtraction obtained in wells without FH 
coating. The blue lines indicated anti-FH antibody titer mean +2SD (56 AU/mL) and +5SD (127 
AU/mL). 
 
4.3.3 Presence of anti-FHs in healthy subjects 
Among 98 healthy controls with CFHR1, one subject had an anti-FH titer of 229 
AU/ml, but in FH-non-coated wells and in the presence of FH excess a significant 
reduction of the absorbance was not detected indicating that it was a false positive 
sample.  
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Plasma samples of 13 healthy controls with 0 copies of CFHR1 have also been 
collected and one of them showed anti-FHs with a titer of 193 AU/mL (Figure 4-
1). The antibody titer decreased around 50% in both FH-non-coated wells and in 
the presence of FH excess, meaning that the antibodies were specific for FH and 
that the sample is a true positive. 
Overall, 1 out of 111 controls showed anti-FHs suggesting a prevalence of 0.9% 
in the healthy population.  
4.3.4 Binding of autoantibodies to FH fragments 
To discriminate which FH epitopes were recognized by anti-FHs and if there was 
a correlation between absence of FHR1 and antibody recognition site, ELISA was 
repeated using wells coated with N terminal FH (SCRs 1-5) and C terminal FH 
(SCRs 15-20) fragments (kindly given by Prof. Peter Zipfel) at the same molarity 
used in FH coated wells during the standard procedure to detect anti-FHs. The 
absorbance of samples from 5 aHUS patients without the homozygous deletion of 
CFHR1 (numbers 19, 13, 30, 21, and 26) and from 7 aHUS patients carrying the 
homozygous CFHR1 deletion (numbers 16, 14, 15, 10, 25, 18, and 8) are shown 
in Figure 4-2. In 3 patients without homozygous deletion of CFHR1 (numbers 19, 
13, and 30) and in 4 patients carrying the homozygous deletion of CFHR1 
(numbers 16, 14, 15, and 10), the absorbance was very high when the coating was 
performed with C terminal FH and very low in presence of N terminal coated FH. 
In 3 patients with the homozygous deletion of CFHR1 (numbers 25, 18, and 8) the 
signal was less intense but higher in presence of FH C terminus than when the 
coating was done using the N terminal FH fragment. In one patient without the 
homozygous CFHR1 deletion (number 21) the absorbance on FH SCRs 15-20 and 
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on FH SCRs1-5 showed similar values of low intensity in both conditions. In 
another patient without the homozygous deletion of CFHR1 (number 26) the anti-
FHs did not recognize either C terminal FH or N terminal FH fragments.  
 
Figure 4-2. Binding site localization of anti-FHs detected in aHUS patients. 
Anti-FH binding to FH N terminal fragment (SCRs 1-5) and FH C terminal fragment (SCRs 15-
20) evaluated in 12 aHUS patients. Seven patients were carriers of the homozygous CFHR1 
deletion (HomCFHR1Δ) while 5 patients presented at least one copy of CFHR1 (No CFHR1Δ). 
The absorbance was shown on the ordinate axis and it was the result from replicated assays.  
 
4.3.5 Copy number evaluation in CFHR1, CFHR3 and CFHR4 
The homozygous deletion of CFHR1 was evaluated by multiplexing PCRs of an 
amplicon laying in CFHR1 intron 3 and of a control amplicon in RNAseP gene as 
decribed in “Materials and Methods”. Concurrent absence of the CFHR1 
amplicon band and presence of the RNAseP band indicated homozygous deletion 
of CFHR1. The power of this multiplex PCR to identify homozygous CFHR1 
deletion was evaluated in 175 subjects already analyzed by MLPA and sensitivity 
and specificity were 100% (Table 4-1). 
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Table 4-1. Sensitivity and specificity of multiplex PCR to detect homozygous deletion of CFHR1 
in 175 subjects analyzed by MLPA. 
 
The multiplex PCR was adopted to investigate the presence of homozygous 
deletion of CFHR1 in all 305 unrelated aHUS analyzed for anti-FHs and in a large 
cohort of healthy controls (1399). Fifty aHUS patients (16.4%) and 71 controls 
(5.1%) resulted homozygous for CFHR1 deletion (OR [95%CI] = 3.67 [2.493-
5.394], p-value = 7.364 x 10-12, Table 4-2). This difference was enhanced when 
we focused on aHUS patients with anti-FHs (24/30, 80%) versus healthy controls 
(71/1399, 5.1%; OR [95%CI] = 74.817 [26.64-188.853], p-value = 3.973 x 10-57, 
Table 4-2). 
Of note, the homozygous deletion of CFHR1 was significantly overrepresented in 
aHUS patients resulted positive for anti-FHs compared to aHUS patients negative 
for anti-FHs (OR [95%CI] = 38.308 [14.354-102.23], p-value = 4.88 x 10-22, 
Table 4-2). Interestingly, the homozygous deletion of CFHR1 was also more 
abundant in aHUS patients negative for anti-FHs (9.5%) compared to healthy 
controls (OR [95%CI] = 1.953 [1.222-3.1222], p-value = 0.007, Table 4-2). 
 
Deleted Not deleted Sensitivity (%) Specificity (%)
Deleted 39 0
Not deleted 0 139
100 100
MLPA
mPCR
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Table 4-2. Homozygous deletion of CFHR1 in aHUS patients (n=305) and healthy controls 
(n=1399). 
 
Copy number analysis of CFHR3 and CFHR1 by MLPA and of CFHR4 by 
multiplex PCR was performed in all 30 patients with anti-FH autoantibodies 
(Table 4-3). I found that the homozygous deletion of CFHR1 previously detected 
in 24 out of 30 patients with anti-FHs by multiplex PCR, was caused by the 
homozygous deletion of CFHR3 and CFHR1 in 20 patients (66.7%) and by the 
heterozygous deletion of CFHR3 and CFHR1 combined with the heterozygous 
deletion of CFHR1 and CFHR4 in 4 patients (13.3%). Four patients (13.3%) 
showed the heterozygous deletion of CFHR3 and CFHR1 and two patients (6.7%) 
no copy number variations in CFHR genes (Table 4-3). 
  
aHUS (n=305) 50 (16.4%) 255 (83.6%) 3.67 [2.493-5.394] 7.364 x 10-12
Controls (n=1399) 71 (5.1%) 1328 (95%)
aHUS anti-FH positive (n=30) 24 (80%) 6 (20%) 74.817 [26.64-188.853] 3.973 x 10-57
Controls (n=1399) 71 (5.1%) 1328 (95%)
aHUS anti-FH positive (n=30) 24 (80%) 6 (20%) 38.308 [14.354-102.23] 4.88 x 10-22
aHUS anti-FH negative (n=275) 26 (9.5%) 249 (90.5%)
aHUS anti-FH negative (n=275) 26 (9.5%) 249 (90.5%) 1.953 [1.222-3.122] 0.007
Controls (n=1399) 71 (5.1%) 1328 (95%)
Hom 
CFHR1∆
No Hom 
CFHR1∆ OR [95%CI] p-value
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Table 4-3. Detection of CFH and CD46 SNPs and CFHR3-CFHR1 and CFHR1-CFHR4 deletions 
in 30 aHUS patients with anti-FHs. 
Genotypes of CFH SNPs (rs3753394, rs800292, rs1061170, rs3753396, rs1410996, and 
rs106548), CD46 SNP rs7144, CFHR3-CFHR1 deletion carrying alleles (D = wild type allele, d = 
allele with deletion), and CFHR1-CFHR4 deletion carrying alleles (D = wild type allele, d = allele 
with deletion). * patient 23 showed the heterozygous CFHR1 c.104delAfsX,  p.D35fsX36. na = 
not available. 
 
4.3.6 CFHR1 sequencing 
To identify additional patients with FHR1 deficiency, the direct sequencing of 
CFHR1 gene was performed in the six patients with anti-FHs that carried at least 
one copy of CFHR1 gene. In patient 23 who showed the heterozygous CFHR1 
deletion I also found a frameshift mutation in CFHR1 exon 2 (c.104delAfsX) that 
resulted in a truncated protein (p.D35fsX36, Table 3). Thus, overall in our cohort 
Patient 
anti-FH Ab 
positive
CFH c.1-332C>T 
(rs3753394)
CFH 
c.184G>A 
Val62Ile 
(rs800292)
CFH 
c.1204T>C 
Tyr402His 
(rs1061170)
CFH 
c.2016A>G 
Gln572Gln 
(rs3753396)
CFH  c.2237-543G>A 
(rs1410996)
CFH 
c.2808G>T 
Glu936Asp 
(rs1065489
)
ΔCFHR3-
CFHR1
ΔCFHR1-
CFHR4
CD46 
c.*783T>C 
(rs7144)
1 C T G G T T A A A A G G d d D D T T
2 T T G G T T A A A A G G d d D D T T
3 C T G G T T A A A A G G d d D D T T
4 C T G G C T A A G A G G D d D d T T
5 C T G G T T A A A A G G d d D D T C
6 C C G G T T A A A A G G d d D D T C
7 C C G G T T A A A A G G d d D D T T
8 C T G G T T A A A A G G d d D D T C
9 C T G G T T A A A A G G d d D D T C
10 C C G G  T T A A A A G G d d D D C C
11 C C G G T T A A A A G G d d D D T T
12 C T G A T T A A A A G G d d D D C C
13 C C G G C T A A G A G G D d D D C C
14 C C G G T T A A A A G G d d D D T T
15 C T G G T T A A A A G G d d D D C C
16 C T G G T T A G G A G T D d D d C C
17 T T G G T T A A A A G G d d D D T C
18 T T G G T T A A A A G G d d D D T T
19 T T G G T T A G G A G T D d D D T T
20 C C G G T T A A A A G G d d D D T C
21 T T G G T T G G G G T T D D D D C C
22 C T G A T T A A A A G G d d D D T C
23* C T G A T T A G G A G T D d D D T C
24 C C G A T T A A A A G G d d D D T C
25 T T G G T T A A A A G G d d D D T C
26 C C G A C T A A G A G G D d D D T T
27 C T G A T T A A A A G G d d D D T T
28 C T G G C T A A G A G G D d D d T C
29 T T G G na A G na G T D d D d T T
30 C T G A C T A A na G G D D D D C C
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of patients with anti-FHs - mediated aHUS, 25 out of 30 patients presented a 
complete FHR1 deficiency (83.3%). 
I have also evaluated the presence of the two different FHR1 isoforms (acidic and 
basic) in patients with anti-FHs. This difference is caused by the nucleotide 
changes c.469C>T, c.475C>G, and c.523G>C that cause the amino acid changes 
from 157His, 159Val, and 175Gln in SCR3 domain (FHR1 basic isoform) to 
157Tyr, 159Leu, and 175Glu (FHR1 acidic isoform). Of note, the SCR3 of the 
FHR1 basic isoform is identical to SCR18 of FH. One patient with the 
heterozygous CFHR3-CFHR1 deletion showed the basic isoform, two patients 
with the heterozygous CFHR3-CFHR1 deletion showed the acidic isoform and 
two patients with two copies of CFHR3 and CFHR1 showed both CFHR1 
isoforms (data not shown). Thus, both acidic and basic isoforms were present in 
our aHUS patients with anti-FH autoantibodies. 
 
4.3.7 Detection of FHR1 in patient sera 
To verify whether the 5 patients who did not show FHR1 deficiency in the above 
analyses had normal FHR1 in their circulation, I next evaluated by Western 
blotting, the presence of FHR1 protein in sera of aHUS patients with anti-FHs 
with at least one copy of CFHR1 (Figure 4-3). Patient numbers 13, 19, 26 (all 
with one copy of CFHR1) and patient numbers 21 and 30 (with two CFHR1 
copies) showed the FHR1 bands. The patient number 23, who had one copy of 
CFHR1 with a frameshift mutation in exon 2 (c.104delAfsX) did not show any 
FHR1 bands, as expected. 
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Figure 4-3. Detection of FHR1 by Western blotting in aHUS patients with anti-FHs and at least 
one copy of CFHR1. 
Patients number 13, 19, 26 had 1 copy of CFHR1, patients 21 and 30 had 2 copies of CFHR1, 
patient number 23 had 1 copy of CFHR1 with a frameshift mutation in exon 2 (c.104delAfsX), 
patient 12 had 0 copies of CFHR1, and “CTR” was an healthy control with 2 copies of CFHR1 by 
MLPA. 
 
4.3.8 Mutations in complement genes in patients with aHUS and 
anti-FHs 
The direct sequencing of CFH, CD46, CFI, CFB, C3, and THBD was performed 
in all 30 patients with anti-FHs. I found mutations in 11 patients (37%, Table 4-4). 
Three patients carried mutations in CFH (10%). One Italian patient showed the 
heterozygous c.2850G>T, p.Gln950His, (rs149474608, ExAc allele frequency = 
0.004) that was previously described in one aHUS patient with anti-FHs, in other 
aHUS patients without anti-FHs, in a patient who have developed TMA after 
renal transplantation, and also in healthy individuals.84, 107, 168-171 Another Italian 
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patient showed the c.2776C>T, p.Cys926Arg and in a Jewish patient I found the 
heterozygous c.2758T>C, p.Trp920Arg. For both p.Cys926Arg and  
p.Trp920Arg, frequency data were not available and these variants were not 
reported in other aHUS cases in literature. Interestingly, p.Cys926Arg and 
p.Trp920Arg are located in FH SCR15 and p.Gln950His in FH SCR16 which are 
all central domains of FH molecule without a clear function. In silico analyses 
using Polyphen2 software have predicted all these CFH mutations as probably 
damaging. 
In other 3 patients I observed heterozygous mutations in CD46 (10%). The 
c.1148C>T, p.Thr383Ile (ExAc allele frequency = 0.0006), was found in an 
Italian patient and it was previously described in an aHUS family and in a woman 
affected by idiopathic, spontaneous pregnancy loss.172, 173 The c.38C>T, 
p.Ser13Phe (ExAc allele frequency = 0.0001) was found in a Japanese patient also 
carrying a nonsense mutation in CFHR1 and it was previously reported in HELLP 
syndrome and in two Chinese aHUS patients.174, 175 Finally, I also found a novel 
mutation in a patient from Turkey, c.762delT, p.Leu254fsX43 that was not 
reported in ExAc database. 
Two patients showed heterozygous mutations in C3 gene (6.7%). The C3 
c.1774C>T, p.Arg592Trp (ExAc allele frequency = 8.2 x 10-6) was detected in an 
Argentine patient who did not carry the homozygous CFHR1 deletion. This 
mutation was described in literature as p.Arg570Trp in a patient with aHUS and 
functional studies demonstrated that it impairs the CD46 binding resulting in a 
C3b resistant to the cleavage mediated by factor I.83 Another C3 mutation was the 
c.1909G>C, p.Gly637Arg (ExAc allele frequency = 0.0002). It was not reported 
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in published data and was predicted probably damaging. Both these mutations are 
localized at the end of the C3 beta chain in the linker domain. 
Lastly, 3 patients with anti-FHs were also carriers of THBD mutations (10%) that 
were previously reported in Delvaeye et al. (c.1693G>T- p.Asp486Tyr, 
c.1502C>T - p.Pro501Leu, and c. 241G>A - p.Val81Ile). Functional studies have 
shown that these variants were less effective in enhancing factor I mediated 
conversion of C3b to iC3b.31  
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Table 4-4. Likely pathogenic variants in CFH, CD46, C3 and THBD genes observed in aHUS 
patients with anti-FHs. 
It was also indicated the ethnicity, the population to which the patient belonged, the allelic 
frequency from ExAC database, the PolyPhen prediction (“Prob D” meant Probabily Damaging), 
and the literature references (Ref). nd = not detected 
 
 
 
  
ID patient Gender Ethnicity Popolation Likely pathogenic variants MAF Prediction by PolyPhen Ref
1 F Caucasian (Eu) Italian nd
2 M Caucasian (Eu) Italian  CFH  c.2850G>T, p.Gln950His 0.004 Prob D 107, 168-171
3 F Caucasian (Eu) Portuguese nd
4 F Caucasian (Eu) German nd
5 M Caucasian (Eu) Italian nd
6 M Caucasian (Eu) Italian C3  c.1909G>C, p.Gly637Arg na Prob D
7 M Caucasian (Eu) Italian THBD  c.1693 G>T, p.Asp486Tyr 0.006 B 31
8 M Caucasian (USA) American nd
9 F Caucasian (Eu) Serbian nd
10 F Caucasian (Eu) Serbian nd
11 F Caucasian (Eu) Italian nd
12 M Caucasian (Eu) Italian nd
13 F Caucasian (Eu) Turkish CD46  c.762delT, p.Leu254fsX43 na Prob D nd
14 F Caucasian (Eu) Bulgarian nd
15 M Caucasian (Eu) Polish CD46  c.1148C>T, p.Thr383Ile 6 x 10-4 B 172-173
16 F Caucasian (USA) American nd
17 F Caucasian (USA) American nd
18 M Caucasian (Eu) Italian nd
19 F Caucasian (Eu) Italian THBD  c.1502C>T, p.Pro501Leu 0.002 B 31
20 F Caucasian (Eu) Dutch nd
21 F Hispanic Argentine  C3 c.1774C>T, p.Arg592Trp 8 x 10-6 Prob D 83
22 M Caucasian (Eu) Polish nd
23* M Asian Japanese CD46  c.38C>T, p.Ser13Phe 0.0001 Prob D 174-175
24 M Jewish Israeli  CFH  c.2758T>C, p.Trp920Arg na Prob D nd
25 M Persian Iranian nd
26 M Hispanic Argentine nd
27 M Caucasian (Eu) Italian CFH c.2776T>C, p.Cys926Arg na Prob D
28 F Caucasian (Eu) Italian nd
29 M African-Arab Yemenian THBD  c. 241G>A, p.Val81Ile 9 x 10-6 B 31
30 M Caucasian (Eu) Belorussian nd
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4.3.9 Susceptibility genetic variants 
I also investigated whether common genetic variants in CFH and CD46 
previously associated with aHUS can promote susceptibility to anti-FH mediated 
aHUS. The prevalence of CFH c.1-332C>T (rs3753394), c.184G>A p.Val62Ile 
(rs800292), c.1204T>C p.Tyr402His (rs1061170), c.2016A>G Gln572Gln 
(rs3753396), c.2237-543G>A (rs1410996), c.2808G>T Glu936Asp (rs106548), 
and CD46 c.*783T>C (rs7144) was evaluated in all 30 aHUS patients with anti-
FHs (Table 4-3) and in 50 “super controls”, subjects showing the homozygous 
deletion of CFHR1 (Table 4-5). The comparison was also performed between the 
patients with both anti-FHs and the homozygous CFHR1 deletion (n = 24) and 
super controls. I observed that the CFH c.2016G (572Gln), c.2237-543G, and  
c.2808T (936Asp) alleles were overrepresented in all anti-FH positive aHUS 
patients compared to super controls with the homozygous CFHR1 deletion 
(Fisher’s exact test, c.2016G: p-value = 0.012, c.2237-543G: p-value= 0.009, and 
c.2808T: p-value=0.016, respectively, Table 4-6). The allelic frequencies did not 
show any differences between cases and controls if I considered the patient group 
with homozygous deletion of CFHR1 (Table 4-6). Considering that the 
significance cut-off after the Bonferroni correction was set at 0.007, the 
significance was lost for all these SNPs. No significant association was found 
considering the other common CFH and CD46 SNPs (Table 4-6).  
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Table 4-5. CFH and CD46 SNPs in super controls. 
Genotypes of CFH SNPs (rs3753394, rs800292, rs1061170, rs3753396, rs1410996, and rs106548) 
and CD46 SNP rs7144 in 50 healthy controls with the homozygous deletion of CFHR1 (super 
controls). na = data not available 
 
Controls 
with Hom 
CFHR1∆
CFH c.1-332C>T  
(rs3753394)
CFH 
c.184G>A 
Val62Ile 
(rs800292)
CFH 
c.1204T>C 
Tyr402His 
(rs1061170)
CFH 
c.2016A>G 
Gln572Gln 
(rs3753396)
CFH c.2237-543G>A  
(rs1410996)
CFH 
c.2808G>T 
Glu936Asp 
(rs1065489)
CD46 
c.*783T>C 
(rs7144)
1 C T G G T T A A  A A G G T T
2 C T G A T T A A  A A G G T T
3 C T G G T T A A  A A G G T T
4 C C G G T T A A  A A G G T T
5 C T G G T T A A  A A G G C C
6 C C G A T T A A  A A G G T T
7 C T G G T T A A  A A G G T T
8 na G G T T A A  A A G G na
9 C T G G T T A A  A A G G C C
10 C T G G T T A A  A A G G T C
11 C T G G T T A A  A A G G T C
12 T T G G T T A A  A A G G C C
13 C C G G T C na G A G G T C
14 C T G G T T A A  A A G G na
15 C C G G T T A A  A A G G T C
16 T T G G T T A A  A A G G T C
17 C T G G T T A A  A A G G T C
18 C T G G T T A A  A A G G T C
19 C T G G T T A A  A A G G T T
20 C C G G T T A A  A A G G T C
21 C C G G T T A A  A A G G T C
22 C C G G T T A A  A A G G T T
23 C C G G T T A A  A A G G T T
24 na G A T T A A  A A G G T C
25 C T G G T T A A  A A G G T C
26 C C G G T C A A G A G G C C
27 C C G G T T A A  A A G G T C
28 na G G T T A A  A A G G T C
29 na G A T T A A  A A G G T C
30 na G G T T A A  A A G G T C
31 na G G T T A A  A A G G T C
32 C C G G T T A A  A A G G T C
33 C T G G T T A A  A A G G T T
34 C C G G T T A A  A A G G T C
35 C T G G T T  A A na G G T T
36 T T G G T T  A A  A A G G T C
37 C T G G T T A A  A A G G na
38 T T G G T T A A  A A G G T T
39 C T G G T T A A  A A G G T C
40 C C G G T T A A  A A G G T T
41 C T G G T T A A  A A G G T T
42 T T G G T T A A  A A G G T C
43 C T G G T T A A  A A G G T T
44 C T G G T T A G G A G T T T
45 C C G G T T A A  A A G G T C
46 C T G G T T A A  A A G G T C
47 C C G G T T A A  A A G G T C
48 C T G A T T A A  A A G G T T
49 C T G G T T A A  A A G G C C
50 na G A T T A A  A A G G T T
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Table 4-6. Frequency of CFH and CD46 susceptibility variants in aHUS patients with anti-FHs and super controls. 
Prevalence of CFH rs3753394, rs800292, rs1061170, rs3753396, rs1410996, rs1065489, and CD46 rs7144 in aHUS patients with anti-FHs and healthy controls with the 
homozygous CFHR1 deletion (hom CFHR1Δ). The comparison was performed considering either the whole cohort of patients with anti-FHs (n=30) or aHUS patients with anti-
FHs also carrying the homozygous CFHR1 deletion (n=24). “M” is referred to the major allele, “m” is referred to the minor allele. *Fisher’s exact test. 
MM Freq MM Mm Freq Mm mm Freq mm p-value M Freq M m Freq m p-value
CFH c.1-332C>T (rs3753394) aHUS with anti-FH (n=30) 9 0.3 14 0.47 7 0.23 0.414 32 0.53 28 0.47 0.709
aHUS with anti-FH and HomCFHR1 Δ (n=24) 7 0.29 12 0.5 5 0.21 0.587 40 0.54 22 0.46 0.983
ctr with HomCFHR1∆  (n=43) 15 0.35 23 0.53 5 0.12 53 0.62 33 0.38
CFH  c.184G>A Val62Ile (rs800292) aHUS with anti-FH (n=30) 23 0.77 7 0.23 0 0.00 0.596 53 0.88 7 0.12 0.238*
aHUS with anti-FH and HomCFHR1∆(n=24) 20 0.83 4 0.17 0 0.00 0.983 44 0.92 4 0.08 0.728*
ctr with HomCFHR1∆  (n=50) 44 0.88 6 0.12 0 0.00 94 0.94 6 0.06
CFH  c.1204T>C Tyr402His (rs1061170) aHUS with anti-FH (n=29) 24 0.83 5 0.17 0 0.00 0.285 53 0.91 5 0.09 0.101*
aHUS with anti-FH and HomCFHR1∆  (n=23) 21 0.91 2 0.09 0 0.00 0.791 45 0.98 3 0.07 0.329*
ctr with HomCFHR1∆   (n=50) 48 0.96 2 0.04 0 0.00 98 0.98 2 0.02
CFH c.2016A>G Gln572Gln (rs3753396) aHUS with anti-FH (n=30) 25 0.83 4 0.13 1 0.03 0.055 54 0.9 6 0.10 0.012*
aHUS with anti-FH and HomCFHR1∆(n=24) 22 0.92 2 0.08 0 0.00 0.812 46 0.96 2 0.04 0.252*
ctr with HomCFHR1∆ (n=49) 48 0.98 1 0.02 0 0.00 97 0.99 1 0.01
CFH  c.2237-543G>A (rs1410996) aHUS with anti-FH (n=28) 1 0.04 7 0.25 20 0.71 0.021 9 0.16 47 0.84 0.009*
aHUS with anti-FH and HomCFHR1∆ (n=23) 0 0.00 3 0.13 20 0.87 0.867 3 0.07 43 0.93 0.384*
ctr with HomCFHR1∆ (n=49) 0 0.00 3 0.06 46 0.94 3 0.03 95 0.97
CFH  c.2808G>T Glu936Asp (rs1065489) aHUS with anti-FH (n=30) 25 0.84 4 0.13 1 0.03 0.051 54 0.9 6 0.10 0.016
aHUS with anti-FH and HomCFHR1∆ (n=24) 22 0.92 2 0.08 0 0.00 0.507 46 0.96 2 0.04 0.246
ctr with HomCFHR1∆ (n=50) 49 0.98 1 0.02 0 0.00 99 0.99 1 0.01
CD46  c.*783T>C (rs7144) aHUS with anti-FH (n=30) 12 0.40 11 0.37 7 0.23 0.181 35 0.58 25 0.42 0.876
aHUS with anti-FH and HomCFHR1∆ (n=24) 10 0.42 10 0.42 4 0.17 0.544 30 0.63 18 0.38 1.000
ctr with HomCFHR1∆ (n=43) 16 0.37 23 0.53 4 0.09 55 0.64 31 0.36
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The association analysis was also performed considered the common 
polymorphisms in C3 c.304C>G, p.Arg102Gly (rs1047286), C3 c.941C>T, 
p.Pro314Leu (rs2230199), CFB c.94C>T, p.Arg32Trp (rs12614), CFB c.95G>A, 
p.Arg32Gln (rs641153) and THBD c.1418C>T, p.Ala473Val (rs1042579). No 
significant associations with the disease have been found with these 
polymorphisms despite a trend was present for C3 c.304G 102Gly and c.941T 
314Leu, which are in partial linkage disequilibrium (LD), caused by an increased 
number of heterozygous individuals for these variants (Table 4-7). 
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Table 4-7. Frequency of C3, CFB, and THBD susceptibility variants in aHUS patients with anti-FHs and super controls. 
Prevalence of C3 rs1047286 and rs2230199, CFB rs12614 and rs64115, and THBD rs1042579 in aHUS patients with anti-FHs and healthy controls with the homozygous CFHR1 
deletion (hom CFHR1Δ). The comparison was performed considering either the whole cohort of patients with anti-FHs (n=30) or aHUS patients with anti-FHs also carrying the 
homozygous CFHR1 deletion (n=24). “M” is referred to the major allele, “m” is referred to the minor allele. *Fisher’s exact test.   
MM Freq MM Mm Freq Mm mm Freq mm p-value M Freq M m Freq m p-value
C3  c.304C>G Arg102Gly (rs2230199) aHUS with anti-FH (n=27) 14 0.52 13 0.48 0 0.00 0.058 41 0.76 13 0.24 0.681
aHUS with anti-FH and hom CFHR1 Δ (n=22) 11 0.50 11 0.50 0 0.00 0.065 33 0.75 11 0.25 0.636
ctr with hom CFHR1∆ (n=24) 17 0.71 5 0.21 2 0.08 39 0.81 9 0.19
C3  c.941C>T Pro314Leu (rs1047286) aHUS with anti-FH (n=27) 16 0.59 11 0.41 0 0.00 0.073 43 0.80 11 0.20 0.822
aHUS with anti-FH and hom CFHR1 Δ (n=22) 13 0.59 9 0.41 0 0.00 0.098 35 0.80 9 0.20 0.842
ctr with hom CFHR1∆ (n=24) 18 0.75 4 0.17 2 0.08 40 0.83 8 0.17
CFB  c.94C>T Arg32Trp (rs12614) aHUS with anti-FH (n=22) 17 0.77 4 0.18 1 0.05 0.565 38 0.86 6 0.14 1.000*
aHUS with anti-FH and hom CFHR1 Δ (n=19) 15 0.79 3 0.16 1 0.05 0.478 33 0.87 5 0.13 1.000*
ctr with hom CFHR1∆ (n=20) 15 0.75 5 0.25 0 0.00 35 0.88 5 0.13
CFB  c.95G>A Arg32Gln (rs641153) aHUS with anti-FH (n=22) 17 0.77 4 0.18 1 0.05 0.634 38 0.86 6 0.14 0.745*
aHUS with anti-FH and hom CFHR1 Δ (n=18) 15 0.83 3 0.17 0 0.00 0.997 33 0.92 3 0.08 1.000*
ctr with hom CFHR1∆ (n=19) 15 0.79 4 0.21 0 0.00 34 0.89 4 0.11
THBD  c.1418C>T  Ala473Val (rs1042579) aHUS with anti-FH (n=27) 16 0.59 11 0.41 0 0.00 0.850 43 0.80 11 0.20 0.614
aHUS with anti-FH and hom CFHR1 Δ (n=22) 14 0.64 8 0.36 0 0.00 0.979 36 0.82 8 0.18 0.854
ctr with hom CFHR1∆ (n=24) 17 0.71 7 0.29 0 0.00 41 0.85 7 0.15
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4.3.10 CFH haplotypes 
Since strong LD is present in the CFH region (Figure 4-4), CFH haplotypes have 
been studied in the 24 aHUS patients with anti-FHs and homozygous deletion of 
CFHR1 and the 50 super controls. The expectation maximization algorithm by 
Haploview software was used to estimate each CFH haplotype frequency. The 
minimal informative SNPs within CFH gene considered for this analysis were 
rs3753394 (promoter), rs800292 (exon 2), rs1061170 (exon 9), rs3753396 (exon 
14), rs1410996 (intron 15), and rs1065489 (exon 19), as described in Rodriguez-
De Cordoba et al..88  
 
Figure 4-4. LD in CFH locus. 
The analysis was obtained with Haplotype software using 6 CFH SNPs as markers (rs3753394, 
rs800292, rs1061170, rs3753396, rs1410996, and rs1065489). The red boxes meant complete LD 
with LOD ≥2 and blue boxes a LOD<2 and D’ =1. 
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The most frequent CFH haplotypes were the CGTAAG (H4a CFH haplotype), 
which was estimated to have an allele frequency of 42.7% in aHUS patients and 
of 54.7% in super controls and the TGTAAG (H4b CFH haplotype) which was 
estimated to have an allele frequency of 40.6% in aHUS patients and of 36.3% in 
super controls (Table 4-8). H1 CFH haplotype (CGCAGG) that is reported in 
literature to be the most common CFH haplotype in healthy subjects was 
estimated to have a frequency of 4.2% in aHUS patients and 2% in super controls 
(Table 4-8). The H3 CFH haplotype, (TGTGGT), that is described strongly 
associated with aHUS, was estimated in 4.2% of aHUS patient chromosomes and 
in 1% of super control chromosomes (Table 4-8). The H2 CFH haplotype 
(CATAAG) were estimated to be more frequent in aHUS patients compared to 
super controls (haplotype frequency = 7.3% and 5.3%, respectively, Table 4-8). In 
summary, no significant association has been found between CFH haplotypes and 
anti-FH-mediated aHUS when I considered as reference sample the “super 
controls”. 
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Table 4-8. Identification of CFH haplotypes. 
CFH haplotypes were identified through Haploview software in 24 aHUS patients with anti-FHs 
and 50 healthy controls both carrying the homozygous deletion of CFHR1. The estimated 
frequencies of each CFH haplotype in aHUS patients and super controls were also shown. The 
minimal informative SNPs within CFH gene considered for this analysis were rs3753394, 
rs800292, rs1061170, rs3753396, rs1410996, and rs1065489. 
 
Interestingly, in patients with anti-FHs, H4a and H4b CFH haplotypes were found 
in strong LD with the CFHR3-CFHR1 deletion (Table 4-9). The CFH H2 was 
also found to be in association with the CFHR3-CFHR1 deletion but the allele 
frequency was lower than CFH H4a and H4b haplotypes (Table 4-9). Instead, the 
CFHR1-CFHR4 deletion in our cohort of patients was associated with CFH H5 
and H3 haplotypes (Table 4-9).  
 
Estimated CFH 
haplotype
Haplotype 
reference 
number
aHUS 
patients 
with anti-FH
Super 
controls p-value
CGTAAG H4a 0.427 0.547 0.174
TGTAAG H4b 0.406 0.363 0.616
CATAAG H2 0.073 0.053 0.628
CGCAGG H1 0.042 0.02 0.447
TGTGGT H3 0.042 0.01 0.201
Haplotype frequency
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Table 4-9. LD between CFH haplotypes and CFHR3-CFHR1 or CFHR1-CFHR4 deletions in 
aHUS patients with anti-FHs. 
 (D = wild type allele, d = allele with deletion). 
 
4.3.11 Analysis of the genetic variants in CFH promoter that could 
predispose to the loss of tolerance toward FH  
In an attempt to investigate possible genetic factors predisposing to lack of 
tolerance toward FH/FHR1 and anti-FHs, I studied the sequence of the CFH distal 
promoter in aHUS patients with anti-FHs looking for possible variants in AIRE 
“autoimmune regulator” consensus regions. AIRE, is the most important DNA 
binding molecule expressed in the thymus involved in immune regulation and 
tolerance. The analysis through Matinspector software (Genomatix) revealed the 
presence of two sequences predicted with a good score as AIRE consensus motifs 
(Figure 4-5). Both sequences were compatible with possible AIRE binding 
sequences as described in Kumar et al.137 I sequenced a region around 600 bp 
upstream the CFH proximal promoter including the two predicted AIRE 
consensus regions but I did not find any mutation or common variant in aHUS 
Estimated CFH 
haplotype
Haplotype 
reference 
number
∆CFHR3-
CFHR1
∆CFHR1-
CFHR4
Frequency 
mean
CGTAAG H4a d D 0.428
TGTAAG H4b d D 0.321
CATAAG H2 d D 0.090
TGTGGT H3 D D 0.068
TGCAGG H5 D d 0.036
CGCAGG H1 D D 0.023
TGTGGT H3 D d 0.018
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patients with anti-FHs, with the only exception of a common variant c.1-778 A>G 
in an Argentinean patient (rs35928059, MAF = 32% in South America 
population). No variations have been observed in two DNA sequences predicted 
as AIRE consensus regions. 
 
 
Figure 4-5. The sequence of CFH promoter. 
Exon 1 (yellow), basal promoter (light grey), proximal promoter (dark grey) and two AIRE 
consensus sequences predicted by Matinspector software - Genomatix (underlined) were shown. 
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4.4 Discussion 
In this study I found 30 out of 305 unrelated aHUS patients with anti-FHs. The 
prevalence (9.8%) was concordant with previously published data (4.6-13.3%).43, 
98, 109 I have also found 1 out of 111 controls with anti-FHs (0.09%) as compared 
to 1-4% healthy positive subjects reported in literature.109 In our healthy controls 
the lower prevalence of anti-FHs is likely determined by the systematic 
approaches adopted to eliminate the false positive samples and to increase the 
ELISA specificity. 
CFHR1 deficiency is present in 83.3% of aHUS patients with anti-FHs. This 
deficiency is caused by the presence of the homozygous CFHR3-CFHR1 deletion 
in 66.7% of patients, the compound heterozygous CFHR3-CFHR1/CFHR1-
CFHR4 deletions in 13.3% of patients, and the heterozygous CFHR3-CFHR1 
deletion combined with a stop codon in CFHR1 gene (c.104delAfsX, 
p.D35fsX36) that leads to a complete FHR1 deficiency in another patient. Several 
studies reported that 79-89% of aHUS patients with anti-FHs were carriers of 
deletion or nonsense mutations in CFHR1.43, 109 All these data indicate that in 
aHUS patients the CFHR1 absence strongly predisposes to anti-FHs development 
and to aHUS.  
Of note, FHR1 deficiency is not an absolute prerequisite for development of anti-
FHs. Similar to data showed in Moore and colleagues, who reported 3 out of 13 
patients without copy number defects in CFHR3 and CFHR1, I have found 3 
patients with anti-FHs carrying one copy of CFHR1 and 2 patients with 2 copies 
of CFHR1. Altogether these results suggest that in a few aHUS patients the 
development of anti-FHs is not dependent on FHR1 deficiency.107 
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In this cohort of patients, most of anti-FHs predominantly targeted the C terminal 
of FH, a crucial domain involved in the regulation of AP complement activation at 
the cell surface, and this specificity is not strongly correlated with the presence of 
homozygous deletion of CFHR1. At variance, Nozal et al. reported that FH 
autoantibodies from 13 aHUS patients with FHR1 deficiency mainly recognized 
SCR19-20 but in 6 patients with at least one copy of CFHR1 the anti-FH 
specificity was more heterogeneous.176 It was well demonstrated that FH C 
terminus is a main domain for regulatory activity. CFH mutations in aHUS 
patients cluster in SCR 19-20 and a transgenic murine model with deficiency of 
FH SCR16-20 spontaneously manifests aHUS.93, 177 Nozal et al. have 
demonstrated that FH 1183-1189 and 1210-1215 within SCR19-20 are the main 
antibody binding sites.176 Bhattacharjee et al. also described autoantibody 
epitopes in SCR20, next to Ser1191 and Val1197 aminoacids, where FH binds 
heparin, endothelial cells and common microbes.48, 121  
In this study I have evidenced that among about 1400 Caucasian healthy controls, 
mostly Italian, 5% are carriers of the homozygous CFHR1 deletion. Only 1 out of 
13 healthy controls with no copies of the CFHR1 gene, resulted positive (0.08%), 
while among 98 controls with at least one copy of CFHR1 none showed anti-FHs. 
This finding suggests that also in healthy subjects the CFHR1 deletion could 
predispose to the anti-FH development but this condition is not sufficient for the 
aHUS manifestation. This hypothesis is supported by the published evidence of 
few unaffected siblings reported with the homozygous CFHR1 deletion showing 
elevated anti-FH titers.110 
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Since the homozygous CFHR1 deletion is present in the 5% of healthy 
population, it cannot be considered sufficient alone to determine the anti-FH –
mediated aHUS which has a prevalence of 1:1,000,000. This observation suggests 
that the aHUS caused by anti-FHs is a complex disease in which multiple hits 
(such as mutations, common variants, and triggers) are necessary for the disease 
to manifest. 
Indeed, in this study, 11 patients with anti-FHs were also carriers of mutations in 
complement genes (37%). This prevalence was higher compared to that present in 
literature (14.7%) which is referred to 95 published cases. CFH, CD46, and 
THBD mutations are the more abundant (both presented 10% of prevalence in our 
patients). Interestingly, the CFH c.2850G>T p.Gln950His, that I have identified in 
1 patient, was also found in other 4 patients without anti-FHs of our aHUS cohort 
(carrier frequency = 0.009). Of note, all patients with CFH c.2850T variant 
showed the CFHR1 deletion at least in one chromosome suggesting the presence 
of a strong LD between this mutation and the deletion of CFHR1. However, only 
one of the 4 patients who carried this variant had anti-FHs. This observation could 
lead to consider the CFH c.2850T like a risk variant for the atypical HUS but not 
a predisposing factor for the autoimmunity against factor H. This conclusion was 
supported by evidences obtained by Mohlin and colleagues who showed that 
serum of patients carrying the CFH c.2850T caused moderate but statistically 
significant lysis of the erythrocytes during the hemolytic assay.168 In the literature, 
concomitance mutations are reported in about 25% of aHUS patients with CFI 
mutations but here no patients showed defects in CFI gene.86 Interestingly, anti-
FHs were also found in combination with C3 and THBD mutations. The presence 
Variants in complement genes 
119 
 
of mutations in complement genes in aHUS patients with anti-FHs have also been 
reported in other studies and together with my findings document that the 
combination of both acquired and genetic factors in some patients could be crucial 
for the aHUS development.107 
CFH common variants were described as additional genetic risk factors that can 
increase the aHUS penetrance.86, 87 Here, an association analysis has been 
performed using “super controls”, healthy individuals with the homozygous 
CFHR1 deletion, a risk factor for aHUS associated to anti-FHs, but no significant 
associations were observed. The lack of CFH polymorphisms associated to an 
increased aHUS risk, such as CFH c.1-332C>T (rs3753394), c.2016A>G 
Gln572Gln (rs3753396), and c.2808G>T Glu936Asp (rs106548), was caused 
from the absence of the predisposing CFH H3 haplotype in these patients with 
anti-FHs. In this study, the CFH H4a (CGTAAG) and CFH H4b (TGTAAG) 
haplotypes were found in most patients with anti-FHs but also in “super controls”. 
Indeed, the CFHR3-CFHR1 deletion was in LD with both CFH H4 haplotypes 
(CGTAAG and TGTAAG). The other CFH haplotype that tags the CFHR3-
CFHR1 deletion in our patients is the H2 haplotype (CATAAG) which shares 
with CFH H4 haplotype the last three variants (AAG), respectively rs3753396 
(CFH exon 14), rs1410996 (CFH intron 15), rs1065489 (CFH exon 19). Spencer 
et al. observed that the rs3753396 “A” variant and the rs1065489 “G” variant 
were in LD with the CFHR3-CFHR1 deletion.178 All these data evidence that a 
strong LD exists between the last portion of CFH sequence and the CFHR3-
CFHR1 deletion. A limited number of DNA breakpoints in CFH genomic region 
are probably present in aHUS patients and controls with CFHR3-CFHR1 deletion 
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who likely share the same CFH sequence in this chromosome region. These data 
also suggest that in aHUS patients with anti-FHs there should not be peculiar 
variants at least in the second portion of CFH sequence compared to healthy 
controls which could have a role in the development of anti-FHs. Similarly, the 
FH H3 haplotype, that has been previously reported associated with aHUS, (29% 
in aHUS patients vs 20.7% in healthy controls, p-value = 0.013 in Rodriguez-De 
Cordoba et al.88), was not overrepresented in our aHUS patients with anti-FHs and 
it showed a similar allele frequency in patient and super control groups (2.1% 
versus 1%).88 Thus, factors predisposing to loss of tolerance toward FH have 
probably to be looked for in other genomic regions. 
Also the CD46 GGAAC haplotype has been reported to be associated with an 
increased risk of aHUS. Moore et al. found that 10 out of 13 aHUS patients with 
anti-FH (77%) carried the CD46 GGAAC haplotype and suggested that it could 
be a possible susceptibility factor for the development of aHUS in patients with 
anti-FHs.107 Here, the CD46 C variant of the rs7144 has been used as a marker for 
the at-risk CD46 haplotype 94 but no significant difference in the prevalence of the 
C variant was found between patients with the factor H autoantibodies and the 
“super controls” reference group. 
The C3 102Gly variant was overrepresented in aHUS patients with anti-FHs 
compared to control group caused by the presence of more than two-fold 
heterozygous in cases than healthy subjects, but the result is not statistically 
significant. Of note, The C3 102Gly was associated with AMD, IgA nephropathy, 
systemic vasculitis, kidney graft dysfunction, and DDD.165, 167, 178, 179 This 
association was not described in aHUS and was not confirmed in another 
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published study on DDD or other membranoproliferative glomerulonephritis.55 Of 
note, the C3 102G variant has a functional effect because it is demonstrated to 
activated AP more efficiently in hemolytic assay and in its presence the FH 
cofactor activity was reduced favoring AP activation.92  
In order to identify the genetic factors that can determine the loss of tolerance and 
autoimmunity against FH in subjects with the homozygous CFHR1 deletion, I 
focused on the CFH promoter looking for possible variants that can influence the 
genetic expression in thymus, the crucial organ for immunological tolerance.138, 
139 First of all, I studied the CFH SNP rs3753394, which is located in an NF-kB 
responsive element within the CFH promoter and it was previously reported to be 
associated with aHUS.87, 180 However, as I have described above, I found that 
rs3753394 T variant was not associated with aHUS caused by anti-FHs using as 
reference group healthy controls with the homozygous CFHR1 deletion. In silico 
analyses of CFH promoter region showed the presence of two sequences 
predicted as possible consensus for the binding of AIRE, an autoimmune regulator 
that is expressed by mTEC cells in thymus and is crucial for the expression of the 
tissue specific antigens and the maintenance of the central tolerance.181 The 
sequencing of the CFH distal promoter region, including the two predicted AIRE 
binding sequences, did not reveal any mutations in patients with anti-FHs 
suggesting that this region is not involved in the loss of the tolerance for FH 
antigene. 
In conclusion in this chapter of the thesis, I have documented that the anti-FH 
mediated aHUS is a complex disease, in which the FHR1 deficiency represents a 
strong risk factor for the anti-FH development and in which additional genetic 
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defects are required for the disease to manifest. However, the presence of the 
FHR1 deficiency is not enough for the anti-FH development. This consideration is 
supported by evidences according to which autoimmune diseases are often 
complex disorders caused by polygenic factors each conferring a small percentage 
of risk that leads to a susceptible state.182, 183 Infections or other trigger events 
could perturb this status promoting the loss of tolerance and the development of 
autoimmunity.
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5  Clinical features of patients with anti-FH 
antibodies 
5.1 Introduction 
Atypical Hemolytic Uremic Syndrome (aHUS) is associated to the presence of 
anti-FHs in about 5-14% of patients in European cohorts.98, 106, 107, 110 Anti-FHs 
mainly develop in the context of FHR1 deficiency and caused the impairment of 
factor H functions compromising the self surface protection from complement 
activation and the development of the disease.115 
Only few clinical reports with the description of aHUS patients with anti-FHs are 
available in the literature. The large majority of cases have been evaluated during 
the acute phase of the disease before any treatment but in patients analyzed at 
follow-up anti-FHs remained detectable also during the convalescence.109 Anti-
FHs affect mainly children between 5 and 15 years and the age at the disease 
onset is different from that described in children affected by aHUS carrying 
mutations in CFH or DGKE mutations, which is in the first years of life.106, 109 
Most of aHUS cases with anti-FHs present prodromal signs, especially upper 
respiratory tract infections or gastrointestinal signs (such as abdominal pain, 
vomiting, and diarrhea).109 Low C3 levels are observed in 41-67% of patients 
indicating the AP of complement is activated.109 On the contrary, C4 is normal in 
the large majority of them.109 The FH antigen levels are not reported to be 
correlated with the anti-FH titer although in the acute phase of the disease they 
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decrease in few patients because FH is bound to autoantibodies forming immune-
complexes.109, 114  
Relapses occur in a large proportion of patients with anti-FH associated aHUS.109 
Moreover, about 30% of patients develop ESRD.106, 110 Plasma exchange is more 
effective than plasma infusion to induce hematological remission, although 35% 
of patients treated with plasma exchange developed renal failure.109 On the 
contrary, the combination of plasma exchange and immunosuppression is reported 
to reduce the risk of aHUS relapses and to protect the renal function.109 Indeed, 
only 14.3% of patients treated with plasma exchange in combination with 
immunosuppression manifested ESRD.109 Eculizumab has been successfully 
adopted in few cases leading to the remission of the disease, discontinuation of 
plasma treatment, and renal recovery in the large majority of cases.109 Finally, 
plasma exchange and immunosuppression are effective administered before the 
transplant to prevent the recurrence of the disease on the graft in most patients. 
Eculizumab is also used to prevent aHUS recurrence after renal transplantation 
but only a limited number of cases are available in the literature.  
In this chapter I described the clinical and biological features of 30 patients 
affected by aHUS and positive for anti-FHs, of whom 25 were also carriers of the 
FHR1 deficiency. 
5.2 Specific aim 
To describe the clinical features of 30 patients with anti-FH associated aHUS. 
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5.3 Results 
Clinical data concerning the acute (n=4) or the remission phase (n=26) were 
obtained for all the 30 aHUS patients with anti-FHs (Table 5-1). 
The mean anti-FH titers was 1164.76±1189.51 AU/mL for samples collected 
during the acute phase of the disease (n=4) and 521.83±504.34 AU/mL for 
samples collected during the remission phase (n=26; ANOVA, p-value = 0.062). 
C3 and C4 level data were available for 28 patients (Table 5-1). Fourteen patients 
(46.7%) showed lower than normal C3 levels and in most of them C3 was 
measured during the convalescence (mean ± SD, 90 mg/dL ± 34, normal range 
90-180 mg/dL). On the contrary, C4 levels were normal in all patients (mean ± 
SD, 28 mg/dL ± 13, normal range 10-40 mg/dL). FH have been measured in 24 
patient samples and resulted in normal range in all cases (mean ± SD, 344 mg/L ± 
110, normal range 172-507 mg/L, Table 5-1) with the only exception of patient 
number 14 (studied in remission and with a high antibody titer, 1557.3 AU/mL) 
who showed 80 mg/L FH. The mean of FH levels did not differ between samples 
collected during the acute and the remission phase of the disease (340±49 mg/L 
n=3 and 345±117 mg/L, n=21, respectively; ANOVA, p-value = 0.951) and the 
FH levels were not correlated to the antibody titer (r2 = 0.0085). 
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Table 5-1. Clinical and biological data of 30 patients with anti-FH associated aHUS. 
F: female; M: male; Phase: indicates the phase of the disease when the samples were collected, 
remission phase (Rem) or acute phase (Acute). na = not available 
 
The large majority of patients with anti-FHs of our cohort were Caucasians.They 
showed an equal gender ratio, with 53.3% males (Table 5-1). The median age of 
disease onset was 7.7 [6.6-9.9] years. All patients with anti-FHs but one 
1 F Caucasian (Eu) 7.0 Rem Vomiting 453.4 30 12 na
2 M Caucasian (Eu) 7.7 Rem Flu like 381.6 141 27 na
3 F Caucasian (Eu) 7.6 Rem Upper respiratory tract infection 280.8 112 29 na
4 F Caucasian (Eu) 8.0 Rem None 513.2 na na na
5 M Caucasian (Eu) 8.8 Rem Vomiting 146.6 85 25 349
6 M Caucasian (Eu) 6.2 Rem Flu like 243.0 81 26 309
7 M Caucasian (Eu) 5.7 Rem None 572.0 94 17 312
8 M Caucasian (USA) 6.7 Rem na 1646.1 77 31 283
9 F Caucasian (Eu) 7.6 Rem Vomiting 876.7 70 19 302
10 F Caucasian (Eu) 6.6 Acute Upper respiratory tract infection 1314.9 103 25 397
11 F Caucasian (Eu) 5.4 Acute Vomiting 2781.0 96 28 na
12 M Caucasian (Eu) 7.8 Rem Vomiting 342.9 185 62 307
13 F Caucasian (Eu) 12.8 Rem None 1590.4 118 22 686
14 F Caucasian (Eu) 15.5 Rem Vomiting and fever 1557.3 35 27 80
15 M Caucasian (Eu) 11.0 Rem Vomiting 862.3 100 30 438
16 F Caucasian (USA) 10.5 Rem Vomiting and fever 877.4 na na 308
17 F Caucasian (USA) 5.3 Rem Flu like 189.15 106 70 446
18 M Caucasian (Eu) 10.1 Rem Vomiting 531.2 75 14 463
19 F Caucasian (Eu) 8.8 Rem na 226.6 78 20 374
20 F Caucasian (Eu) 30.2 Rem Caesarean 111.8 149 38 432
21 F Hispanic 17.6 Rem Oral contraceptive 96.6 39 25 244
22 M Caucasian (Eu) 7.6 Rem Upper respiratory tract infection 102.1 89 39 362
23 M Asian 9.2 Acute Vomiting and fever 123.1 54 29 307
24 M Jewish 5 Rem None 77.6 126 35 226
25 M Persian 15.0 Acute Upper respiratory tract infection 440.15 95 27 317
26 M Hispanic 6.5 Rem None 141.2 96 27 362
27 M Caucasian (Eu) 7.1 Rem Upper respiratory tract infection 65.2 65 14 246
28 F Caucasian (Eu) 8.1 Rem Vomiting and fever 57.1 99 22 372
29 M African-Arab 1.3 Rem Upper respiratory tract infection 303.9 68 11 na
30 M Caucasian (Eu) 6.9 Rem Vomiting 1321.7 63 31 337
Disease triggers
Anti-FH 
titer 
(AU/mL)
C3 level 
(90-180 
mg/mL)
C4 level 
(10-40 
mg/mL)
FH level 
(172-507 
mg/L)
ID Gender Ethnicity
Age at 
disease 
onset (years)
Phase
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developed aHUS during childhood or adolescence (96.7%). A woman developed 
anti-FH aHUS at 30 years of age after the caesarean delivery and a child 
manifested aHUS at 16 months (he also carries a THBD mutation, see Table 4-4). 
The distribution of the age at disease onset in patients with anti-FHs was 
unimodal with a clear incidence peak around 8 years of age (Figure 5-1, panel A). 
The distribution of age at the disease onset was different from that of aHUS 
patients negative for anti-FHs and carrying mutations in genes such as CFH, 
MCP, CFI, THBD, C3, CFB and DGKE, who showed a bimodal distribution with 
a peak of earlier onset of aHUS, often before 4 years of age, and a second peak 
during adulthood (Figure 5-1, panel B). 
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Figure 5-1. Distribution of age at disease onset in aHUS patients analyzed for anti-FHs. 
In panel A patients positive for anti-FHs (n=30) and in panel B patients negative for anti-FHs and 
with mutations in complement genes (n=99). 
 
Since in the chapter 4 of this thesis, I have shown that the homozygous CFHR1 
deletion was also more abundant in aHUS patients without anti-FHs compared to 
healthy controls (see Table 4-2), I made further analyses to better understand the 
significance of such association. The percentage of samples analyzed for anti-FHs 
during the acute phase of the disease was 13.3% (4 out of 30) in the group of 
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patients positive for anti-FHs and 19% (5 out of 26) in the group of patients 
negative for anti-FHs and carrying the deletion of CFHR1. Thus, most samples 
were collected during the remission phase in both groups indicating that in 
patients with anti-FHs the antibodies remain detectable after the acute phase, and 
suggesting that most of the anti-FH negative samples were likely true negatives. 
Moreover, in the group of patients negative for anti-FHs and carrying the 
homozygous CFHR1 deletion, the median age at the disease onset was 
significantly different from that of patients positive for anti-FHs carrying the 
homozygous deletion of CFHR1 (median = 24.1 [7.6-38.6] versus 7.7 [6.5-9.1] 
years, Mann-Whitney test, p-value = 0.017). The distribution of age at the disease 
onset also appeared different between these groups of patients (Figure 5-2).  
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Figure 5-2. Distribution of age at disease onset in aHUS patients carrying the homozygous 
deletion of CFHR1. 
In panel A patients positive for anti-FHs (n=24) and in panel B patients negative for anti-FHs 
(n=26). 
 
 
On the contrary, no difference was found in the age of disease onset between 
patients negative for anti-FHs and carrying the homozygous CFHR1 deletion and 
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patients with mutations in complement genes (median = 24.1 [7.6-38.6] versus 
10.6[1.32-31.9] years, Mann-Whitney test, p-value = 0.094, Figure 5-3). 
 
 
Figure 5-3. Distribution of age at disease onset in aHUS patients negative for anti-FHs. 
In panel A patients with the homozygous deletion of CFHR1 (n=26) and in panel B patients with 
mutations in complement genes (n=99). 
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By logistic regression I have estimated the risk for an aHUS patient to present 
anti-FHs when the homozygous deletion of CFHR1 and the age at disease onset 
between 4 and 12 years were present. Twenty-four out of 30 aHUS patients with 
anti-FHs (80%) versus 26 out of 275 aHUS patients without anti-FHs (9.4%) 
showed homozygous deletion of CFHR1 (OR [95% CI] = 38.31 [14.354-
102.231], p-value = 4.88 x 10-22, Table 5-2). Twenty-four out of 30 aHUS patients 
with anti-FHs (80%) versus 27 out of 275 aHUS patients without anti-FHs (9.8%) 
developed the disease between 4 and 12 years of age (OR [95% CI] = 36.74 
[13.805-97.87], p-value = 1.67 x 10-21, Table 5-2). Moreover, the presence of both 
the homozygous CFHR1 deletion and the age at disease onset between 4 and 12 
years further increased the risk to have anti-FHs (OR [95% CI ] = 108 [33.665-
346.472], p-value = 6.94 x  10-33, Table 5-2). 
 
 
Table 5-2. Estimation of risk for an aHUS patient to have anti-FHs in the presence of homozygous 
deletion of CFHR1 and in presence of the age at disease onset between 4 and 12 years. 
OR = odds ratio 
 
 
Positive Negative Sensitivity Specificit OR [CI 95%] p-value
Hom CFHR1∆ 24 26 0.80 0.91 38.31 [14.354-102.231] 4.88 x 10-22
No hom CFHR1∆ 6 249
Onset 4-12 years 24 27 0.80 0.90 36.74 [13.805-97.87] 1.67 x 10-21
Onset <4 or ≥13 years 6 248
Hom CFHR1∆ and onset 
at 4-12 years 20 5 0.67 0.98 108 [33.665-346.472] 6.94 x 10
-33
Others 10 270
anti-FH Ab
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Prodromal signs were observed in the majority of the anti-FH positive patients. 
Six patients (21%) had upper respiratory tract infections (1 of them with vomiting 
and 2 with fever), 12 patients (43%) showed gastrointestinal symptoms (4 of them 
with fever), and 3 flu-like symptoms. One patient developed post-partum aHUS 
and another one during oral contraception. Five patients did not show any trigger 
event and for other 2 patients trigger data were not available (Table 5-1). 
Fourteen patients with anti-FHs developed relapses of the disease (47%) and there 
was no difference between carriers or non-carriers of abnormalities in 
complement genes (45% vs 42%, respectively; Fisher’s exact test, p-value = 
1.000, Table 5-3). Overall, 14 patients (46.7%) developed end stage renal disease 
(ERSD), of whom 6 carrying genetic defects (Table 5-3).  
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Table 5-3. Outcome and treatment of 30 patients with anti-FH associated aHUS. 
ESRD is End Stage Renal Disease. na = not available 
 
Twenty-three out of 30 patients were treated with either fresh frozen plasma 
infusion or with plasma exchange (Table 5-3). Ten out of 23 patients treated with 
plasma developed aHUS relapses (43.5%), and 10 (43.5%) developed end stage 
renal disease (ERSD). Eleven patients were treated with steroids (of whom 9 in 
combination with plasma therapy) and 7 developed ESRD (of whom 6 have 
received steroids and plasma combined therapies) and 4 underwent full remission 
(Table 5-3). Three patients received kidney transplantation and disease recurrence 
ID Relapses ESRD Death Plasma infusion
Plasma 
exchange Dialysis Steroids
Kidney 
trasplant
Recurrence 
on graft
1 No No No Yes Yes Yes Yes No
2 No No No Yes No No Yes No
3 Yes No No No Yes Yes No No
4 No No No Yes Yes No No No
5 No Yes No No No Yes No Yes No
6 Yes Yes No No Yes Yes No No
7 No No No No Yes No No No
8 No Yes No No Yes Yes No No
9 No Yes Yes No Yes Yes Yes Yes No
10 Yes No No Yes No No No No
11 Yes No No Yes No No No No
12 Yes Yes No No Yes No Yes No
13 Yes No No Yes Yes No No No
14 No Yes No Yes No Yes No No
15 No Yes No Yes Yes Yes Yes No
16 No No No No Yes Yes No No
17 Yes Yes No No No Yes No No
18 Yes No No Yes Yes No Yes No
19 No Yes No No No Yes No No
20 No No No Yes No No No No
21 Yes Yes No No No Yes Yes Yes Yes
22 Yes Yes No No Yes Yes Yes No
23 Yes Yes No Yes Yes Yes Yes No
24 Yes Yes No No Yes Yes Yes No
25 Yes No No na na na Yes No
26 No No No Yes No No No No
27 No No No No No Yes No No
28 No No No No No Yes No No
29 No No No Yes No No No No
30 Yes Yes No Yes Yes Yes No No
TreatmentOutcome
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was observed in one of them. Of note, this patient was also a carrier of a C3 
heterozygous mutation, p.Arg592Trp (Table 5-3, also see Table 4-4). 
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5.4 Discussion 
In this chapter I have reported the clinical and biological data of 30 patients with 
aHUS and anti-FHs. All these patients were recruited in the last two decades 
through the International Registry of HUS/TTP of our clinical centre in Ranica 
and belong to a multicentre study. For all of them the diagnosis of aHUS caused 
by anti-FHs was made retrospectively and the large majority of patient data was 
referred to the convalescence phase. Therefore, it is important to note that some 
data limitations are present caused by the retrospective nature of this study. 
In our cohort of patients, the presence of anti-FHs leads to C3 consumption, as 
usually described in aHUS patients carrying mutations and suggesting an 
activation of the AP of complement. Nevertheless, the C3 levels are only slightly 
reduced indicating that a trend to C3 normalization occurred during the remission 
phase of the disease. Despite the presence of anti-FHs in the patient plasma/serum 
samples, the levels of FH are normal, probably because the large majority of 
samples are collected during the convalescence when the autoantibody titer is 
decreased.  
In our cohort, anti-FHs are observed especially in children with a peak of disease 
onset around 8 years, which is different from the age of aHUS onset which occurs 
in patients carrying mutations in complement genes.62, 100 This finding is 
consistent with data observed in other published cohorts of patients in whom the 
anti-FH aHUS is prevalent among cases with onset between 5 and 15 years.106, 109, 
184  
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In our aHUS cases positive for anti-FHs, the age of aHUS onset is different from 
that of patients negative for anti-FHs but carrying the homozygous CFHR1 
deletion, which is more similar to the age of onset in patients carrying mutations. 
Thus, I would hypothesize that in this group of patients the disease is caused by 
genetic defects. 
In this study, 60% of aHUS patients with anti-FHs present prodromal signs, 
mostly upper respiratory tract infections and gastrointestinal symptoms. Published 
clinical reports show that respiratory infections, abdominal pain and vomiting are 
the most common triggers in aHUS patients with anti-FHs.106, 109 These data can 
support the hypothesis according to which the autoimmunity toward FH could 
develop as a result of an infection in subjects with a predisposed background (the 
absence of FHR1). 
The percentage of relapses (47%) in our cohort is similar to that reported in other 
studies in literature and the presence of combined genetic defects seems not to 
increase the risk of aHUS relapses. The incidence of ESRD is 46.7% which is 
quite similar to that in mutation-associated aHUS reported in published data 
(42%-60%) and appears different from the percentage of ESRD reported in other 
studies on anti-FH-associated aHUS (around 30%).109 The worse outcome could 
depend by the presence of a high prevalence of mutations in our cohort (37%, see 
§ 4.3.8) which in combination with the autoantibodies can increase the risk of 
renal failure. 
A large proportion of patients treated with plasma exchange or infusion developed 
ESRD (43.5%) and this data is according to the literature where about 35% of 
cases show renal impairment despite the plasma exchange therapy. In this study, a 
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favourable outcome in patients treated with plasma in combination with steroids is 
not observed while in other studies plasma exchange and immunosuppression 
show a better outcome decreasing the percentage of patients who developed 
ESRD (14.3%).109, 184 I wish to emphasize that my analysis of response to plasma 
and steroids is limited, because it is based on retrospective data; because of the 
rarity of anti-FH associated aHUS patients, it necessarily includes cases from 
several centres, where different plasma and immunosuppression protocols may 
have been used. Of note, none of our patients received anticomplement therapy. 
Regard the kidney transplant, the limited number of our cases makes hard to make 
comparisons with published data. Of note, among 3 patients who underwent 
kidney transplant, a graft loss for aHUS recurrence was observed in only one who 
also carried a C3 mutation which is per se correlated to a high incidence of ESRD 
in patients with aHUS.62 
In conclusion, in this chapter of the thesis, I have described the clinical features of 
a consistent group of aHUS patients with anti-FHs documenting that infections 
may have an important role in triggering full-blown disease.  In addition, the 
concomitant presence of the homozygous CFHR1deletion and a disease onset 
between 4 and 12 years can predict with high sensitivity the presence of anti-FHs 
in a patients affected by aHUS. All these data could help the clinicians to identify 
patients with an autoimmune form of aHUS (especially when plasma therapy is 
already ongoing) and to adopt an appropriate therapy. 
  
 139 
 
6  Analysis of class I and II MHC genes in 
patients with atypical hemolytic uremic syndrome 
and anti-factor H autoantibodies 
6.1 Introduction 
Atypical hemolytic uremic syndrome (aHUS) is usually determined by 
dysregulation of alternative pathway (AP) of complement system caused by 
genetic defects.57  62   
Anti-FH-mediated aHUS is associated with the deficiency of FHR1, a FH 
homologous protein.107, 123 The FH domains characterized by more similarities 
with FHR1 are SCR18, 19, and 20 and the main FH epitopes recognized by 
autoantibodies are included in this conserved region. Specifically, FH SCR18 has 
3 residues that differ from those in FHR1 SCR3 (FH Tyr1058, Val1060, and 
Gln1076 that correspond to FHR1 His157, Leu159, and Gln175), FH SCR19 
shows 100% of amino acid sequence identity with FHR1 SCR4, and FH SCR20 
has only two residues different from FHR1 SCR5 (FH Ser1191 and Val1197 
corresponding to FHR1 Leu290 and Ala296), as shown in Figure 6-1. 
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Figure 6-1: Clustal W alignment: the amino acid sequence alignment of the last 3 SCRs of FH 
(18-20) and of FHR1 (3-5) are shown. 
 * = indicates positions which have a single, fully conserved residue; : = indicates conservation 
between amino acid groups of strongly similar properties (score > 0.5 in the Gonnet PAM 250 
matrix); . = indicates conservation between amino acid groups of weakly similar properties (score 
< 0.5 in the Gonnet PAM 250 matrix). Red lines indicate SCR borders. Green arrows indicated 
residues recognized by autoantibodies. 
 
In most cases, the FHR1 deficiency is caused by homozygous deletion of CFHR1 
that is described in about 13% of aHUS cases (16.4% in our patients) and in about 
5% of Caucasian healthy controls (data reported in chapter 4 of this thesis).107  
Currently, the mechanisms involved in the loss of tolerance of the immune system 
against FH remain unknown. The deficiency of FHR1 observed in the large 
majority of aHUS patients with anti-FHs suggests its main role in autoimmune 
pathogenesis but it is not sufficient alone to cause autoantibody development. 
Genetic predisposition for most autoimmune diseases is polygenic as suggested by 
a large number of genome-wide association studies in which hundreds of risk loci 
HLA study 
141 
 
for autoimmune diseases have been identified.151, 185 Some of these genetic 
variants are associated with several autoimmune diseases, suggesting that the 
causative genes influence general mechanisms of immune regulation and self-
tolerance.151 In autoimmune diseases, the strongest associations have been found 
with the MHC, indicating that some disease-associated MHC molecules may 
present self-antigens and activate auto-reactive T cells.151  
There are 3 class I MHC genes (A, B, and C) and 3 class II MHC loci (DR, DQ, 
and DP). Each class II MHC locus contain A and B genes that encode for the 
alpha and beta chains of class II MHC heterodimer molecules.134 The β chain of 
HLA-DR molecules is encoded by four HLA-DRB genes: DRB1 and three 
additional paralogues (DRB3, DRB4 and DRB5). Each individual presents two 
haplotypes that generally contain HLA-DRA1, HLA-DRB1 plus one additional 
HLA-DRB gene. All HLA genes are polymorphic and the allele nomenclature is 
based on serologic methods and molecular typing. All alleles have at least a four 
digit name, in which the first set of two digits corresponds to the serological 
antigen (or allele group) and the second set of two digits corresponds to a specific 
allele subtype. Alleles whose numbers differ in the second sets of digits differ in 
one or more nucleotide substitutions that determine amino acid changes in the 
MHC molecule (from hla.alleles.org). 
Class I MHC molecules are expressed on all nucleated cells and are involved in 
the presentation of endogenous proteins, such as viral and tumor antigens, to 
CD8+ T cells. Instead, class II MHC molecules are expressed only on APCs 
(dendritic cells, B lymphocytes, macrophages, and a few other cells) and provide 
a system to display extracellular peptides derived from bacterial infections or not-
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self proteins to CD4+ T cells. Both MHC class I and II are also involved in the 
maturation process of T lymphocytes in thymus. During the positive selection, T 
cells whose TCRs recognize self MHC molecules continue their differentiation 
and are committed to the CD4 or CD8 lineage based on the recognition of MHC 
class I rather than MHC class II. Then, during the negative selection, T cells 
whose TCRs strongly recognize self-peptide-MHC complex are deleted. These 
selections eliminate the potentially self-reactive T cells and ensure the self- 
tolerance.134 
The peptide binding to MHC molecules depends on the peptide size and on non-
covalent interactions by residues both in the peptides and the binding cleft of 
MHC molecules.134 Since many residues in MHC peptide-binding cleft are 
polymorphic, the MHC alleles can bind several peptides with different affinity.134 
A weak affinity between self-peptides and MHC molecules can determine 
structural alterations in TCR-peptide-MHC complex that compromise its overall 
stability leading to the loss of immunological tolerance of self-antigens.160, 161 My 
hypothesis is that a FH peptide could be not properly presented to CD4+ T cells in 
thymus in presence of specific MHC class II molecules causing the escape of 
auto-reactive CD4+ T cells during the negative selection. The FHR1 homologous 
peptide could be presented more efficiently by the same MHC class II molecules, 
preventing the generation of self-reactive T cells and as a consequence anti-FHs. 
Thus, according with this hypothesis, the FHR1 deficiency should increase the 
susceptibility for the autoimmune aHUS in patients carrying specific MHC class 
II variants. 
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In this chapter, I report the results of a case/control study in which I studied the 
MHC class II loci in 24 aHUS patients with anti-FHs and in 64 healthy controls 
carrying the homozygous deletion of CFHR1, here defined as “super controls”. I 
also included MHC class I analyses since MHC class I alleles are also reported to 
be implicated in the pathogenesis of autoimmunity in many diseases and I could 
not exclude at all their involvement. In this study I report DRB1*11:04 as a 
possible candidate HLA allele that could predispose to anti-FH-mediated aHUS. 
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6.2 Specific aims 
 
To evaluate the presence of HLA-A, B, C, DRB1, DRB3, DRB4, DRB5, DQA1, 
DQB1, DPA1, and DPB1 risk alleles in aHUS patients with anti-FH antibodies 
versus healthy controls both carrying the homozygous CFHR1 deletion. 
To evaluate the OR for each risk HLA allele. 
To evaluate the presence of risk allele in aHUS patients positive for anti-FHs who 
do not carry the homozygous CFHR1 deletion. 
To test in silico the affinity of FHR1/FH peptides with the newly identified 
predisposing MHC molecules. 
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6.3 Results 
6.3.1 Power analysis 
I planned a study with 24 aHUS cases with anti-FH antibodies and 64 healthy 
controls both carrying the FHR1 deficiency. Data obtained in chapter 4 of this 
thesis showed that 1 out of 13 controls (7%) with the homozygous CFHR1 
deletion was positive for anti-FHs. In literature the prevalence of anti-FH 
antibodies in healthy controls was reported to be about 1-4%. Therefore, I 
arbitrarily decided to consider 4% the estimated probability for a healthy control 
carrying the homozygous CFHR1 deletion to develop anti-FHs. Considering that 
the probability to develop anti-FHs among aHUS patients with the homozygous 
CFHR1 deletion is about 48% (data reported in chapter 4 of this thesis), I could 
reject the null hypothesis that the probability of anti-FH antibodies in cases and 
controls was equal with a power of 0.995. The Type I error probability associated 
with this test of this null hypothesis was 0.05. I used Chi-squared test or Fisher’s 
exact test to evaluate this null hypothesis. 
6.3.2 HLA study 
HLA-A, B, C, DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, DPA1, and DPB1 
allelic frequencies (obtained considering the incidence of one allele/total allele 
number) and carrier frequencies (obtained from the number of individuals with at 
least one specific allele/total individual number) were established in 24 aHUS 
cases and 64 controls (not all analyzed for all HLA genes) carrying the FHR1 
deficiency. About half of patients were Italians (n = 10) but there were also 1 
Portuguese, 3 Caucasian Americans, 1 German, 2 Serbian, 1 Israel Jewish, 1 
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Japanese, 1 Bulgarian, 1 Iranian, 2 Polish, and 1 Dutch. All cases carried the 
FHR1 deficiency. The healthy controls were mostly Italian (n = 57) but I also 
included in the analyses 3 Israel Jews and 4 Iranians. 
MHC class I 
The results of the comparison of HLA-A allele and carrier frequencies between 
aHUS and healthy controls are shown in Table 6-1 (2 digits) and Table 2 (4 
digits). Sixteen alleles were detected and the most common in both aHUS cases 
and controls were the 01, 02, and 24 alleles. The 03 allele appeared also common 
in controls but not in aHUS cases despite no statistical difference was evident 
comparing the allele frequencies in patient and control groups (Table 6-1). 
 
 
Table 6-1: Statistical comparison of HLA-A allele and carrier frequencies in 24 aHUS patients 
with anti-FHs and 54 healthy controls both carriers of FHR1 deficiency. 
n freq n freq n freq n freq
01 10 0.21 12 0.11 0.174 9 0.38 12 0.22 0.260
02 9 0.19 26 0.24 0.598 8 0.33 22 0.41 0.713
03 2 0.04 12 0.11 0.229 2 0.08 11 0.20 0.323
11 3 0.06 8 0.07 1.000 3 0.13 7 0.13 1.000
23 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
24 9 0.19 14 0.13 0.486 7 0.29 14 0.26 0.983
25 1 0.02 2 0.02 1.000 1 0.04 2 0.04 1.000
26 3 0.06 3 0.03 0.373 3 0.13 3 0.06 0.365
29 2 0.04 4 0.04 1.000 2 0.08 4 0.07 1.000
30 1 0.02 5 0.05 0.667 1 0.04 5 0.09 0.660
31 1 0.02 8 0.07 0.277 1 0.04 7 0.13 0.423
32 5 0.10 5 0.05 0.286 4 0.17 5 0.09 0.445
33 1 0.02 2 0.02 1.000 1 0.04 2 0.04 1.000
68 1 0.02 4 0.04 1.000 1 0.04 4 0.07 1.000
69 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
80 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
P -value
Allele Carrier
HLA-A Allele
P -value
Pt (n=48) Ctr (n=108) Pt (n=24) Ctr (n=54)
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Alleles were defined with 2 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
Twenty-two different alleles were detected considering the 4 digit resolution and 
the most frequent were 01:01, 02:01, and 24:02 alleles in both groups. The 03:01 
was present in 11% of healthy controls versus 4% of aHUS cases but the 
prevalence was not significantly different between the two groups. The 29:01 
allele has been identified only in one patient and not in controls (Table 6-2). 
Overall, HLA-A allele and carrier frequencies were comparable between patients 
and controls and no significant association was found in both 2 and 4 digit 
resolutions. 
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Table 6-2: Statistical comparison of HLA-A allele and carrier frequencies in 24 aHUS patients 
with anti-FHs and 54 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 4 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
In Table 6-3 and 6-4 I report the results of the association study regard HLA-B 
alleles (2 and 4 digits, respectively). Twenty-three 2 digit alleles were detected 
and the most frequent in cases and controls was the 35 allele. The 51 allele was 
more represented in healthy subjects than in aHUS cases but the allelic frequency 
difference between the two groups was not significant (aHUS 4% versus controls 
14%, ns, Table 6-3).  
 
n freq n freq n freq n freq
01:01 10 0.21 12 0.11 0.174 9 0.38 12 0.22 0.260
02:01 7 0.15 25 0.23 0.314 6 0.25 21 0.39 0.351
02:05 2 0.04 1 0.01 0.224 2 0.08 1 0.02 0.223
03:01 2 0.04 12 0.11 0.229 2 0.08 11 0.20 0.323
11:01 3 0.06 8 0.07 1.000 3 0.13 7 0.13 1.000
23:01 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
24:02 9 0.19 12 0.11 0.300 7 0.29 12 0.22 0.709
24:03 0 0.00 2 0.02 1.000 0 0.00 2 0.04 1.000
25:01 1 0.02 2 0.02 1.000 1 0.04 2 0.04 1.000
26:01 3 0.06 3 0.03 0.373 3 0.13 3 0.06 0.365
29:01 1 0.02 0 0.00 0.308 1 0.04 0 0.00 0.308
29:02 1 0.02 4 0.04 1.000 1 0.04 4 0.07 1.000
30:01 1 0.02 4 0.04 1.000 1 0.04 4 0.07 1.000
30:02 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
31:01 1 0.02 8 0.07 0.277 1 0.04 7 0.13 0.423
32:01 5 0.10 5 0.05 0.286 4 0.17 5 0.09 0.445
33:01 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
33:03 1 0.02 1 0.01 0.522 1 0.04 1 0.02 0.523
68:01 0 0.00 3 0.03 0.553 0 0.00 3 0.06 0.549
68:02 1 0.02 1 0.01 0.522 1 0.04 1 0.02 0.523
69:01 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
80:01 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
Pt (n=48) Ctr (n=108) Pt (n=24) Ctr (n=54)
P -value
Allele Carrier
HLA-A Allele
P -value
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Table 6-3: Statistical comparison of HLA-B allele and carrier frequencies in 24 aHUS patients 
with anti-FHs and 53 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 2 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
The analysis was repeated considering 4 digit resolution and 34 alleles have been 
detected. The most common were the 35:02 in aHUS cases and the 35:01 and 
51:01 in controls while the 07:05, 15:09, 50:02, and 53:01 alleles were found only 
in 4 different aHUS patients and not in controls (Table 6-4). Overall, no 
statistically significant difference was observed in allele and carrier frequencies 
between the case and the control groups. 
 
n freq n freq n freq n freq
07 2 0.04 4 0.04 1.000 2 0.08 4 0.08 1.000
08 4 0.08 5 0.05 0.461 4 0.17 5 0.09 0.448
13 3 0.06 5 0.05 0.705 3 0.13 4 0.08 0.671
14 1 0.02 3 0.03 1.000 1 0.04 3 0.06 1.000
15 3 0.06 3 0.03 0.376 3 0.13 3 0.06 0.369
18 4 0.08 5 0.05 0.461 3 0.13 5 0.09 0.699
27 1 0.02 2 0.02 1.000 1 0.04 2 0.04 1.000
35 9 0.19 22 0.21 0.944 9 0.38 20 0.38 0.815
37 0 0.00 2 0.02 1.000 0 0.00 2 0.04 1.000
38 4 0.08 7 0.07 0.740 3 0.13 7 0.13 1.000
39 2 0.04 2 0.02 0.589 2 0.08 2 0.04 0.585
40 2 0.04 3 0.03 0.647 2 0.08 2 0.04 0.585
41 1 0.02 1 0.01 0.528 1 0.04 1 0.02 0.529
44 5 0.10 9 0.08 0.675 4 0.17 9 0.17 1.000
45 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
47 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
49 0 0.00 5 0.05 0.325 0 0.00 5 0.09 0.317
50 2 0.04 1 0.01 0.229 2 0.08 1 0.02 0.551
51 2 0.04 15 0.14 0.095 2 0.08 14 0.26 0.127
53 1 0.02 0 0.00 0.312 1 0.04 0 0.00 0.312
55 0 0.00 6 0.06 0.177 0 0.00 5 0.09 0.317
57 2 0.04 1 0.01 0.229 2 0.08 1 0.02 0.228
58 0 0.00 3 0.03 0.552 0 0.00 3 0.06 0.548
P -value
HLA-B Allele
Allele Carrier
Pt (n=48) Ctr (n=106)
P -value
Pt (n=24) Ctr (n=53)
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Table 6-4: Statistical comparison of HLA-B allele and carrier frequencies in 24 aHUS patients 
with anti-FHs and 53 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 4 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
The comparison of HLA-C allele and carrier frequencies between cases and 
controls is reported in Tables 6-5 and 6-6.  
n freq n freq n freq n freq
07:02 1 0.02 4 0.04 1.000 1 0.04 4 0.08 1.000
07:05 1 0.02 0 0.00 0.312 1 0.04 0 0.00 0.312
08:01 4 0.08 5 0.05 0.461 4 0.17 5 0.09 0.448
13:02 3 0.06 5 0.05 0.705 3 0.13 4 0.08 0.671
14:01 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
14:02 1 0.02 2 0.02 1.000 1 0.04 2 0.04 1.000
15:01 2 0.04 2 0.02 1.000 2 0.08 2 0.04 0.585
15:09 1 0.02 0 0.00 0.312 1 0.04 0 0.00 0.312
15:24 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
18:01 4 0.08 5 0.05 0.461 3 0.13 5 0.09 0.699
27:05 1 0.02 2 0.02 1.000 1 0.04 2 0.04 1.000
35:01 3 0.06 10 0.09 0.756 3 0.13 10 0.19 0.744
35:02 5 0.10 5 0.05 0.287 5 0.21 4 0.08 0.127
35:03 1 0.02 6 0.06 0.436 1 0.04 6 0.11 0.424
35:158 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
37:01 0 0.00 2 0.02 1.000 0 0.00 2 0.04 1.000
38:01 4 0.08 7 0.07 0.740 3 0.13 7 0.13 1.000
39:01 2 0.04 2 0.02 0.589 2 0.08 2 0.04 0.585
40:01 2 0.04 2 0.02 0.589 2 0.08 2 0.04 0.585
40:02 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
41:01 1 0.02 1 0.01 0.528 1 0.04 1 0.02 0.529
44:03 2 0.04 3 0.03 0.647 2 0.08 3 0.06 0.644
45:01 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
47:01 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
49:01 0 0.00 5 0.05 0.325 0 0.00 5 0.09 0.317
50:01 1 0.02 1 0.01 0.528 1 0.04 1 0.02 0.529
50:02 1 0.02 0 0.00 0.312 1 0.04 0 0.00 0.312
51:01 2 0.04 12 0.11 0.228 2 0.08 12 0.23 0.203
51:07 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
51:08 0 0.00 2 0.02 1.000 0 0.00 2 0.04 1.000
53:01 1 0.02 0 0.00 0.312 1 0.04 0 0.00 0.312
55:01 0 0.00 6 0.06 0.178 0 0.00 5 0.09 0.317
57:01 2 0.04 1 0.01 0.229 2 0.08 1 0.02 0.228
58:01 0 0.00 3 0.03 0.552 0 0.00 3 0.06 0.548
P -value
HLA-B Allele
Allele Carrier
Pt (n=48) Ctr (n=106)
P -value
Pt (n=24) Ctr (n=53)
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Table 6-5: Statistical comparison of HLA-C allele and carrier frequencies in 24 aHUS patients 
with anti-FHs and 55 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 2 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
Twelve alleles were found for HLA-C gene considering the 2 digit resolution. The 
04, 06, 07, and 12 were the more abundant in both case and control groups (Table 
6-5). Repeating the analysis with a higher resolution, among 21 alleles, the most 
common were 04:01, 06:02, 07:01, and 12:03 in both cases and controls. The 
14:03 and 15:05 alleles were present exclusively in aHUS patients. No significant 
differences were found in allele and carrier frequencies comparing cases and 
controls (Table 6-6). 
 
n freq n freq n freq n freq
01 0 0.00 8 0.07 0.107 0 0.00 7 0.13 0.094
02 1 0.02 5 0.05 0.668 1 0.04 5 0.09 0.661
03 4 0.08 11 0.10 1.000 4 0.17 11 0.20 1.000
04 9 0.19 20 0.18 0.890 9 0.38 19 0.35 0.997
05 3 0.06 6 0.05 1.000 2 0.08 6 0.11 1.000
06 7 0.15 10 0.09 0.456 7 0.29 8 0.15 0.226
07 11 0.23 20 0.18 0.637 10 0.42 20 0.36 0.846
08 1 0.02 3 0.03 1.000 1 0.04 3 0.05 1.000
12 7 0.15 12 0.11 0.699 6 0.25 11 0.20 0.842
14 2 0.04 5 0.05 1.000 2 0.08 5 0.09 1.000
15 2 0.04 3 0.03 0.640 2 0.08 3 0.05 1.000
16 1 0.02 7 0.06 0.437 1 0.04 7 0.13 0.423
P -value
HLA-C Allele
Allele Carrier
Pt (n=48) Ctr (n=110)
P -value
Pt (n=24) Ctr (n=55)
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Table 6-6: Statistical comparison of HLA-C allele and carrier frequencies in 24 aHUS patients 
with anti-FHs and 55 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 4 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
  
n freq n freq n freq n freq
01:02 0 0.00 8 0.07 0.107 0 0.00 7 0.13 0.094
02:02 1 0.02 5 0.05 0.668 1 0.04 5 0.09 0.661
03:02 0 0.00 3 0.03 0.554 0 0.00 3 0.05 0.315
03:03 2 0.04 6 0.05 1.000 2 0.08 6 0.11 1.000
03:04 2 0.04 2 0.02 0.585 2 0.08 2 0.04 0.581
04:01 9 0.19 20 0.18 0.890 9 0.38 19 0.35 0.997
05:01 3 0.06 6 0.05 1.000 3 0.13 6 0.11 1.000
06:02 7 0.15 9 0.08 0.347 7 0.29 8 0.15 0.226
07:01 6 0.13 14 0.13 0.825 6 0.25 14 0.25 0.811
07:02 4 0.08 5 0.05 0.456 4 0.17 5 0.09 0.443
07:04 1 0.02 1 0.01 0.517 1 0.04 1 0.02 0.518
08:02 1 0.02 3 0.03 1.000 1 0.04 3 0.05 1.000
12:02 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
12:03 7 0.15 11 0.10 0.574 6 0.25 11 0.20 0.842
14:01 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
14:02 1 0.02 4 0.04 1.000 1 0.04 4 0.07 1.000
14:03 1 0.02 0 0.00 0.304 1 0.04 0 0.00 0.304
15:02 1 0.02 3 0.03 1.000 1 0.04 3 0.05 1.000
15:05 1 0.02 0 0.00 0.304 1 0.04 0 0.00 0.304
16:01 1 0.02 3 0.03 1.000 1 0.04 3 0.05 1.000
16:02 0 0.00 4 0.04 0.315 0 0.00 4 0.07 0.308
P -value
HLA-C Allele
Allele Carrier
Pt (n=48) Ctr (n=110)
P -value
Pt (n=24) Ctr (n=55)
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MHC class II 
Thirteen HLA-DRB1 alleles were found, of whom the most frequent were the 03, 
07, 11, 13, and 15 in aHUS cases and the 04, 07, 11, and 13 in controls but no 
significant differences were present in the allelic and/or carrier frequencies 
between the two groups (Table 6-7).  
 
 
Table 6-7: Statistical comparison of HLA-DRB1 allele and carrier frequencies in 24 aHUS 
patients with anti-FHs and 64 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 2 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
To go deeper into the results of DRB1, I repeated the case-control study 
considering the 4 digit resolution (Table 6-8). Thirty-three different alleles have 
been detected and the most common in patients were the 03:01, 07:01, 11:04, and 
15:01 alleles while in controls were the 07:01 and 11:01 alleles. The 01:03, 04:08 
and 13:11 alleles were found only in 3 different Italian patients and not in 
n freq n freq n freq n freq
01 4 0.08 10 0.08 1.000 4 0.17 8 0.13 0.729
03 7 0.15 9 0.07 0.209 6 0.25 9 0.14 0.370
04 4 0.08 13 0.10 1.000 4 0.17 13 0.20 1.000
07 6 0.13 13 0.10 0.862 6 0.25 12 0.19 0.726
08 0 0.00 4 0.03 0.576 0 0.00 4 0.06 0.571
09 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
10 0 0.00 2 0.02 1.000 0 0.00 2 0.03 1.000
11 12 0.25 32 0.25 0.845 10 0.42 28 0.44 0.948
12 0 0.00 2 0.02 1.000 0 0.00 2 0.03 1.000
13 7 0.15 18 0.14 0.877 7 0.29 16 0.25 0.902
14 1 0.02 7 0.05 0.450 1 0.04 6 0.09 0.689
15 5 0.10 9 0.07 0.533 5 0.21 8 0.13 0.330
16 2 0.04 8 0.06 0.730 2 0.08 7 0.11 1.000
P -value
HLA-DRB1 Allele
Allele Carrier
Pt (n=48) Ctr (n=128)
P -value
Pt (n=24) Ctr (n=64)
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controls. Interestingly, I found that carrier frequency of DRB1*11:04 allele was 
higher in aHUS patients compared to controls (38% versus 13%, p-value, 
unadjusted = 0.019). The significance cut-off after the Bonferroni correction for 
multiplying tests (the number of alleles for each MHC gene) was set at 0.002 for 
DRB1 and thus, the association with 11:04 allele did not reach statistical 
significance. Logistic regression showed that the presence of HLA-DRB1*11:04 
allele in individuals carriers of the homozygous CFHR1 deletion increased the 
probability to be an aHUS patient with anti-FH antibodies (OR = 4.2, 95% CI 
[1.384-12.742], p-value, unadjusted = 0.011). 
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Table 6-8: Statistical comparison of HLA-DRB1 allele and carrier frequencies in 24 aHUS patients 
with anti-FHs and 64 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 4 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
I have also performed the case/control study considering the DRB3, DRB4, and 
DRB5 genes and the results are reported in Tables 6-9, 6-10, and 6-11, 
respectively. In this analysis I only considered the results of higher resolution 
n freq n freq n freq n freq
01:01 3 0.06 6 0.05 0.706 3 0.13 5 0.08 0.678
01:02 0 0.00 4 0.03 0.576 0 0.00 3 0.05 0.559
01:03 1 0.02 0 0.00 0.273 1 0.04 0 0.00 0.273
03:01 7 0.15 9 0.07 0.209 6 0.25 9 0.14 0.370
04:01 2 0.04 3 0.02 0.615 2 0.08 3 0.05 0.611
04:02 0 0.00 3 0.02 0.563 0 0.00 3 0.05 0.559
04:03 0 0.00 3 0.02 0.563 0 0.00 3 0.05 0.559
04:04 0 0.00 3 0.02 0.563 0 0.00 3 0.05 0.559
04:05 1 0.02 1 0.01 0.472 1 0.04 1 0.02 0.473
04:08 1 0.02 0 0.00 0.273 1 0.04 0 0.00 0.273
07:01 6 0.13 13 0.10 0.862 6 0.25 12 0.19 0.726
08:01 0 0.00 2 0.02 1.000 0 0.00 2 0.03 1.000
08:02 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
08:04 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
09:01 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
10:01 0 0.00 2 0.02 1.000 0 0.00 2 0.03 1.000
11:01 2 0.04 17 0.13 0.104 2 0.08 16 0.25 0.136
11:02 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
11:03 1 0.02 3 0.02 1.000 1 0.04 3 0.05 1.000
11:04 9 0.19 10 0.08 0.070 9 0.38 8 0.13 0.019
11:24 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
12:01 0 0.00 2 0.02 1.000 0 0.00 2 0.03 1.000
13:01 2 0.04 10 0.08 0.734 2 0.08 10 0.16 0.500
13:02 3 0.06 5 0.04 0.685 3 0.13 4 0.06 0.385
13:03 0 0.00 2 0.02 1.000 0 0.00 2 0.03 1.000
13:05 1 0.02 1 0.01 0.472 1 0.04 1 0.02 0.473
13:11 1 0.02 0 0.00 0.273 1 0.04 0 0.00 0.273
14:01 1 0.02 5 0.04 1.000 1 0.04 5 0.08 1.000
14:04 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
14:54 0 0.00 1 0.01 1.000 0 0.00 1 0.02 1.000
15:01 5 0.10 7 0.05 0.410 5 0.21 7 0.11 0.392
15:02 0 0.00 2 0.02 1.000 0 0.00 2 0.03 1.000
16:01 2 0.04 8 0.06 0.730 2 0.08 7 0.11 1.000
P -value
HLA-DRB1 Allele
Allele Carrier
Pt (n=48) Ctr (n=128)
P -value
Pt (n=24) Ctr (n=64)
HLA study 
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analysis because a limited number of alleles were present in DRB3-4-5 genes due 
to a lower variability compared to the main DRB1 gene. I observed the presence 
of DRB3 gene in 21 aHUS cases (87.5%) versus 23 controls (74.2%), of DRB4 in 
10 aHUS cases (41.7%) versus 12 controls (38.7%), and of DRB5 in 6 aHUS 
cases (25%) versus 7 controls (22.6%) and these differences were not statistically 
significant. The comparison of DRB3, DRB4, and DRB5 allele and carrier 
frequencies between cases and controls did not reveal any significant associations 
of these additional DRB genes with the risk of aHUS with anti-FHs. 
 
 
Table 6-9: Statistical comparison of HLA-DRB3 allele and carrier frequencies in 24 aHUS patients 
with anti-FHs and 31 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 4 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
 
n freq n freq n freq n freq
01:01 4 0.08 6 0.10 1.000 4 0.17 6 0.19 1.000
02:01 1 0.02 0 0.00 0.436 1 0.04 0 0.00 0.436
02:02 19 0.40 24 0.39 0.918 15 0.67 19 0.61 0.851
03:01 3 0.06 2 0.03 0.651 3 0.13 1 0.03 0.307
absence 21 0.44 30 0.48 0.771 17 0.75 22 0.71 0.773
P -value
HLA-DRB3 Allele
Allele Carrier
Pt (n=48) Ctr (n=62)
P -value
Pt (n=24) Ctr (n=31)
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Table 6-10: Statistical comparison of HLA-DRB4 allele and carrier frequencies in 24 aHUS 
patients with anti-FHs and 31 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 4 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
 
Table 6-11: Statistical comparison of HLA-DRB5 allele and carrier frequencies in 24 aHUS 
patients with anti-FHs and 31 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 4 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
The comparison of DQA1 allele and carrier frequencies between aHUS and 
healthy controls is shown in Tables 6-12 and 6-13 (2 and 4 digits, respectively). I 
found 5 alleles in DQA1 gene and the more abundant were the 01 and 05 in both 
patients and control groups. Considering the higher typing resolution there were 7 
alleles and the most frequent were the 01:01, 01:02, 02:01, and 05:01 in aHUS 
patients and 01:02, 02:01, 03:01, and 05:01 in controls. All alleles were equally 
represented in both groups.  
n freq n freq n freq n freq
01:01 10 0.21 16 0.26 0.702 9 0.38 12 0.39 0.851
absence 38 0.79 46 0.74 0.702 23 0.96 27 0.87 0.378
Pt (n=48) Ctr (n=62)
P -value
Pt (n=24) Ctr (n=31)HLA-DRB4 Allele
Allele Carrier
P -value
n freq n freq n freq n freq
01:01 5 0.10 3 0.10 0.293 5 0.21 3 0.10 0.276
01:02 0 0.00 1 0.03 1.000 0 0.00 1 0.03 1.000
02:02 2 0.04 4 0.13 0.694 2 0.08 4 0.13 0.686
absence 41 0.85 54 0.97 0.980 23 0.96 30 0.97 1.000
P -value
HLA-DRB5 Allele
Allele Carrier
Pt (n=48) Ctr (n=62)
P -value
Pt (n=24) Ctr (n=31)
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Table 6-12: Statistical comparison of HLA-DQA1 allele and carrier frequencies in 24 aHUS 
patients with anti-FHs and 31 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 2 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
 
Table 6-13: Statistical comparison of HLA-DQA1 allele and carrier frequencies in 24 aHUS 
patients with anti-FHs and 31 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 4 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
The DQB1 allele and carrier frequencies in aHUS and in healthy controls are 
shown in Tables 14 and 15 (2 and 4 digits, respectively). The lower resolution 
showed 5 DQB1 alleles of whom the 02, 03, 05, and 06 were the most abundant in 
patients and controls (Table 6-14). 
n freq n freq n freq n freq
01 17 0.35 20 0.32 0.885 14 0.58 17 0.55 0.988
02 6 0.13 8 0.13 0.822 6 0.25 7 0.23 0.912
03 4 0.08 8 0.13 0.546 4 0.17 8 0.26 0.519
04 0 0.00 3 0.05 0.255 0 0.00 3 0.10 0.248
05 21 0.44 23 0.37 0.610 17 0.71 18 0.58 0.488
P -value
HLA-DQA1 Allele
Allele Carrier
Pt (n=48) Ctr (n=62)
P -value
Pt (n=24) Ctr (n=31)
n freq n freq n freq n freq
01:01 5 0.10 4 0.06 0.500 5 0.21 4 0.13 0.482
01:02 10 0.21 9 0.15 0.539 8 0.33 8 0.26 0.756
01:03 2 0.04 7 0.11 0.294 2 0.08 7 0.23 0.271
02:01 6 0.13 8 0.13 0.822 6 0.25 7 0.23 0.912
03:01 4 0.08 8 0.13 0.546 4 0.17 8 0.26 0.519
04:01 0 0.00 3 0.05 0.255 0 0.00 3 0.10 0.248
05:01 21 0.44 23 0.37 0.610 17 0.71 18 0.58 0.488
P -value
HLA-DQA1 Allele
Allele Carrier
Pt (n=48) Ctr (n=62)
P -value
Pt (n=24) Ctr (n=31)
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Table 6-14: Statistical comparison of HLA-DRQ1 allele and carrier frequencies in 24 aHUS 
patients with anti-FHs and 64 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 2 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
By deepening the analysis with 4 digits, 15 alleles were observed. The most 
common DQB1 alleles were the 02:01, 03:01, and 06:02 in aHUS patients and the 
02:01, 03:01, 03:02, and 05:01 in controls (Table 6-15). The 06:04 allele was 
found in 3 aHUS cases and not in controls (p-value, unadjusted = 0.031). The 
significance was lost after Bonferroni correction for multiple tests (significance 
threshold = 0.003). One aHUS patients carrying DQB1*06:04 allele also showed 
the DRB1*11:04 allele. 
 
n freq n freq n freq n freq
02 10 0.21 24 0.19 0.922 8 0.33 22 0.34 0.872
03 21 0.44 49 0.38 0.626 16 0.67 40 0.63 0.910
04 0 0.00 4 0.03 0.576 0 0.00 4 0.06 0.571
05 7 0.15 29 0.23 0.331 7 0.29 25 0.39 0.541
06 10 0.21 22 0.17 0.735 9 0.38 20 0.31 0.764
P -value
HLA-DQB1 Allele
Allele Carrier
Pt (n=48) Ctr (n=128)
P -value
Pt (n=24) Ctr (n=64)
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Table 6-15: Statistical comparison of HLA-DQB1 allele and carrier frequencies in 24 aHUS 
patients with anti-FHs and 50 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 4 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
The results of comparison of DPA1 allele and carrier frequencies between aHUS 
and healthy controls is reported in Tables 16 and 17 (low and high resolution, 
respectively). The 01:03 allele was the most frequent in both aHUS patients and 
controls and no differences were evident between the two groups. 
 
 
n freq n freq n freq n freq
02:01 10 0.21 15 0.15 0.514 8 0.33 14 0.28 0.843
02:02 0 0.00 4 0.04 0.305 0 0.00 4 0.08 0.297
03:01 15 0.31 28 0.28 0.830 13 0.54 24 0.48 0.804
03:02 2 0.04 11 0.11 0.224 2 0.08 11 0.22 0.200
03:03 3 0.06 1 0.01 0.100 3 0.13 1 0.02 0.097
03:04 1 0.02 0 0.00 0.324 1 0.04 0 0.00 0.243
04:02 0 0.00 4 0.04 0.305 0 0.00 4 0.08 0.297
05:01 4 0.08 11 0.11 0.774 4 0.17 10 0.20 1.000
05:02 2 0.04 5 0.05 1.000 2 0.08 5 0.10 1.000
05:03 1 0.02 6 0.06 0.428 1 0.04 5 0.10 0.657
06:01 0 0.00 3 0.03 0.551 0 0.00 3 0.06 0.546
06:02 5 0.10 3 0.03 0.113 5 0.21 3 0.06 0.103
06:03 2 0.04 7 0.07 0.719 2 0.08 7 0.14 0.709
06:04 3 0.06 0 0.00 0.033 3 0.13 0 0.00 0.031
06:09 0 0.00 2 0.02 1.000 0 0.00 1 0.02 1.000
P-value
HLA-DQB1 Allele
Allele Carrier
Pt (n=48) Ctr (n=100)
P -value
Pt (n=24) Ctr (n=50)
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Table 6-16: Statistical comparison of HLA-DPA1 allele and carrier frequencies in 24 aHUS 
patients with anti-FHs and 31 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 2 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
 
Table 6-17: Statistical comparison of HLA-DPA1 allele and carrier frequencies in 24 aHUS 
patients with anti-FHs and 31 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 4 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. DPA1*01:XXX was an allele not discriminated. 
 
Regarding HLA-DPB1, 13 alleles have been observed considering 2 digit 
resolution. The alleles more frequent in patients and controls were the 02, 03, and 
04. At 4 digit resolution, the 04 allele included 04:01 and 04:02 alleles that were 
represented in equal measure in case and control groups. The 05:01 and 09:01 
alleles were present in only 2 different aHUS patients and in not in controls. 
Overall DPB1 allele and carrier frequencies showed no differences between aHUS 
patients and controls. 
n freq n freq n freq n freq
01 38 0.79 53 0.85 0.539 24 1.00 30 0.97 1.000
02 10 0.21 9 0.15 0.539 10 0.42 8 0.26 0.340
P -value
HLA-DPA1 Allele
Allele Carrier
Pt (n=48) Ctr (n=62)
P -value
Pt (n=24) Ctr (n=31)
n freq n freq n freq n freq
01:03 38 0.79 52 0.84 0.700 24 1.00 30 0.97 0.897
01:XXX 0 0.00 1 0.02 1.000 0 0.00 1 0.03 1.000
02:01 9 0.19 7 0.11 0.408 9 0.38 6 0.19 0.233
02:02 1 0.02 2 0.03 1.000 1 0.04 2 0.06 1.000
P -value
HLA-DPA1 Allele
Allele Carrier
Pt (n=48) Ctr (n=62)
P -value
Pt (n=24) Ctr (n=31)
HLA study 
162 
 
 
Table 6-18: Statistical comparison of HLA-DPB1 allele and carrier frequencies in 24 aHUS 
patients with anti-FHs and 31 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 2 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
 
 
Table 6-19: Statistical comparison of HLA-DPB1 allele and carrier frequencies in 24 aHUS 
patients with anti-FHs and 31 healthy controls both carriers of FHR1 deficiency. 
Alleles were defined with 4 digits. P-values obtained from Chi-square test (or Fisher’s exact test 
when the number of individuals for each category was five or less) were reported without 
Bonferroni correction. 
n freq n freq n freq n freq
01 2 0.04 1 0.02 0.579 2 0.08 1 0.03 0.575
02 8 0.17 11 0.18 0.915 7 0.29 11 0.35 0.837
03 5 0.10 8 0.13 0.772 5 0.21 7 0.23 1.000
04 25 0.52 34 0.55 0.925 21 0.88 27 0.87 1.000
05 2 0.04 0 0.00 0.188 2 0.08 0 0.00 0.186
09 1 0.02 0 0.00 0.436 1 0.04 0 0.00 0.436
10 3 0.06 2 0.03 0.651 3 0.13 2 0.06 0.643
13 1 0.02 1 0.02 1.000 1 0.04 1 0.03 1.000
14 1 0.02 2 0.03 1.000 1 0.04 2 0.06 1.000
17 0 0.00 1 0.02 1.000 0 0.00 1 0.03 1.000
19 0 0.00 1 0.02 1.000 0 0.00 1 0.03 1.000
29 0 0.00 1 0.02 1.000 0 0.00 1 0.03 1.000
P -value
HLA-DPB1 Allele
Allele Carrier
Pt (n=48) Ctr (n=62)
P -value
Pt (n=24) Ctr (n=31)
n freq n freq n freq n freq
01:01 2 0.04 1 0.02 0.579 2 0.08 1 0.03 0.575
02:01 8 0.17 11 0.18 0.915 7 0.29 11 0.35 0.837
03:01 5 0.10 8 0.13 0.772 5 0.21 7 0.23 1.000
04:01 17 0.35 26 0.42 0.619 15 0.63 22 0.71 0.708
04:02 8 0.17 8 0.13 0.778 7 0.29 7 0.23 0.807
05:01 2 0.04 0 0.00 0.188 2 0.08 0 0.00 0.186
09:01 1 0.02 0 0.00 0.436 1 0.04 0 0.00 0.436
10:01 3 0.06 2 0.03 0.651 3 0.13 2 0.06 0.643
13:01 1 0.02 1 0.02 1.000 1 0.04 1 0.03 1.000
14:01 1 0.02 2 0.03 1.000 1 0.04 2 0.06 1.000
17:01 0 0.00 1 0.02 1.000 0 0.00 1 0.03 1.000
19:01 0 0.00 1 0.02 1.000 0 0.00 1 0.03 1.000
29:01 0 0.00 1 0.02 1.000 0 0.00 1 0.03 1.000
P -value
HLA-DPB1 Allele
Allele Carrier
Pt (n=48) Ctr (n=62)
P -value
Pt (n=24) Ctr (n=31)
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In conclusion, the case/control study showed that DRB1*11:04 and the 
DQB1*06:04 alleles were the only HLA alleles with a trend association with 
aHUS and anti-FHs but after the Bonferroni correction the significance was lost 
for both. 
Thus, I performed further analyses on these two HLA alleles since the loss of 
significance could be linked to the low number of patients and controls that was a 
limitation of this study. I investigated the presence of DRB1*11:04 and 
DQB1*06:04 alleles in 4 aHUS patients positive for anti-FHs and without the 
FHR1 deficiency and in an healthy control presenting anti-FHs and the 
homozygous deletion of CFHR1, for whom the HLA loci were analyzed in 4 digit 
resolution. Only 1 aHUS patient from Turkey with anti-FHs resulted to carry the 
HLA-DRB1*11:04 allele. Interestingly, I also analyzed an Italian patient affected 
by Dense Deposit Disease, a rare kidney disease in which the AP of complement 
system is involved, with anti-FHs and the homozygous CFHR1 deletion, and he 
showed the DRB1*11:04 allele. None of the above subjects was a carrier of the 
DQB1*06:04 allele. 
The DRB1*11:04 allele has been reported to have carrier frequency ranges from 
2% to about 30% in different populations (www.allelefrequencies.net). In Table 
6-20, I reported the carrier frequencies of DRB1*11:04 allele in our aHUS 
patients and in healthy controls according to specific populations to which 
patients belonged. I also considered the cumulative carrier frequencies of 
DRB1*11:04 allele in European and not European patient and control populations, 
and the cumulative carrier frequencies in the overall patient and control 
populations. 
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Table 6-20: Comparison of HLA-DRB1*11:04 carrier frequencies in 28 aHUS patients with anti-
FHs of our cohort and in some healthy controls reported on www.allelefrequencies.net. 
The reported populations were those belonging to at least one aHUS patient. In the “overall” lines 
were shown the cumulative frequencies in European (Italians excluded) and not-European patients 
and controls. The allele frequency for each control population was obtained from the frequency 
mean reported on allele.frequencies.net (“Italy Bergamo”, “Italy North pop3”, “Italy pop4”, “Italy 
pop5”, “Italy Rome”, “Netherlands”, “Netherlands Leiden”, “Netherlands UMCU”, “Poland”, 
“Poland Wielkopolska Region”, “Poland DKMS”, “Portugal Azores Terceira Island”, “Portugal 
Center”, “Portugal North”, “Portugal South”, “Bulgaria”, “Serbia”, “Germany pop 3”, “Germany 
pop 6”, “Germany pop 8”, “Turkey pop 1”,  “Iran”, “Israel Ashkenazi Jews”, “Israel Ashkenazi 
Jews pop 2”, “Israel Non-Ashkenazi Jews”, “Japan Hyogo Osaka and Nagano”,  “USA 
Caucasian”, “USA NMDP European Caucasian”, “Argentina Buenos Aires”). 
 
The DRB1*11:04 allele was found to be more frequent in aHUS patients with 
anti-FH compared to controls reported on allele.frequencies.net database. 
Considering the cumulative frequency in the overall populations, the difference 
was statistically significant (36% aHUS versus 6% controls, Chi-square test, p-
value = 7.65 x 10-10). Of note, this comparison showed that the DRB1*11:04 allele 
is more abundant in Italians controls (26%) compared to other analyzed European 
(7%) and not-European populations (6%). Moreover, the 11:04 allele resulted 
n carriers freq n carriers freq
Italy 11 4 0.36 5,848 1,525 0.26
Netherlands 1 0 1,816 98 0.05
Poland 2 1 20,952 1,752 0.08
Portugal 1 1 275 15 0.05
Bulgaria 1 0 55 17 0.31
Serbia 2 1 na na na
Germany 1 0 48,662 3,394 0.07
Overall European (Italians excluded) 8 3 0.38 71,760 5,276 0.07
Turkey 1 1 250 31 0.12
Iran 1 0 na na na
Israel (Jews) 1 0 4,837 1,583 0.33
Japan 1 0 195 0 0.00
American (Caucasian) 3 2 1,304,545 76,227 0.06
Argentine 2 0 466 29 0.06
Overall Not European 9 3 0.33 1,310,293 77,871 0.06
Overall patients 28 10 0.36 1,387,901 84,672 0.06
Populations ControlsaHUS
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quite common in Bulgaria and in Jewish populations, but overall both European 
and not-European populations showed a carrier frequency < 13%. 
To increase the number of healthy controls, I have used 228 “Not Finnish-
European” healthy controls from 1000 Genomes project available on 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20140725_hla_genoty
pes  which were typed by Sanger sequencing on HLA genes in 4 digit 
resolution.186 Sixteen individuals were carriers of the DRB1*11:04 (7%) and I 
selected the controls that also carried the homozygous CFHR3-CFHR1 deletion 
that is the most common polymorphism  that determine the lack of CFHR1 
(n=8).42 Two out of 8 controls with the homozygous deletion of CFHR1 were 
carriers of DRB1*11:04 and were Italians. Thus, overall, I observed 9/24 (38%) 
aHUS cases versus 10/72 (14%) controls carrying the homozygous deletion of 
CFHR1 and the DRB1*11:04 (Chi-square test, p-value = 0.025).  
 
6.3.3 In silico analysis 
NetMHCIIpan Server is available online software to predict the affinity between 
MHC class II molecules and binding peptides. I performed an affinity analysis 
with NetMHCIIpan 3.0 considering FH C terminus peptides containing the 
residues known to be involved in the anti-FH binding. In this region, 2 amino 
acidic differences were present between FH and FHR1 sequences (FH= 
Ser1191and Val11197 and FHR1= Leu290 and Ala296). The analysis showed that 
RWTAKQKLYSRTGES and WTAKQKLYSRTGESV FH peptides have a low 
affinity for the DRB1*11:04 molecules (Table 6-21). 
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Table 6-21: Binding prediction of MHC class II DRB1*11:04 molecule for C-terminus 
FH‐derived peptides (15 mer) determined by NetMHCIIpan 3.0 available online. 
The affinity (nM) represents the IC50 values obtained during the analysis. SB = strong binder, WB 
= weak binder. 
 
The same analysis performed with the homologous RWTAKQKLYLRTGES and 
WTAKQKLYLRTGESA FHR1 peptides predicted a higher affinity for 
DRB1*11:04 molecules than FH peptides (Table 6-22). Interestingly, the C 
terminus FH derived peptides showed overall a lower affinity for DRB1*11:04 
molecules than the C terminus FHR1 peptides (affinity means: FH 220.4 nM ± 
155.4 versus FHR1 62.4 nM ± 34.6, ANOVA, p-value = 0.022). 
 
Table 6-22: Binding prediction of MHC class II DRB1*11:04 molecule for C-terminus 
FHR1‐derived peptides (15 mer) determined by NetMHCIIpan 3.0 available online. 
The affinity (nM) represents the IC50 values obtained during the analysis. SB = strong binder, WB 
= weak binder.  
FH Peptides Binding core register Position Affinity(nM) BindingLevel 
LRWTAKQKLYSRTGE WTAKQKLYS 2 37.83 SB
RWTAKQKLYSRTGES  WTAKQKLYS 1 77.99 WB
WTAKQKLYSRTGESV WTAKQKLYS 0 131.24 WB
TAKQKLYSRTGESVE  LYSRTGESV 5 298.78 WB
AKQKLYSRTGESVEF LYSRTGESV 4 269.69 WB
KQKLYSRTGESVEFV  LYSRTGESV 3 233.58 WB
QKLYSRTGESVEFVC  LYSRTGESV 2 493.67 WB
FHR1 Peptides Binding core register Position Affinity(nM) BindingLevel 
LRWTAKQKLYLRTGE WTAKQKLYL 2 20.57 SB
RWTAKQKLYLRTGES  WTAKQKLYL 1 29.86 SB
WTAKQKLYLRTGESA AKQKLYLRT 0 44.76 SB
TAKQKLYLRTGESAE   LYLRTGESA 1 75.28 WB
AKQKLYLRTGESAEF  LYLRTGESA  4 72.63 WB
KQKLYLRTGESAEFV   LYLRTGESA  3 69.99 WB
QKLYLRTGESAEFVC   LYLRTGESA  2 123.7 WB
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6.4 Discussion 
In this chapter I focus on the association study between MHC class I and II alleles 
and the development of anti-FH in aHUS. I used as controls, a group of healthy 
subjects (57 Italians, 3 Jews, and 4 Iranians) carrying the homozygous deletion of 
CFHR1 that is the main known susceptibility factor for the anti-FH 
development.107 “Super controls” represent an ideal reference in the association 
studies. Indeed, I expect that in super controls other risk factors, in addition to the 
FHR1 deficiency, will be underrepresented, since the combination of more risk 
factors increases the probability to develop the disease and reduces the probability 
to belong to the healthy control group. On the contrary, the group of patients 
should be enriched for risk factors that contribute to the development of the 
disease. Here, I identify an association with DRB1*11:04 allele: 38% of aHUS 
patients versus 13% of healthy controls are carriers of DRB1*11:04 allele. Despite 
the threshold of statistical significance is not reached after the Bonferroni 
correction using the 64 super controls, I find that the DRB1*11:04 allele is over-
represented in our aHUS patients compared to several control populations 
reported on www.allele.frequencies.net and thus I cannot exclude at all the 
involvement of this HLA allele as a predisposing factor for anti-FH development.  
These findings suggest a major role of DRB1*11:04 allele in the pathogenesis of 
anti-FHs in aHUS patients although the low number of cases constitutes a limit 
for the analyses and further studies in other aHUS cohorts should confirm this 
data. 
Anti-FHs are strongly associated to the presence of FHR1 deficiency that has a 
frequency about 5% in the European population and together with the HLA-
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DRB1*11:04 allele could increase the autoimmunity risk toward FH. In most 
autoimmune diseases multiple genetic polymorphisms contribute to the 
pathogenesis and each variant gives a small contribution to the disease.151 DRB1 
alleles have received great attention in the association studies in the research field 
of autoimmune diseases mainly because MHC class II molecules are involved in 
the activation CD4+ T cells that regulate humoral immune responses to protein 
antigens. Previously reports have shown that HLA-DRB1*11:04 allele was 
strongly associated with autoimmune diseases such as systemic sclerosis and 
systemic juvenile idiopathic arthritis.187, 188 Most studies reported HLA typing in 2 
digit resolution and HLA-DRB1*11 has been found significantly over-represented 
in sarcoidosis patients compared to healthy controls and in association with 
idiopathic thrombotic thrombocytopenic purpura (TTP), a thrombotic 
microangiopathy like aHUS caused by anti-ADAMTS13 antibodies.189-192 
Interestingly, anti-FHs associated aHUS has been reported in a 17-years old 
Caucasian woman in association with anti-ADAMTS13 and affected by 
HUS/TTP.131 Unfortunately, the HLA typing was not reported but the 
combination of anti-FHs and anti-ADAMTS13 suggest that there could be a 
unique predisposing factor to the autoimmunity and the HLA-DRB1*11 is well 
known to be associated to anti-ADAMT13 and TTP. 
A susceptibility factor in the immune system can trigger the disease in presence of 
specific predisposing variants in autoantigene coding genes. This “trigger-and-
target” model is well described in Stanescu et al.193 where the authors identified 
HLA-DQA1 (the trigger) and PLA2R1 (the target) variants in association with 
idiopathic Membranous Nephropathy. In this paper the authors also reported the 
example of vitiligo, an autoimmune disease where predisposing HLA alleles in 
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combination with variants in autoantigen TYR gene, have been found. According 
with this model, in anti-FH mediated aHUS the “trigger” would be the presence of 
HLA-DRB1*11:04 allele and “the target” the deficiency of FHR1 which is a FH 
autoantigen homologous protein and also a well known predisposing factor for 
autoantibodies against FH. 
Finally, in silico analysis predict DRB1*11:04 allele derived MHC molecules to 
bind more strongly C terminal FHR1 peptides than the homologous FH peptides 
which present a lower affinity. Interestingly, structure analyses of human and 
mouse autoimmune TCR-peptide-MHC complexes showed that the TCR binds 
self-peptide-MHC complex with an altered topology or with suboptimal anchors 
compared to foreign antigens bound to the same MHC molecules.160, 161 I 
hypothesize that a weak affinity between FH peptides and MHC DRB1*11:04 
molecules can determine a stability impairment of TCR-FH peptide-MHC 
complex that can lead to the loss of tolerance toward FH antigen. The tolerance 
could be guaranteed in individuals with FHR1 where auto-reactive CD4+ T cells 
can be eliminated during the negative selection in thymus.  
In conclusion, in this chapter of my thesis, I report HLA-DRB1*11:04 allele as a 
possible predisposing candidate genetic variant for anti-FH mediated aHUS 
development. Further works will be necessary to confirm this finding and to 
explore the presence of other genetic susceptibility factors that alone or in 
combination with this HLA-DRB1*11:04 allele and the FHR1 deficiency can 
increase the risk for anti-FH development in aHUS. 
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7  Conclusions 
In this thesis genetic and clinical features of 30 patients with anti-FH-associated aHUS 
have been described. 
An accurate ELISA method has allowed to detect anti-FH antibodies and to reduce the 
percentage of false positive samples, leading to estimate that the prevalence of anti-FHs 
in our patient cohort is 9.8%. 
The FHR1 deficiency was strongly associated with the development of anti-FHs and 
together with the age of disease onset between 4 and 12 years, it can predict the 
presence of anti-FHs in a patient with a diagnosis of aHUS. Interestingly, the FHR1 
deficiency was also observed in the only healthy control resulted positive for anti-FHs 
suggesting that the lack of FHR1 can be also a risk factor for the development of 
autoantibodies in non affected subjects. 
The protein domains recognized by anti-FHs were located at FH C terminus that is 
highly similar to FHR1. This observation suggests that the FHR1 is the crucial protein 
involved in the mechanism to maintain the central tolerance against FH and that its lack 
can predispose to autoimmunity.  
Moreover, the presence of infectious prodromal signs and an age at the disease onset 
around 8 years indicate that common infections may trigger the development of 
autoantibodies in subjects with at risk genetic background.  
Some pathogens are known to produce a number of RCA-like proteins with typical SCR 
domain structure that mimic human complement regulators, to evade the host immune 
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system.46 I would hypothesize that if a pathogen producing a FHR1-like protein infects 
subjects with FHR1 deficiency, through a protein mimicry mechanism, the microbial 
protein could favor the activation of self reactive T cells which have escaped the thymus 
negative selection. T clones reactive against FHR1 are preferentially generated in FHR1 
deficient subjects also carrying predisposing HLA alleles.   
Here, the HLA-DRB1*11:04 allele was found to be abundant in aHUS patients with 
anti-FHs compared to healthy controls carrying the FHR1 deficiency, despite this 
finding has to be confirmed in other cohorts of patients. The association between HLA-
DRB1*11:04 and the development of anti-FHs in aHUS could explain why the 
prevalence of anti-FH-associated aHUS is less than the frequency of the homozygous 
CFHR1 deletion in healthy population. Indeed, the presence of both risk factors, the 
HLA-DRB1*11:04 allele and the FHR1 deficiency, in combination with environmental 
triggers (infections) is required to determine a susceptibility state for the development 
of anti-FHs. Of note, the presence of both the HLA-DRB1*11:04 allele and the FHR1 
deficiency are not sufficient to determine the development of anti-FHs because some 
controls show both risk factors and do not have the disease. In view of the very low 
prevalence of the anti-FH associated aHUS (1:1,000,000), it is expected that other rare 
genetic variants or a rare combination of common variants are involved in the 
pathogenesis. 
Thus, the presence of mutations in complement regulators (such as FH, MCP, FI), in 
THBD, and in activators of the AP of complement (such as C3 and FB) have been 
evaluated in our patients. A consistent percentage of patients are carriers of likely 
pathogenetic variants which can induce a complement activation that is per se a strong 
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stimulus for the adaptive immune system and can lead to the proliferation of the self 
reactive T clones and determine the onset of anti-FHs and of an autoimmune phenotype. 
Moreover, it is well known that aHUS is a low penetrance disease and that multiple 
genetic risk factors, including mutations and at risk polymorphisms and haplotypes, are 
needed for the disease to manifest, at least in some individuals. 
Interestingly, in our patients with anti-FHs, the polymorphic variants in complement 
genes, that have been documented as risk factors in patients with aHUS carrying 
mutations, do not seem to contribute to the disease. This was documented by comparing 
patients with, super controls, which are unaffected subjects carrying the major risk 
factor for this disease (i.e. the deficiency of FHR1). To the best of my knowledge, super 
controls have never been used in studies on anti-FH-associated aHUS and could 
represent a more effective approach in the association analysis since aHUS is a complex 
genetic disease despite its rarity. From this study it emerges that super controls shared 
with the patients the same CFH common variants and thus CFH seems not to be 
involved in the genetic predisposition to develop anti-FH-associated aHUS. The CFH 
promoter was also analyzed considering that maintaining self-tolerance may depend on 
FH levels, especially in the thymus. The absence of any associations with promoter 
variants has excluded the contribution of the CFH promoter to the disease. However, I 
cannot exclude that distal regions of the promoter, introns or intergenic regions can 
regulate FH levels in the thymus and determine a predisposition to autoimmunity. 
Finally, common variants present in the other complement genes, which are already 
reported in association with complement mediated disease or with and increased 
complement activity, appear not to be involved as well.  
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In conclusion, here I have documented that the anti-FH-associated aHUS is a rare 
complex disease in which genetic and environmental factors are both involved. Anti-
FH-mediated aHUS can represent a prototype of autoimmune disease in which 
antibodies are directed against a target protein for which a genetic defect has been found 
and a specific HLA allele predisposes to autoimmune response.   
In future studies whole exome sequencing of patients and controls will be done to 
identify other genetic factors implicated in the pathogenesis of anti-FHs focusing on the 
genomic loci known to be involved in autoimmunity. Super controls will be used as 
reference to evaluate the presence of predisposing variants in aHUS patients which 
could increase the OR for the disease and/or the presence of protective variants in super 
controls that do not manifest the disease although carrying the major risk for anti-FH 
development. 
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